---
document_datetime: 2023-09-21 19:39:31
document_pages: 124
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-3726-ii-0020-epar-assessment-report-variation_en.pdf
document_name: lynparza-h-c-3726-ii-0020-epar-assessment-report-variation_en.pdf
version: success
processing_time: 170.8331378
conversion_datetime: 2025-12-18 10:39:17.0472
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 February 2019 EMA/208498/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Lynparza

International non-proprietary name: olaparib

Procedure No. EMEA/H/C/003726/II/0020

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 7                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................9                                                 |
| 2. Scientific discussion..............................................................................                     | 10                                                                                                        |
| 2.1. Introduction                                                                                                          | ...................................................................................................... 10 |
| 2.1.1. Disease or condition                                                                                                | ........................................................................................ 10               |
| 2.1.2. Epidemiology and risk factors, screening tools/prevention                                                           | .................................... 10                                                                   |
| 2.1.3. Biologic features                                                                                                   | ............................................................................................. 10          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis............................................                    | 10                                                                                                        |
| 2.1.5. Management...................................................................................................       | 11                                                                                                        |
| 2.2. Non-clinical aspects............................................................................................      | 13                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 13                                                                                                        |
| 2.2.2. Conclusion on the non-clinical aspects                                                                              | ............................................................... 14                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 15     |
| 2.3.1. Introduction....................................................................................................    | 15                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 15           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 17                                                                                                        |
| 2.3.4. PK/PD relationship and modelling ......................................................................             | 19                                                                                                        |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 21                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 22                                                                                                        |
| 2.4. Clinical efficacy ..................................................................................................  | 22                                                                                                        |
| 2.4.1. Dose response study........................................................................................         | 22                                                                                                        |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 22  |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 74                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 83                                                                                                        |
| 2.5. Clinical safety ....................................................................................................  | 83                                                                                                        |
| 2.5.1. Discussion on clinical safety............................................................................           | 110                                                                                                       |
| 2.5.2. Conclusions on clinical safety ..........................................................................           | 113                                                                                                       |
| 2.5.3. PSUR cycle ...................................................................................................      | 114                                                                                                       |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 114                 |
| 2.7. Update of the Product information......................................................................               | 117                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 117                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 117                                                                                                       |
| 3.1. Therapeutic Context                                                                                                   | ......................................................................................... 117             |
| 3.1.1. Disease or condition                                                                                                | ...................................................................................... 117                |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 117                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 118                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 118                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 119                                                                                                       |
| 3.1. Unfavourable effects.........................................................................................         | 119                                                                                                       |
| 3.2. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 120                                                               |
| 3.3. Effects Table....................................................................................................     | 121                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 3.4. Benefit-risk assessment and discussion...............................................................            |   122 |
|-----------------------------------------------------------------------------------------------------------------------|-------|
| 3.4.1. Importance of favourable and unfavourable effects............................................                  |   122 |
| 3.4.2. Balance of benefits and risks ..........................................................................       |   122 |
| 3.4.3. Additional considerations on the benefit-risk balance .........................................                |   123 |
| 3.5. Conclusions..................................................................................................... |   123 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

Adverse drug reaction

AE(s)

Adverse event(s)

AML

Acute myeloid leukaemia

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

AUC

Area under plasma concentration-time curve

AUCss

Area under plasma concentration-time curve during any dosing interval at steady state

bd

Twice daily

BGI gBRCA test

Analysis of the BRCA1 and BRCA2 genes performed by the BGI Clinical

Laboratory in China (Shenzen)

BICR

Blinded independent central review

BoR

Best overall response

BRCA

Breast cancer susceptibility gene (in accordance with scientific convention,

gene and mutation is italicised whereas protein is not italicised)

## BRCAm

gBRCA or s BRCA-mutated

BRCAwt /VUS

gBRCA

and s BRCA wildtype/variant of uncertain significance

CDx

Companion diagnostic

CDS

Core Data Sheet

CHMP

Committee for Medicinal Products for Human Use, formerly known as the

Committee for Proprietary Medicinal Products (CPMP)

CI

Confidence interval

CLIA

Clinical Laboratory Improvement Amendments

Cmax (Cmax ss)

Maximum plasma concentration (at steady state)

Cmin (Cmin ss)

Minimum plasma concentration (at steady state)

CR

Complete response

CrCL

Creatinine clearance

CRF

Case report form

CSR

Clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

CTD

Common Technical Document

CTSQ

Cancer Therapy Satisfaction Questionnaire

CYP

Cytochrome P450

DCO

Data cut-off

DDI

Drug-drug interaction

DNA

Deoxyribonucleic acid

DoR

Duration of Response

DSBs

(DNA) double-strand breaks

ECOG

Eastern Cooperative Oncology Arm

eCRF

Electronic case report form

EFR

Evaluable for response

EMA

European Medicines Agency

EORTC

European Organisation for Research and Treatment of Cancer

ER

Estrogen receptor

EU

European Union

FAS

Full Analysis Set

FDA

Food and Drug Administration

FIGO

Fédération Internationale de Gynécologie Obstérique (International

Federation of Gynaecology and Obstetrics)

FTIM

First time in man

## gBRCAm gBRCAwt /VUS

Germline

BRCA-mutated

Germline

BRCA wildtype/variant of uncertain significance

GVP

Good Pharmacovigilance Practices

h

Hours

Hb

Haemoglobin

HER2

Human epidermal growth factor receptor 2

HR

Hazard ratio

HRD

Homologous recombination deficient/deficiency

HRQoL

Health-related quality of life

HRR

Homologous recombination repair

ICH

International Council for Harmonisation

IND

Investigational new drug

IVIVC

in vitro-in vivo correlation

ITT

Intention-to-treat

iv

Intravenous

IVRS

Interactive voice response system

MATE

Human Multi-Drug And Toxin Extrusion Transporter

MCV

Mean corpuscular volume

MDS

Myelodysplastic syndrome

MedDRA

Medical Dictionary for Regulatory Activities

MTP

Multiple testing procedure

N

Total number of patients

NA

Not applicable

NCCN

National Comprehensive Cancer Network

NDA

New Drug Application

NE

Not estimable

NR

Not reported

OAT

Organic anion transporter

OATP

Organic anion-transporting polypeptide

OCT

Organic cation-transporter

ORR

Objective response rate

OS

Overall survival

PARP

Polyadenosine 5'diphosphoribose polymerase

PBPK

Physiologically-based pharmacokinetic

PD

Pharmacodynamics

PFS

Progression-free survival

PFS2

Time from start of randomisation to second progression or death

P-gp

P-glycoprotein

PgR

Progesterone receptor

PK

Pharmacokinetics

POC

Proof-of-concept

PPE

Palmar-plantar erythrodysaesthesia

PR

Partial response

PRO

Patient reported outcomes

PSR

Platinum-sensitive relapsed

PT

Preferred term

QC

Quality control

qd

Once daily

QLQ-C30

Quality of Life Questionnaire Core 30 item module

QoL

Quality of life

QSR

Quality Systems Regulation

QT

Electrocardiogram interval measured from the beginning of the QRS

complex to the end of the T wave

QTcF

QT interval corrected for heart rate using Fridericia correction

QTcI

QT interval corrected for heart rate using individual-specific correction

RECIST

Response Evaluation Criteria in Solid Tumours

RMP

Risk management plan

SAE

Serious adverse event

SAP

Statistical analysis plan

sBRCA

Somatic BRCA ( BRCA variant found in the tumour but not in the germline)

sBRCA VUS

Somatic BRCA variant of uncertain significance

sBRCAm

Somatic BRCA- mutated

sd

Standard deviation

SEER

Surveillance, Epidemiology and End Results

SOC

System organ class

SmPC

Summary of Product Characteristics

sNDA

Supplemental new drug application

tBRCAm

Tumour BRCA- mutated

tBRCAwt /VUS

Tumour

BRCA wild type/variant of uncertain signifance

TEAE

Treatment emergent adverse event

TFST

Time to first subsequent therapy or death (defined as time from

randomisation to start of first subsequent therapy or death [ie, following

discontinuation of randomised study treatment])

## TNBC

Triple negative breast cancer

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

TNT Triple Negative Trial TIM-1 TNO Intestinal Model TSST Time to second subsequent therapy or death (defined as time from randomisation to the start of second subsequent therapy or death) TTP Time to progression UGT UDP-glucuronosyltransferase ULN Upper limit of normal vs Versus VUS Variants of uncertain significance WBC White blood cell wt Wildtype

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 12 March 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the use of Lynparza tablets as a monotherapy for the treatment of adult patients with BRCA1/2-mutated HER2 negative metastatic breast cancer who have previously been treated with chemotherapy; these patients could have received chemotherapy in the neoadjuvant, adjuvant or metastatic setting. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC for Lynparza tablets are updated.  Section 4.8 of the SmPC for the Lynparza capsules and relevant sections of the package leaflet have been updated accordingly. Furthermore, RMP version 16 has also been provided.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/1/2011 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific Advice

The applicant requested Scientific Advice to the CHMP related to clinical aspects of the dossier.

The MAH received scientific advice pertaining to clinical aspects of the dossier from the CHMP on 21/01/2010 (EMA/CHMP/SAWP/61318/2010) related to an early study design that the MAH did not pursue and follow-up scientific advice on 25/07/2013 (EMEA/H/SA/1215/2/FU/1/2013/II) in regard to new design of the study.

<div style=\"page-break-after: always\"></div>

In the second scientific advice, the CHMP advised that HER2-positive patients be excluded from this trial as there are other therapeutic options that have a demonstrated survival benefit in the relapsed setting and the proportion of patients with BRCA 1/2-mutated and HER2-positive breast cancer is considered very small, to which the applicant agreed.  Only hormone receptor positive patients who failed at least one hormonal treatment or were unsuitable for hormonal therapy were allowed into the trial.  The MAH proposed to include ER and/or PgR+ patients after progression on one or more lines of endocrine treatment. Including ER/PR positive patients after progression on one endocrine treatment while subsequent anti-hormonal agents can be active, was considered acceptable at the discretion of the treating physician, as a switch to another anti-hormonal agent was not considered feasible due to short or no response to 1st-line treatment, although this could be subjective.

The Applicant was asked to define in more detail in the protocol 'suitable for single-agent chemotherapy', e.g. in relation to different lines of chemotherapy. In the first-line metastatic setting, for example, this could mean poor tolerability or early relapse on prior adjuvant anthracycline/taxane therapy.

The CHMP highlighted the need to study a homogenous population for ease of assessment, such as limiting to second and third line patients.  However, feasibility to do as such was considered challenging and therefore, applicant also included first line patients.

Regarding the physician's choice of capecitabine, vinorelbine, or eribulin as a comparator arm in the OlympiAD study, the CHMP questioned the absence of a platinum therapy as a treatment option. In the first-line metastatic setting, and especially in case of BRCA1 mutations, it was considered likely that many clinicians would opt for cisplatin or carboplatin alone or in combination with gemcitabine or paclitaxel, especially in symptomatic or early progressive disease. Enrolment criteria would exclude these patients.

Whilst resistance to prior platinum-based therapy as exclusion criterion was accepted due to expected cross-resistance to PARP inhibitors, it was harder to accept, and not understood, that platinum therapy is not an option as a comparator.

The use of the more common dose of capecitabine of 1000 mg/m 2  was recommended.  However, a dose of 2500 mg/m 2  was used in OlympiAD, to be consistent with the prescribing information.

PFS as a primary endpoint for OlympiAD was proposed due to the relatively small target population and the expected crossover to alternative PARP inhibitors after progression in the control arm, and due to other sequential treatment options.  The CHMP recommended that patients be followed for PFS2; PFS2 as assessed by investigators is a secondary endpoint in OlympiAD.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

Bart Van der Schueren

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 12 March 2018     |
| Start of procedure:                                  | 31 March 2018     |
| CHMP Co-Rapporteur Assessment Report                 | 1 June 2018       |
| CHMP Rapporteur Assessment Report                    | 25 May 2018       |
| PRAC Rapporteur Assessment Report                    | 5 June 2018       |
| PRAC members comments                                | 6 June 2018       |
| Updated PRAC Rapporteur Assessment Report            | 8 June 2018       |
| PRAC Outcome                                         | 14 June 2018      |
| CHMP members comments                                | 18 June 2018      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 22 June 2018      |
| Request for supplementary information (RSI)          | 28 June 2018      |
| CHMP Rapporteur Assessment Report                    | 21 August 2018    |
| PRAC Rapporteur Assessment Report                    | 24 August 2018    |
| PRAC members comments                                | 29 August 2018    |
| Updated PRAC Rapporteur Assessment Report            | 27 August 2018    |
| PRAC Outcome                                         | 6 September 2018  |
| CHMP members comments                                | 10 September 2018 |
| Updated CHMP Rapporteur Assessment Report            | 14 September 2018 |
| 2 nd Request for supplementary information (RSI)     | 20 September 2018 |
| CHMP Rapporteur Assessment Report                    | 22 October 2018   |
| PRAC Rapporteur Assessment Report                    | 16 November 2018  |
| PRAC members comments                                | 21 November 2018  |
| PRAC Outcome                                         | 29 November 2018  |
| CHMP members comments                                | 3 December 2018   |
| Updated CHMP Rapporteur Assessment Report            | 7 December 2018   |
| 3 rd Request for supplementary information (RSI)     | 13 December 2018  |
| CHMP Rapporteur Assessment Report                    | 14 February 2019  |
| CHMP members comments                                | 26 February 2019  |
| Opinion                                              | 28 February 2019  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Disease or condition

The  claimed  indication  is  for  the  treatment  of  adult  patients  with  BRCA1/2-mutated  HER2  negative metastatic breast cancer who have previously been treated with chemotherapy.

## 2.1.2. Epidemiology and risk factors, screening tools/prevention

Breast cancer is a life-threatening disease and is the second leading cause of cancer death among women and the fourth leading cause of cancer death overall 1 .

In 2018, it is estimated that there will be 268,670 newly diagnosed breast cancer cases in the US, and approximately 41,400 people will die from breast cancer 1 . Across 40 European countries, the estimated age-adjusted annual incidence in 2012 was 92.8/100,000 and the mortality 23.1/100,000 2 .

## 2.1.3. Biologic features

Approximately 5% of breast cancers are associated with a germline mutation in the BRCA1 and/or BRCA2 gene with approximately 3% associated with the BRCA2 gene (generally hormone receptor positive). The presence of BRCA1 mutations is associated with a lifetime risk of breast cancer ranging from 60% to 70% (Antoniou et al 2003). BRCA2 mutations are associated with a lifetime risk of breast cancer between 40% to 60% in women and 5% to 10% in men.

Approximately 70% of BRCA1 mutated breast cancer present as triple negative breast cancer (TNBC). In contrast, breast cancer patients carrying mutations in the BRCA2 gene are more likely to be positive for expression of the estrogen receptor (ER) and PgR and only approximately 20% are TNBC 3 .

Although there are phenotypic differences in breast cancers resulting from gBRCA1 or gBRCA2 mutations, their important commonality is that mutations in either gene could result in development of tumours that are deficient in homologous recombination.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

The diagnosis of breast cancer is based on clinical examination in combination with imaging, and confirmed by pathological assessment. Disease stage is assessed according to the TNM system (ESMO clinical practice guideline). Although treatable, metastatic breast cancer (MBC) remains an incurable disease with a median overall survival (OS) of approximately 3 years and a 5-year survival of only approximately 25% 4 , 5 .

1  American Cancer Society 2018

2  EUCAN 2017

3 Mavaddat et al 2012

4 Cardoso F, Spence D, Mertz S et al. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015). Breast 2018; 39:131-138.

5 Howlader N, Noone AM, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975\\_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

<div style=\"page-break-after: always\"></div>

## 2.1.5. Management

The  selection  of  appropriate  therapy  for  advanced  breast  cancer  comprising  locally  advanced  and metastatic breast cancer is complex because of the many treatment options and biologic heterogeneity of the disease (ABC4 consensus guidelines). The potential treatment options are determined in accordance with ER and PR and HER2 status of the tumour. Treatment options for patients presenting with metastatic breast  cancer  may  also  be  influenced  by  what  adjuvant  therapy  was  used,  how  soon  after  adjuvant therapy the patient relapses, and by sites of metastasis.

For patients with HER2-negative metastatic breast cancer, there is no preferred first-line chemotherapy. Sequential monotherapy with single agent capecitabine, vinorelbine, or eribulin are among the preferred choices in metastatic breast cancer patients previously treated with an anthracycline and a taxane in the adjuvant or metastatic setting and for whom further hormonal treatments are not indicated 6 . Additional choices  include  gemcitabine,  platinum  agents,  taxanes  and  liposomal  anthracyclines 7 .  Combination chemotherapy is reserved for patients with rapid clinical progression, life-threatening visceral metastases, or need for rapid symptom and/or disease control 6,7 .

Currently,  single  agent  chemotherapy  after  previous  exposure  to  anthracyclines  and  taxanes  has  a median progression free survival (PFS) of approximately 4 months and an overall survival (OS) of 9 to 16 months when given early in the metastatic setting.

There is no targeted therapy available to date for the treatment of TNBC. The prognosis for patients with TNBC and/or those who carry gBRCA1 mutations with metastatic disease may even be worse than the overall metastatic breast cancer population. According to current NCCN guidelines (2018), carboplatin is considered  as  one  of  recommended  regimens  for  recurrent  or  metastatic  disease.  In  advanced  TNBC patients (regardless of BRCA status) previously treated with anthracyclines with or without taxanes in the (neo)adjuvant  setting,  carboplatin  showed  comparable  efficacy  and  a  more  favourable  toxicity  profile, compared  with  docetaxel,  and  is  considered,  therefore,  an  important  treatment  option.  However  in patients with BRCA-associated advanced TNBC or endocrine-resistant advanced breast cancer a platinum regimen is considered as a preferred option, if not previously administered 7 .

For  the  treatment  of  hormone  receptor  (HR)-positive,  HER2-negative  locally  advanced  or  metastatic breast cancer, CDK4/6 inhibitors have been recently approved in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

Everolimus, an mTOR inhibitor, is also approved for the treatment of hormone receptor-positive, HER2 negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic  visceral  disease  after  recurrence  or  progression  following  a  non-steroidal  aromatase inhibitor.

There are currently no treatments approved in the European Union (EU) specifically for BRCAm patients with  metastatic  breast  cancer  and  these  patients  are  treated  according to their  hormone  receptor  and HER2 status.

## About the product

Olaparib  is  a  potent  inhibitor  of  human  poly  (ADP-ribose)  polymerase  enzymes  (PARP-1,  PARP-2,  and PARP-3),  and  has  been  shown  to  inhibit  the  growth  of  selected  tumour  cell  lines  in  vitro  and  tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies.

PARPs are required for the efficient repair of DNA single strand breaks and an important aspect of PARPinduced repair requires that after chromatin modification, PARP auto-modifies itself and dissociates from

6  NCCN 2017

7  ESMO ABC4

<div style=\"page-break-after: always\"></div>

the DNA to facilitate access for base excision repair (BER) enzymes. When olaparib is bound to the active site of DNA-associated PARP it prevents the dissociation of PARP and traps it on the DNA, thus blocking repair. In replicating cells this also leads to the formation of DNA double-strand breaks (DSBs) when replication forks meet the PARP-DNA adducts. In normal cells, homologous recombination repair (HRR) pathway is effective at repairing these DNA DSBs. In cancers that lack functional components of HRR such as BRCA1 or 2, DNA DSBs cannot be repaired accurately or effectively. Instead, alternative and error-prone pathways are activated, such as the classical non-homologous end joining (NHEJ) pathway, leading to increased genomic instability. After a number of rounds of replication, genomic instability can reach insupportable levels and result in cancer cell death, as cancer cells already have a high DNA damage load relative to normal cells. In the absence of BRCA1 or BRCA2 mutations, HRR pathway may be compromised by other mechanisms, although the causative aberrancy and penetrance are not fully elucidated. Absence of fully functional HRR pathway is one of the key determinants of platinum sensitivity in ovarian and other cancers.

Lynparza,  50  mg  capsule  formulation,  was  approved  on  16  December  2014  in  monotherapy  for  the maintenance  treatment  of  adult  patients  with  platinum-sensitive  relapsed  BRCA-mutated  (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.

Subsequently a tablet formulation (100 mg and 150 mg) was approved on 8 May 2018 as monotherapy for  the  maintenance  treatment  of  adult  patients  with  platinum-sensitive  relapsed  high-grade  epithelial ovarian,  fallopian  tube,  or  primary  peritoneal  cancer  who  are  in  response  (complete  or  partial)  to platinum-based chemotherapy.

The proposed target patient population in this application is focused on BRCAm HER2-negative metastatic breast cancer. The pivotal study included patients with gBRCAm TNBC as well as BRCAm ER and/or PgR+ patients.

The  applicant  claimed  the  use  of  the  already  approved  tablet  formulation  in  the  following  proposed indication:  'Lynparza  is  indicated  as  monotherapy  for  the  treatment  of  adult  patients  with  BRCA1/2mutated HER2 negative metastatic breast cancer who have previously been treated with chemotherapy. These patients could have received chemotherapy in the neoadjuvant, adjuvant or metastatic setting.'

The recommended indication is:

'Lynparza  is  indicated  as  monotherapy  for  the  treatment  of  adult  patients  with  germline  BRCA1/2mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1).

Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy'

The recommended dose of Lynparza is 300 mg (two 150 mg tablets) taken twice daily, equivalent to a total daily dose of 600 mg. The 100 mg tablet is available for dose reduction.

It  is  recommended  that  treatment  be  continued  until  progression  of  the  underlying  disease  or unacceptable toxicity. There are no data on retreatment with Lynparza following subsequent relapse (see section 5.1).

Patients  must  have  confirmation  of  a  deleterious  or  suspected  deleterious  gBRCA1/2  mutation  before Lynparza  treatment  is  initiated.  gBRCA1/2  mutation  status  should  be  determined  by  an  experienced laboratory using a validated test method. Data demonstrating clinical validation of tumour BRCA1/2 tests in breast cancer are not currently available.

<div style=\"page-break-after: always\"></div>

Genetic counselling for patients tested for mutations in BRCA1/2 genes should be performed according to local regulations.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The MAH provided an updated ERA. The PECsurfacewater is calculated based on the sum of the PECsurfacewater calculated for both the ovarian cancer (0.026 μg/L) and breast cancer (0.090 μg/L) indications

Table 1: Summary of main study results

| Substance (INN/Invented Name):                                      | Substance (INN/Invented Name):                  | Substance (INN/Invented Name):                                                                                              | Substance (INN/Invented Name):                                                                                                                  |
|---------------------------------------------------------------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| CAS-number (if available):                                          | CAS-number (if available):                      | CAS-number (if available):                                                                                                  | CAS-number (if available):                                                                                                                      |
| PBT screening                                                       |                                                 | Result                                                                                                                      | Conclusion                                                                                                                                      |
| Bioaccumulation potential- log K ow                                 | OECD107 (study 06-0182/C)                       | 1.55                                                                                                                        | Not > 4.5: not PBT                                                                                                                              |
| PBT-assessment                                                      | PBT-assessment                                  | PBT-assessment                                                                                                              | PBT-assessment                                                                                                                                  |
| Parameter                                                           | Result relevant for conclusion                  |                                                                                                                             | Conclusion                                                                                                                                      |
| Bioaccumulation                                                     | log K ow BCF                                    | 1.55 NA                                                                                                                     | Not B                                                                                                                                           |
| Persistence                                                         | DT 50 or ready biodegradability                 | DT50, total system, 20°C = 259 (S1) & 251 (S2) DT50, total system, 12°C = 553 (S1) & 536 (S2)                               | vP                                                                                                                                              |
| Toxicity                                                            | NOEC or CMR                                     | NA                                                                                                                          |                                                                                                                                                 |
| PBT-statement :                                                     | The compound is not considered as PBT nor vPvB. | The compound is not considered as PBT nor vPvB.                                                                             | The compound is not considered as PBT nor vPvB.                                                                                                 |
| Phase I                                                             | Phase I                                         | Phase I                                                                                                                     | Phase I                                                                                                                                         |
| Calculation                                                         | Value                                           | Unit                                                                                                                        | Conclusion                                                                                                                                      |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | If Fpen=0.01 if Fpen=0.0001094                  | 4.0 µ g/L 0.44 µg/L                                                                                                         | Then < 0.01 µg/L                                                                                                                                |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate  | Phase II Physical-chemical properties and fate                                                                              | Phase II Physical-chemical properties and fate                                                                                                  |
| Study type                                                          | Test protocol                                   | Results                                                                                                                     | Remarks                                                                                                                                         |
| Adsorption-Desorption                                               | Modified OECD 106 (study 12-0285/A)             | High Organic Carbon (HOC) sediment mean K d =111 K oc = 1986 Low Organic Carbon (LOC) sediment mean K d = 3.8 K oc = 27487  | KFoc values indicated that [ 14 C]Olaparib was of low mobility in the HOC sediment (KFoc 500-2000), and immobile in the LOC sediment (KFc>5000) |
| Ready Biodegradability Test                                         | OECD 301F (study 06-0182/J)                     | Negligible biodegradation (day 28: <6% )                                                                                    | Not readily biodegradable                                                                                                                       |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems    | OECD 308 (study 08-0028/C)                      | DT50, water, 20°C = 3.2 (S1) & 7.4 ( S2 ) DT50, sediment = no degradation or dissipation observed. DT50, total system, 20°C | 2 sediments: S1: silty clay high OC S2: sand, low OC Shifting Transformation products: <10%                                                     |

<div style=\"page-break-after: always\"></div>

|                                               |                                  | = 259 ( S1 ) & 251 ( S2 ) DT50, total system, 12°C = 553 ( S1 ) & 536 ( S2 )   | = 259 ( S1 ) & 251 ( S2 ) DT50, total system, 12°C = 553 ( S1 ) & 536 ( S2 )   | = 259 ( S1 ) & 251 ( S2 ) DT50, total system, 12°C = 553 ( S1 ) & 536 ( S2 )   | Olaparib is very persistent Sediment toxicity study triggered.                                                                                                                                                                 |
|-----------------------------------------------|----------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Adsoprtion/desorption to sludge               | OPPTS 835.1110 (study 08-0028/B) | Kd sludge(ads) = 25                                                            | Kd sludge(ads) = 25                                                            | Kd sludge(ads) = 25                                                            | [ 14 C]AZD2281 did not show significant adsorption to sewage sludge and therefore, is not predicted to adsorb to bio-solids during wastewater treatment. A Kd value of 25 was calculated assuming a linear adsorption isotherm |
| Hydrolysis                                    | OECD 111 (study 06- 0182/D)      | <10 %(5 days) at pH 5, 7 and 9 Hydrolytically stable                           | <10 %(5 days) at pH 5, 7 and 9 Hydrolytically stable                           | <10 %(5 days) at pH 5, 7 and 9 Hydrolytically stable                           | Hydrolytically stable (less than 10% hydrolysis over 120 hours at environmental relevant pHs)                                                                                                                                  |
| Phase IIa Effect studies                      | Phase IIa Effect studies         | Phase IIa Effect studies                                                       | Phase IIa Effect studies                                                       | Phase IIa Effect studies                                                       | Phase IIa Effect studies                                                                                                                                                                                                       |
| Study type                                    | Test protocol                    | Endpoint                                                                       | value                                                                          | Unit                                                                           | Remarks                                                                                                                                                                                                                        |
| Algae, Growth Inhibition Test/ Species        | OECD 201 (study 06-0182/F)       | NOEC                                                                           | 83                                                                             | mg/L                                                                           | EC 50 = > 83 mg/L                                                                                                                                                                                                              |
| Daphnia sp . Reproduction Test                | OECD 211 (study 06-0182/H)       | NOEC                                                                           | 0.32                                                                           | µg/L                                                                           | 21 day LOEC = 1.0 mg/L                                                                                                                                                                                                         |
| Fish, Early Life Stage Toxicity Test/ Species | OECD 210 (study 06-0182/I)       | NOEC                                                                           | 0.32                                                                           | µg/L                                                                           | 32 day LOEC 1.0 mg/L                                                                                                                                                                                                           |
| Activated Sludge, Respiration Inhibition Test | OECD 209 (study 06-0182/E)       | NOEC                                                                           | 100                                                                            | µg/L                                                                           | 3 hour EC 50 > 100 mg/L                                                                                                                                                                                                        |

PNECmicroorganism = 10 000 μg/L

PNECsurfacewater = 32 µg/L

PECgroundwater = 0.011 µg/L and PNECgroundwater = 32 µg/L

PECsurfacewater/PNECmicroorganism = 4.4 × 10 -6  (then &lt;0.1): Olaparib is unlikely to present a risk to microorganisms

PECsurfacewater/PNECsurfacewater  =  1.4  ×  10 -3   (then  &lt;1): Olaparib  is  unlikely  to  present  a  risk  to organisms in surface water

PECgroundwater/PNECgroundwater =  3.4  ×  10 -4 (then  &lt;1): Olaparib  is  unlikely  to  present  a  risk  to  the groundwater environment

## Phase IIb Studies

| Toxicity to riparius                                                                                                                                                                                                                                             | Chironomus (study                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PECsediment = PECsurface water × Kdsediment (111) PECsediment = 0.044 μ g/L × 111 L/kg = 4.9 µg/kg PNECsediment = NOEC from the chironomus test / 100 PNECsediment = 600 µg/kg / 100 = 6 µg/kg PEC/PNECsediment = 0.82 (then <1): no further testing is required | PECsediment = PECsurface water × Kdsediment (111) PECsediment = 0.044 μ g/L × 111 L/kg = 4.9 µg/kg PNECsediment = NOEC from the chironomus test / 100 PNECsediment = 600 µg/kg / 100 = 6 µg/kg PEC/PNECsediment = 0.82 (then <1): no further testing is required | PECsediment = PECsurface water × Kdsediment (111) PECsediment = 0.044 μ g/L × 111 L/kg = 4.9 µg/kg PNECsediment = NOEC from the chironomus test / 100 PNECsediment = 600 µg/kg / 100 = 6 µg/kg PEC/PNECsediment = 0.82 (then <1): no further testing is required |

## 2.2.2. Conclusion on the non-clinical aspects

Considering the above data, olaparib is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 2: Tabular overview of clinical studies

| Studynunber (description)                                          | Design                                                                                                                                                                                | Efficacy endpoint                    | Total nunberof patients   | Nunber of BRCAmbreast cancer patientsa   | Status                             |
|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------|------------------------------------------|------------------------------------|
| PhaseI studies:Tolerability and prelininary efficacy               | PhaseI studies:Tolerability and prelininary efficacy                                                                                                                                  |                                      |                           |                                          |                                    |
| D0810C00002(firsttime in man study)                                | First time in human with eficacy expansion at 200 mg bd                                                                                                                               | BoR, DoR, PFS                        | 98                        | 7 (local testing)                        | Complete                           |
| D0810C00024 (formulation comparison study)                         | Comparativebioavailability of two oral fommulations of olaparibin patients with advanced solid tumours with efficacy expansion in gBRCAm ovarian and breast cancer patients           | shrinkage, BoR, Tumour ORR, PFS      | 196                       | 14 (local testing)                       | Complete                           |
| Phase II studies                                                   | Phase II studies                                                                                                                                                                      |                                      |                           |                                          |                                    |
| D0810C00008 (proof-of- concept study)                              | Open-label, single-am, POC study to assess the efficacy and safety of olaparib 400 mg bd (capsule) in gBRCAm advancedbreastcancerpatients.                                            | ORR, DoR, BoR, tumour shrinkage, PFS | 54                        | 27 (local testing)                       | Complete                           |
| D0810C00020 (relapsed ovarian and breast cancer monotherapy study) | Open-label, non-randomised study of olaparib in patients ovarian cancer and patients with known gBRCAm or with known hereditarygBRCAm or non-hereditary triple negative breast cancer | BoR, ORR, PFS, OS, DoR, DCR          | 90                        | (local testing) 26                       | Complete                           |
| D0810C00042(advanced gBRCAm tumours study)                         | Open-label,non-randomised study of olaparib inpatients with advanced gBRCAm tumours                                                                                                   | Response rate. ORR, PFS,OS, DoR, DCR | 298                       | 62 (local testing)                       | Complete                           |
| Phase III studies                                                  | Phase III studies                                                                                                                                                                     |                                      |                           |                                          |                                    |
| study) D0819C00003 (pivotal                                        | metastaticHER2-negativebreastcancer Open-label, controlled trial in gBRCAm patients with                                                                                              | PFS, OS, PFS2, ORR DCR, HRQoL        | 302                       | ~302 (local & centralised testing)       | Ongoing for extended OS follow- up |

these testing methods ispresented inSection 4.1.4.

BRCA mutation status was determined by various methods dependent on the study: (1) 1ocal germline testing,as recorded on CRFs at study enrolment, or BRACAnalysis CDx test) or BGI Clinical Laboratory (Shenzen) to determine gemmline (gBRCA) mutation status. Further information relating to

bd twice daily; BoR best overallresponse; BRCA breast cancer susceptibility gene; DCR disease control rate; DoR duration ofresponse, gBRCA genmline BRCA mutation; PFS progression-free survival; PFS2 time to second progression or death; ORR Objective response rate; OS overall survival. CSR, Module 5.3.3.2 and Study 02 CSR, Module 5.3.3.2.

## 2.3.2. Pharmacokinetics

No new clinical PK study was submitted to support the proposed indication in BRCAm patients with HER2negative metastatic breast cancer. A population PK analysis (Olaparib MS-05) performed using an earlier developed model and including sparse data collected in patient with breast cancer OlympiAD was provided.

<div style=\"page-break-after: always\"></div>

## Population PK analysis (Olaparib-MS-05)

## Objectives

The  objectives  of  this  analysis  were  to:  1)  characterise  olaparib  PK  in  patients  with  metastatic  breast cancer  in  OlympiAD  study;  2)  obtain  individual  PK  parameter  estimates  with  plasma  concentrations available;  3)  explore  and  model  (if  feasible)  the  relationship  between  olaparib  plasma  exposure  and selected efficacy and safety variables.

## Methods

A  total  of  302  patients  were  randomised  2:1  (olaparib:  physician's  choice  chemotherapy)  into  the OlympiAD study.  Plasma samples for PK were collected in a sub-group of patients randomised to olaparib treatment group, at Day 1 Cycle 2 at following time window, Pre-dose, between 0 and 0.5 hour postdose, between 0.5 and 1.5 hour post-dose, between 3 and 6 hours post-dose, and between 6 and 12 hours post-dose.  The final PK data sets comprised 174 olaparib plasma concentrations from 36 olaparibtreated subjects. Of 36 subjects, 7 subjects had dose reduction from 300 mg bd to 250, 200 and 50 mg during the course of olaparib treatment.

The  population  PK  model  from  Olaparib-MS-02  and  Olaparib-MS-03  served  as  basis  for  the  model development,  but  was  further  refined  where  deemed  necessary.    Patient  covariate  relationships  were examined in a stepwise procedure to examine the impact of individual patient characteristics on olaparib PK. Individual  PK  parameters  as  well  as  exposure  estimates  for  subsequent  exposure-response assessment were derived based on the final PK model.  The average AUC, Cmax, Cmin of 2 olaparib dose administrations  during  the  safety  event  day,  abbreviated  as  dAUC,  dCmax,  dCmin,  respectively,  were used as exposure on the safety event day for the safety exposure- response analysis.  Since efficacy or safety events may associate with exposure from the beginning of olaparib treatment to the event day, an overall measure of exposure in mean AUC was used, using average olaparib concentration from the start of olaparib dose administrations to the efficacy or safety event day multiplied by dose interval (12 hours), abbreviated  as  average  cumulative  AUC  (acAUC),  was  used  for  exposure-response  analysis  for  both safety and efficacy events.  The exposure metric acAUC is similar to steady state AUC, but considers the dose interruption and reduction over the period of olaparib treatment.

The relationship between olaparib exposure and safety/efficacy was explored graphically and modeled if supported by data.

## Results

The exposure to olaparib in the Phase III study OlympiAD was determined using population PK analysis (N=36) and the estimated Gmean (coefficient of variation %) for Cmax,ss, AUCss and Cmin,ss after 300 mg tablet bd were 6.41 μg/mL (41%), 41.2 μg.h/mL (42%) and 1.17 (87%) μg.h/mL.

The model structure for plasma concentration data from OlympiAD was the same as the previous models (Olaparib-MS-02 and Olaparib-MS-03): a linear 2-compartment model with sequential zero and first-order absorption rates and first-order elimination. Covariates including age, body weight, gender, race, tablet strength, hepatic and renal function markers were evaluated in the population analysis, and none of them were identified as significant covariates impacting olaparib PK.  The estimates of geometric mean steadystate exposure in AUCss, Cmax,ss and Cmin,ss in patients with metastatic breast cancer were similar to those from patients with ovarian cancer in SOLO2 study.

The relationships between exposure and efficacy (progression free survival [PFS], overall survival [OS] and time from randomisation to second progression or death  [PFS2]) was examined with Kaplan-Meier

<div style=\"page-break-after: always\"></div>

plots stratified by tertiles of exposure and showed no pattern that would suggest response differs at the exposures analysed in this study.  No testing via modelling was performed.

Graphical  exploratory  analyses  were  conducted  to  explore  the  exposure-safety  analysis  for  anaemia, fatigue  and  haemoglobin  (Hb).  No  significant  exposure-safety  relationship  was  found,  except  a  weak relationship between olaparib exposure in acAUC and Hb levels.  A relationship was observed between olaparib  exposure  in  acAUC  and  haemoglobin  concentrations,  and  can  be  described  by  an  indirect response model.  The model predicted a small decrease in haemoglobin concentrations with the increase in olaparib exposure and model simulation indicated a negligible change haemoglobin concentration for the majority of olaparib exposures observed.

A comparison of steady state olaparib exposure for the capsule and tablet formulations determined using population PK analysis is provided below.

Table 3: Comparison of steady state olaparib exposure for the capsule and tablet formulations determined using population PK analysis

| PK parameter   | Summary statistic     | Capsule 400 mg bd: pooled PK analysis: Olaparib-MS-01   | Tablet 300 mg bd SOL02 study: Olaparib -MS-03   | Tablet 300 mgbd OlympiAD study: Olaparib -MS-05   | Tablet 300 mg bd: pooled PK analysis: Olaparib -MS- 02   |
|----------------|-----------------------|---------------------------------------------------------|-------------------------------------------------|---------------------------------------------------|----------------------------------------------------------|
| Cmx (μg/mL)    | n Gmean (range) [GCV] | 68 5.73 (1.57-14.2)                                     | 94 7.12 (3.9-15) [26.9]                         | 36 6.41 (2.16-17.7) [40.9]                        | 131 9.10 (4.26-25.5) [38.7]                              |
| AUC. (μg.h/mL) | Gmean (range) [GCV]   | 68 48.1 (8.57-154)                                      | 94 40.7 (17-120) [39.5]                         | 36 41.2 (17.6-140) [42.0]                         | 131 59.7 (25.5-183) [49.7]                               |
| Cminm (μg/mL)  | n Gmean (range) [GCV] | 68 1.26 (0.08-8.08)                                     | 94 1.15 (0.28-6.2) [72.3]                       | 36 1.17 (0.11-8.00) [87.0]                        | 131 1.95 (0.35-11.5) [86.5]                              |

a For Olaparib-MS-01 pooled population PK analysis GCV were not reported. Data for studies 1, 2, 12 and 24 are shown.

AUCs area under the plasma concentration-time curve during a dosing interval; bd twice daily;

Cmxs maximum plasma concentration at steady state; Cmins minimum plasma concentration; Gmean

Geometric mean; GCV Geometric coefficient of variation %; PK pharmacokinetic.

Data source: Table 6 0laparib-MS-01 Module 5.3.3.5, Table 9 0laparib-MS-02 Module 5.3.3.5, Table 4 Olaparib-MS-05 Module 5.3.3.5, and Table 13 Olaparib-MS-03 Module 5.3.3.5.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Olaparib  is  a  potent  inhibitor  of  human  poly  (ADP  ribose)  polymerase  enzymes  (PARP  1,  PARP  2,  and PARP 3),  and  has  been  shown  to  inhibit  the  growth  of  selected  tumour  cell  lines  in  vitro  and  tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies.

PARPs are required for the efficient repair of DNA single strand breaks and an important aspect of PARP induced repair requires that after chromatin modification, PARP auto modifies itself and dissociates from the DNA to facilitate access for base excision repair (BER) enzymes. When olaparib is bound to the active site of DNA associated PARP it prevents the dissociation of PARP and traps it on the DNA, thus blocking repair. In replicating cells this leads to DNA double strand breaks (DSBs) when replication forks meet the

<div style=\"page-break-after: always\"></div>

PARP  DNA  adduct.  In  normal  cells,  homologous  recombination  repair  (HRR),  which  requires  functional BRCA1 and 2 genes, is effective at repairing these DNA DSBs. In the absence of functional BRCA1 or 2, DNA DSBs cannot be repaired via HRR. Instead, alternative and error prone pathways are activated, such as  the  non-homologous  end  joining  (NHEJ)  pathway,  leading  to  increased  genomic  instability.  After  a number of rounds of replication, genomic instability can reach insupportable levels and result in cancer cell death, as cancer cells have a high DNA damage load relative to normal cells (See SmPC Section 5.1).

## Primary and secondary pharmacology

## Effect of olaparib on the QT interval

The relationship between QT interval corrected for heart rate (QTc) and plasma concentrations was evaluated in Studies 04 and 07. Following the 300 mg bd tablet dose olaparib had no clinically significant effect on QT interval (QT interval corrected for heart rate using Fridericia's correction [QTcF] and QT interval corrected for heart rate using individual-specific correction [QTcI]).

## Germline BRCA diagnostic testing

Patients were required to have documented evidence of a deleterious or suspected deleterious mutation in either BRCA1 or BRCA2 to be enrolled into the OlympiAD study. Evidence of a qualifying BRCA mutation could be from either an existing BRCA mutation result generated by local testing or from prospective testing performed by BGI or by Myriad using either the Integrated BRACAnalysis test (also referred to as the Myriad CLIA gBRCA test) or the BRACAnalysis CDx test (also referred to as the Myriad CDx gBRCA test).

Table 4: Number of samples in analysis sets in OlympiAD

|            | FASN   | CRF gBRCA status   | CRF gBRCA status   | CRF gBRCA status   | BGIgBRCA status   | BGIgBRCA status   | BGIgBRCA status   | Myriad CLLA status   | Myriad CLLA status   | Myriad CLLA status   | MyriadCDrgBRCAstatus   | MyriadCDrgBRCAstatus   | MyriadCDrgBRCAstatus   |
|------------|--------|--------------------|--------------------|--------------------|-------------------|-------------------|-------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|
| Study anm: |        | gBRCAm             | Non- gBRCAm        | Not reported-      | gBRCAm            | Non- gBRCAm       | Nottested gBRCAm  |                      | Non- gBRCAm          | Not testedgBRCAm     |                        | Nou- gBRCAm            | Not tested-            |
| Olapanlb   | 205    | 117                |                    | 88                 | 32                | 0                 | 173               | 109                  | 2                    | 94                   | 202                    | 2                      | =                      |
| Chemo      | 97     | 50                 | 0                  | 47                 | 9                 | 0                 | 88                | 59                   | 0                    | 38                   | 56                     | 0                      | 2                      |
| Total      | 302    | 167                | 0                  | 135                | 41                | 0                 | 261               | 168                  | 2                    | 132                  | 297                    | 2                      | 3                      |

- a Local sites were only required to report prior gBRCA status where it was being used to guide randomisation.

b BGI testing Was only performed for cases screened in China.

C Testing at Myriad was performed in the CLIA lab until 7th July 20l5. After this date testing switched to the CDx lab.

d Includes l variant with a qualified interpretation (See Below/Unclassified) due to umclear evidence aroumd pathogenicity.

In total, 2126 subjects were screened for entry into OlympiAD. Within patients meeting the clinical study eligibility criteria, 167 subjects were randomised based on an existing local gBRCAm result, 65 based on a Myriad gBRCAm CLIA result, 29 based on a Myriad gBRCAm CDx result and 41 based on a gBRCAm result from BGI testing. Among 302 randomised patients with gBRCA1/2 mutations, the gBRCAm status was confirmed by the Myriad BRACAnalysis CDx assay in 297 patients.

Previously reported data have shown an association between the mutated gBRCA1 or BRCA2 gene and disease histology, with gBRCA1 mutations being associated with TNBC and BRCA2 mutations being associated with HR+ disease 8 .  These reported associations were also seen in the HR+ and TNBC patients in OlympiAD. The mutation types as gBRCAm by Myriad testing were reported.

8 Mavaddat et al 2012

<div style=\"page-break-after: always\"></div>

Table 5: BRCA mutation types in breast cancer observed in OlympiAD

| Mutation type        | Breast cancer (n=297)   | HR+ (n=151)   | TNBC (n=146)   |
|----------------------|-------------------------|---------------|----------------|
| Frameshift           | 62.3%                   | 62.9%         | 61.6%          |
| Nonsense             | 20.2%                   | 21.2%         | 19.2%          |
| Missense             | 7.7%                    | 6.6%          | 8.9%           |
| Large Rearrangement  | 4.4%                    | 2.6%          | 6.2%           |
| Other mutation types | 6.1%                    | 6.6%          | 5.5%           |
| BRCA1                | 55.2%                   | 30.4%         | 80.8%          |
| BRCA2                | 43.4%                   | 68.9%         | 17.1%          |
| BRCA1&BRCA2          | 1.4%                    | 0.7%          | 2.1%           |
| BRCAI RING domain    | 10.8%                   | 7.9%          | 13.7%          |
| BRCAl exon 11        | 23.2%                   | 9.9%          | 37.0%          |

## Exploratory analysis of tumour samples

Patients who entered screening part 2 of the OlympiAD study were requested to provide tumour tissue material  for  exploratory  analyses  if  such  material  was  available.  There  was  no  mandatory  re-biopsy required  in  cases  where  patients  did  not  have  tumour  material  available.  Only  161  of  the  overall  302 patients (53%) were able to provide a tumour sample.

A comparison between gBRCA and tBRCA results identified that the deleterious or suspected deleterious mutation present in the germline was detected in the tumour in 141/143 cases (in 1 case, 2 mutations were reported in the germline and both mutations were also reported in the tumour sample).

Locus-specific LOH data were reported in 125 of the 143 tBRCA tested patients (87.4%). Overall, tumour LOH was observed for 118/125 (94.4%) deleterious mutations observed in the germline.

BRCA analysis  using  the  Myriad  myChoice  HRD  plus  test  generated  a  valid  homologous  recombination deficiency (HRD) score in 130 samples. Of these, 108 (83.1%) had a HRD score ≥ 42 and the HRD scores &lt;42 were seen in 16.3%. A higher proportion of negative HRD scores in the hormone receptor positive (HR+) patients (13/59 [22%]) versus the triple negative breast cancer (TNBC) patients (8/70 [11%]) was reported. A higher proportion of patients with TNBC had mutations in TP53 (86%) than with HER2/HR+ (22%).

## 2.3.4. PK/PD relationship and modelling

## Analysis of tumour samples

Study 07, a Phase I open-label study to identify an effective biological dose to be used for further clinical studies of olaparib by using biomarkers of PARP activity to delineate a PARP inhibitory concentration response curve for the selected doses of olaparib in breast tumour, was submitted with the initial MA application.

Intermediate and high risk breast cancer patients were randomly allocated to 1 of 5 dose cohorts (10 mg bd, 30 mg bd, 100 mg bd, 200 mg bd, and 400 mg bd) and received treatment for 4 or 5 days prior to surgery. Overall, 60 patients were randomized, 12 in each dose cohort, and all patients completed treatment.

<div style=\"page-break-after: always\"></div>

Tumour biopsy samples were obtained before surgery from 60 intermediate and high risk breast cancer patients. Determination of concentrations of olaparib in tumour biopsies showed that measurable concentrations (&gt;40 ng/g) were present in all but one of the samples collected from patients dosed at 30, 100, 200 and 400 mg bd. The extent of PARP inhibition in tumour samples ranged from about 20% to 80% compared with baseline and no clear relationship with dose could be showed.

Exposure/response (E-R) analysis for efficacy event in OlympiAD trial (DCO (25 September 2017))

The final E-R analysis data set for efficacy events included 36 subjects. There were only 12, 11 and 13 patients at the lower, middle and upper tertiles of acAUC exposure.

Kaplan-Meier survival estimate plots stratified by tertiles of acAUC for PFS2 and OS are shown below.

## KaplanMeierPFS2byacAUC

Figure 1 Kaplan-Meier survival estimates for PFS2 stratified by tertiles of acAUC

<!-- image -->

Note: acAUC Average cumulative AUC; PFS Progression free survival.

## KaplanMeier OS byacAUC

Figure 2 Kaplan-Meier survival estimates for OS stratified by tertiles of acAUC

<!-- image -->

<div style=\"page-break-after: always\"></div>

The PKPD analysis in Olaparib-MS-02 did not show any significant exposure-safety relationship, except for haemoglobin (Hb) level where increased olaparib exposure was associated with a reduction in Hb level. The PKPD analyses of OlympiAD and SOLO2 in the Phase III studies also showed an exposure response relationship for Hb. In Olaparib-MS-05, the simulations from the Hb model indicated a very small change in mean Hb concentration time course until olaparib exposure approached the upper bound of 95% CI of predicted AUCss (100 µg.h/mL).  The predicted mean Hb concentrations around the upper bound of 95% CI of the predicted AUCss were still above 10g/dL. No significant concentration dependent relationship was found for nausea, vomiting, platelet count, dysguesia, constipation, dyspepsia, or neutropenia.

## 2.3.5. Discussion on clinical pharmacology

The applicant claims the use of olaparib tablets in the treatment of patients with BRCA-Mutated HER2Negative Metastatic Breast Cancer metastatic breast cancer.

With regards to PK data, the MAH submitted an overview of the pharmacokinetics of the tablet formulation and a population PK analysis (Olaparib MS-05) performed using an earlier developed model and including sparse data collected in patient with breast cancer OlympiAD. The PK properties (ADME) of olaparib were presented and assessed satisfactorily in previous applications related to the use of olaparib in the treatment of ovarian cancer. The biopharmaceutical performances of the capsule and tablet formulation were elucidated. The tablet showed higher bioavailability (approximately doubled) and less variablebehaviour. In the pivotal phase 3 study supporting the breast cancer indication, only the currently approved tablet formulation was used. No formal PK study was performed in the target population (claimed indication). However, sparse sampling data were collected for the purpose of population-PK analysis. The results of the population PK analysis should be interpreted with caution due to the small number of evaluable patients (N=36) in this analysis.

The exposure to olaparib following administration of 300mg bd tablet formulation observed in the Phase III study OlympiAD (Olaparib-MS-05, N=36) was comparable to that in SOLO2 (Olaparib-MS-03, N=94) and was within the range previously predicted for the capsule formulation at 400mg bd (Olaparib-MS-01). However, it was slightly lower (AUCss was 32% lower) than the one observed in the pooled Phase I tablet population PK analysis due to study variability (Olaparib-MS-02). A comparison of steady-state olaparib exposure for the capsule and tablet formulations determined using the population PK analysis (OlaparibMS-01, Olaparib-MS-02 and Olaparib MS-03) was provided. In addition, potential causes of the apparent differences in olaparib exposure between the SOLO2 study and the pooled tablet analysis were further investigated and it appeared that this difference was due to variability between studies. Section 5.2 of the SmPC has been updated to reflect that patient gender was also not a significant covariate.

For  the  applied  indication  i.e.  germline  breast  cancer  susceptibility  genes  (gBRCA1/2)  mutated  human epidermal  growth  factor  receptor  2  (HER2)-negative  metastatic  breast  cancer,  patients  must  have confirmation of a deleterious or suspected deleterious gBRCA1/2 mutation before Lynparza treatment is initiated. gBRCA1/2 mutation status should be determined by an experienced laboratory using a validated test method (see SmPC section 4.2). Genetic counselling for patients tested for mutations in gBRCA1/2 genes should be performed according to local regulations.

Data in regard to analytical and clinical validation in breast cancer patients of the in-vitro diagnostic tests proposed  to  be  used  for  the  detection  of  deleterious  or  suspected  deleterious  BRCA1/2  mutations  in tumours  have  not  been  provided.  It  is  reflected  in  section  4.2  of  the  SmPC  that  data  demonstrating clinical validation of tumour BRCA1/2 tests in breast cancer are not currently available.

Exploratory analysis of tumour samples in study OlympiAD showed that a higher proportion of patients with TNBC had mutations in TP53 (86%) than with HER2-/HR+ (22%) which is consistent with results from  other  studies  and  suggest  a  potential  mechanistic  rationale  for  investigating  TP53  mutation  in

<div style=\"page-break-after: always\"></div>

patients  with  BRCAm  tumours.  In  high-grade  serous  ovarian  cancer  (HGSOC),  mutations  in  TP53  are nearly  universal  and  exploratory  analysis  of  results  from  the  Study  19,  the  phase  II  double-blind, randomised,  placebo-controlled,  multicentre  study  conducted  in  advanced  platinum-sensitive  HGSOC, suggested a role of disruptive p53 mutations in predicting OS in patients treated with olaparib.

The MAH is recommended to further investigate the prognostic and predictive value of tests that would allow  quantitative  assessment  of  genomic  instability  and  homologous  recombination  deficiencies  in patients with different histological types of breast tumours, including those with specific mutations and large genomic rearrangements in BRCA1, BRCA2 and other HRR-related genes.

In terms of exposure-efficacy relationship no definitive conclusion can be made due to a limited number of samples.

## 2.3.6. Conclusions on clinical pharmacology

No new biopharmaceutical or clinical pharmacology study were provided to support the proposed indication in BRCAm in patients with HER2-negative metastatic breast cancer which is considered acceptable. Available pharmacology data on olaparib provides sufficient characterisation of the key PK characteristics of olaparib and provides sufficient data in support of an adequate labelling for special populations and DDI.

The germline BRCA1/2 mutation status was centrally confirmed in blood samples in the majority of patients randomised in the pivotal study and exploratory analyses of available tumour samples were conducted. The MAH is recommended to further investigate predictive and prognostic biomarkers.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No dose response study was submitted (see discussion on clinical efficacy).

## 2.4.2. Main study

## Study D0819C00003 (OlympiAD)

A Phase III, open label, randomised, controlled, multi-centre study to assess the efficacy and safety of Olaparib Monotherapy Versus Physician's Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations

## Methods

This was a Phase III, open-label, randomised, controlled, multi-centre study of patients with metastatic breast cancer and gBRCAm, designed to assess the efficacy and safety of single agent olaparib versus standard of care (study physician's choice of capecitabine, vinorelbine or eribulin).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Only required if a patient's gBRCAm status was umknown.

Response Evaluation Criteria in Solid Tumors version i.i.

Figure 3: Study design, study OlympiAD

## Study participants

## Main inclusion criteria

Patients were required to fulfil all of the following criteria to be eligible for inclusion in the study (patients with unknown BRCA mutation status were required to fulfil inclusion criteria 1, 3, 4, 9, 10 and 11 prior to BRCA mutation testing):

1. Patients had to be male or female ≥18 years of age with histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
2.  Documented  mutation  in  BRCA1  or  BRCA2  that  was  predicted  to  be  deleterious  or  suspected deleterious (known or predicted to be detrimental/lead to loss of function. Patients with BRCA1 and/or BRCA2 mutations that were considered to be non-detrimental were not eligible for the study.
3.  Patients  must  have  received  treatment  with  an  anthracycline  (eg,  doxorubicin,  epirubicin)  unless contraindicated and a taxane (eg, paclitaxel, docetaxel) in either a neoadjuvant/adjuvant or metastatic setting.

<div style=\"page-break-after: always\"></div>

4. Patients who had received platinum (cisplatin or carboplatin, either as monotherapy or in combination) for  advanced  breast  cancer  were  eligible  to  enter  the  study  provided  there  had  been  no  evidence  of disease progression during the platinum chemotherapy.

5.  Patients  who  had  received  prior  platinum  based  chemotherapy  were  eligible  if  platinum  was  given either  as  potentially  curative  treatment  for  a  prior  non-breast  cancer  (eg,  ovarian  cancer)  with  no evidence of disease for ≥5 years prior to study entry or as adjuvant/neoadjuvant treatment for breast cancer provided at least 12 months had elapsed between the last dose of platinum-based treatment and randomisation.

6. Patients with ER and/or PgR positive disease were required to have received and progressed on at least 1 endocrine therapy (adjuvant or metastatic), or had disease that the treating physician believed to be inappropriate for endocrine therapy.

7. At least 1 lesion (measurable and/or non-measurable) that could be accurately assessed at baseline by CT (MRI where CT was contraindicated) and was suitable for repeated assessment as per RECIST version 1.1.

8. Patients were required to have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

-Haemoglobin ≥10.0 g/dL with no blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days

-Absolute neutrophil count (ANC) ≥1.5x109/L

-Platelet count ≥100x10 9 /L

-Total bilirubin ≤1.5x institutional upper limit of normal (ULN)

-Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase)/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase) ≤2.5x institutional ULN unless liver metastases are present in which case they must be ≤5xULN

-Serum or plasma creatinine ≤1.5x institutional ULN

9. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 21 days of randomisation.

10. Postmenopausal or hysterectomised; women of childbearing potential were eligible with a negative urine or serum pregnancy test documenting evidence of non-childbearing status

11.  Patient  was  willing  and  able  to  comply  with  the  protocol  for  the  duration  of  the  study,  including undergoing treatment and scheduled visits and examinations

12. Formalin fixed, paraffin embedded tumour sample from the primary tumour if available.

For  inclusion  in  the  optional  exploratory  genetic  research  and/or  the  optional  tumour  biopsy  research, patients were required to fulfil the following criteria:

-Provision of informed consent for genetic research

-Provision of informed consent for tumour biopsy research

## Main exclusion criteria

Any of the following was regarded as a criterion for exclusion from the study (patients with an unknown BRCA mutation status were required to fulfil exclusion criteria 3, 5, 6, 8, 9, 11, 13, 14, 15, 16, 18, and 19 prior to BRCA mutation testing):

<div style=\"page-break-after: always\"></div>

1. BRCA1 and/or BRCA2 mutations that were considered to be non-detrimental (eg, variants of uncertain clinical  significance,  or  variant  of  unknown  significance,  or  variant  favour  polymorphism,  or  benign polymorphism, etc.)

2. Cytotoxic chemotherapy or non-hormonal targeted therapy within 21 days of Cycle 1 Day 1 was not permitted. It was required that endocrine therapy had been discontinued 7 or more days before Cycle 1 Day 1. Palliative radiotherapy was to have been completed 14 or more days before Cycle 1 Day 1. It was permitted that the patient received a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study, as long as these were started at least 5 days prior to study treatment.

3. Patients with HER2-positive disease (3+ by IHC or ISH amplified ≥2.0)

4. Exposure to an investigational product within 30 days or 5 half-lives (whichever was longer) prior to randomisation

5. Any previous treatment with a PARP inhibitor, including olaparib

6.  Patients  with  second  primary  cancer;  exceptions:  adequately  treated  non-melanoma  skin  cancer, curatively  treated  in  situ  cancer  of  the  cervix,  ductal  carcinoma  in  situ,  stage  1  grade  1  endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years prior to study entry.

7. Resting electrocardiogram (ECG) with QT interval corrected for heart rate (QTc) &gt;470 msec detected on  2  or  more  time  points  within  a  24-hour  period,  or  family  history  of  long  QT  syndrome.  If  an  ECG demonstrated QTc &gt;470 msec, a patient would be eligible only if a repeat ECG demonstrated QTc ≤470 msec

8.  Patients  must  not  have  received  more  than  2  prior  lines  of  cytotoxic  chemotherapy  for  metastatic disease. Prior treatments with hormonal therapy and non-hormonal targeted therapy were allowed and not counted as a prior line of cytotoxic chemotherapy. For the purposes of this protocol, the combination of an aromatase inhibitor and everolimus was not considered cytotoxic chemotherapy

9.  Concomitant  use  of  known  potent  cytochrome  P450  (CYP)  3A  inhibitors  such  as  ketoconazole, itraconazole,  ritonavir,  indinavir,  saquinavir,  telithromycin,  clarithromycin  and  nelfinavir.  For  further details refer to CSP Appendix I

10. Persistent toxicities  (≥CTCAE grade 2) caused by previous cancer therapy, excluding alopecia and CTCAE grade 2 peripheral neuropathy

11. Patients with myelodysplastic syndrome (MDS)/treatment-related acute myeloid leukaemia

12. Major surgery within 2 weeks of starting study treatment: patients were to have recovered from any effects of any major surgery

13. Immunocompromised patients, eg, patients who were known to be serologically positive for human immunodeficiency virus

14.  Patients  considered  a  poor  medical  risk  due  to  a  serious,  uncontrolled  medical  disorder,  nonmalignant systemic disease or active, uncontrolled infection. Examples included, but were not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive bilateral lung disease  on  high  resolution  CT  scan  or  any  psychiatric  disorder  that  would  limit  ability  to  comply  with study  procedures  and  any  other  medical  condition  that,  in  the  opinion  of  the  Investigator,  placed  the patient at unacceptable risk of toxicity

15. Patients with a history of treated central nervous system (CNS) metastases were eligible, provided they  met  all  of  the  following  criteria:  disease  outside  the  CNS  was  present;  no  clinical  evidence  of

<div style=\"page-break-after: always\"></div>

progression  since  completion  of  CNS-directed  therapy;  minimum  of  2  weeks  between  completion  of radiotherapy and Cycle 1 Day 1 and recovery from significant (grade ≥3) acute toxicity with no ongoing requirement for &gt;10 mg of prednisone per day or an equivalent dose of other corticosteroid

16. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

17. Pregnant or breast feeding women

18. Previous allogeneic bone marrow transplant

19.  Whole  blood  transfusions  in  the  last  120  days  prior  to  enrolment  into  the  study,  which  had  the potential  to  interfere  with  gBRCA  testing  (packed  red  blood  cells  and  platelet  transfusions  were acceptable: for timing, refer to inclusion criterion number 8).

## Treatments

## Olaparib

The planned dose of 300 mg bd comprised two 150 mg tablets bd. The 100 mg tablets were used to manage dose reductions.

## Chemotherapy

Dosing and treatment regimen information for capecitabine, vinorelbine and eribulin were included in the local package inserts supplied with the drug.

-Oral capecitabine 2500 mg/m 2  to be taken daily (divided in 2 doses) for 14 days, repeated every 21 days

-Intravenous (IV) vinorelbine 30 mg/m 2  on Day 1 and Day 8, repeated every 21 days

-Intravenous eribulin mesylate 1.4 mg/m 2  or eribulin (active substance) 1.23 mg/m 2  on Day 1 and Day 8, repeated every 21 days.

Study centre personnel were instructed to follow the prescribing information for toxicity management and dose  reduction.  Standard  or  reduced  doses  of  capecitabine  could  be  used  after  the  first  cycle  as  per standard clinical practice. No switch to olaparib was permitted in this study.

Other  medication  considered  necessary  for  the  patient's  safety  and  well-being  could  be  given  at  the discretion  of  the  Investigator(s).  The  administration  of  all  medication  (including  study  drugs)  was recorded in the eCRFs until 30 days following the last CSP treatment.

## Objectives

## Primary objective

The  primary  objective  of  the  study  was  to  determine  the  efficacy  of  single  agent  olaparib  versus physician's choice chemotherapy (capecitabine, vinorelbine or eribulin) by progression-free survival (PFS) using blinded independent central review (BICR) data assessed by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).

<div style=\"page-break-after: always\"></div>

## Secondary objectives

1. To compare the efficacy of single agent olaparib versus physician's choice chemotherapy (capecitabine, vinorelbine or eribulin) by assessment of OS, time to second progression or death (PFS2) and ORR using BICR data assessed by RECIST version 1.1.

2.  To  assess  the  effect  of  olaparib  on  the  Health-related  Quality  of  Life  (HRQoL)  as  measured  by  the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module (EORTC QLQ-C30) global quality of life (QoL) scale.

3. To assess the efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant  in  either  of  the  BRCA  genes  using  variants  identified  with  current  and  future  BRCA  mutation assays (gene sequencing and large rearrangement analysis).

4. To determine the exposure to olaparib in patients receiving olaparib monotherapy.

5. To assess the safety and tolerability of single agent olaparib versus physician's choice chemotherapy (capecitabine, vinorelbine or eribulin).

## Exploratory objectives

1.  To  explore  the  impact  of  olaparib  on  symptoms  and  HRQoL  as  measured  by  the  EORTC  QLQ-C30 disease related multi-item symptom and functional scales.

2. To explore patients' treatment satisfaction (as measured by the Satisfaction with Therapy scale of the Cancer  Therapy  Questionnaire  [CTSQ]  and  the  other  subscales  and  items  of  the  CTSQ)  with  olaparib, compared to physician's choice chemotherapy.

3. To investigate the health economic impact of treatment and the disease on hospital related resource use.

4. To explore methods of estimating OS adjusting for the impact of the physician's choice chemotherapy group  receiving  subsequent  PARP  inhibitors  or  imbalances  between  the  treatment  arms  for  other potentially active agents.

5.  To  explore  whether resistance mechanisms to olaparib can be identified through analysis of tumour and blood samples - archival tumour (mandatory if available), blood samples at baseline and on disease progression (mandated) and serial biopsies at baseline and disease progression (optional).

6. To determine the frequency of and describe the nature of BRCA mutation(s) in tumour samples and to compare this with gBRCA mutation status.

7. Future exploratory research into factors that may influence development of cancer and/or response to treatment (where response is defined broadly to include efficacy, tolerability or safety) may be performed on the collected and stored archival tumour samples (mandatory if available), blood samples at baseline and on disease progression (mandated) and serial biopsies at baseline and disease progression (optional).

8. To collect and store DNA according to each country's local and ethical procedures for future exploratory research into genes/genetic variation that may influence response (ie, distribution, safety, tolerability and efficacy) to study treatments and/or susceptibility to disease (optional).

## Outcomes/endpoints

## Primary endpoint

PFS: the time from randomisation until the date of objective radiological disease progression according to RECIST  version  1.1,  or  to  death  (by  any  cause  in  the  absence  of  disease  progression),  regardless  of

<div style=\"page-break-after: always\"></div>

whether  the  patient  withdraws  from  randomised  therapy  or  receives  another  cancer  therapy  prior  to disease progression.

## Secondary endpoints

OS: the time from the date of randomisation until death due to any cause.

PFS2: the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.

ORR: the number of responders (CR or PR) divided by the number of patients in the treatment group in the EFR analysis set (ITT population with measurable disease at baseline).

EORTC  QLQ-C30:  A  30-question  patient  reported  outcome  measure  of  HRQoL  commonly  used  in oncology.

Global QoL scale: A measure of overall health and QoL consisting of 2 items from the QLQ-C30.

TFST and TSST were also analysed as supportive endpoints for PFS and PFS2, respectively:

Time to first subsequent therapy (TFST): the time from randomisation to the earlier of first subsequent cancer therapy start date following study treatment discontinuation or death.

Time to second subsequent therapy (TSST):  the time from randomisation to the earlier of the second subsequent therapy start date following study treatment discontinuation, or death.

## Sample size

The  primary  endpoint  of  the  study  was  PFS.  Approximately  310  patients  were  to  be  randomised.  The study  was  sized  assuming  a  true  treatment  effect  was  a  PFS  HR  of  0.635,  assuming  90%  power  and 2.5% alpha (1-sided), with 2:1 randomisation (olaparib: physician's choice of chemotherapy). Assuming PFS was exponentially distributed, a PFS HR of 0.635 equated to a 2.3-month improvement in median PFS over an assumed 4-month median PFS for the control arm.

Assuming  that  the  study  accrual  period  was  approximately  22  months,  230  progression  events  were anticipated to be observed approximately 27 months after the first patient was randomised in the study. Patients were planned to be followed until the final analysis of PFS2 and OS (when approximately 190 death events occurred). This was anticipated to be 39 months after the first patient was randomised in the study.

## Randomisation

First patient enrolled: 27 March 2014

Data cut-off date: 9 December 2016

Prior to randomisation to olaparib or chemotherapy, the Investigator was required to declare his or her choice  of  chemotherapy  (capecitabine,  vinorelbine,  or  eribulin).  Randomisation  was  performed  via  an interactive voice response system/interactive web response system (IVRS/IWRS) Centralised Randomisation Centre.

Moreover, randomisation was stratified by whether patients:

- had received prior chemotherapy regimens for metastatic breast cancer (yes/no),
- were ER and/or PgR positive versus ER and PgR negative,

<div style=\"page-break-after: always\"></div>

- had prior platinum treatment for breast cancer (yes/no).

## Blinding (masking)

Due to different routes and schedules of administration of the treatment options in the physician's choice of chemotherapy arm as well as their different toxicity profiles, this study could not be blinded. Given the open label design of the study, rigorous methodology was employed to ensure robustness of the primary endpoint assessment, with a primary analysis of radiological PFS based on BICR of all patient screening and on-study scans.

## Statistical methods

In OlympiAD, the primary population defined in the protocol for analysis of all efficacy endpoints included all  randomised  patients  (ie,  the  full  analysis  set  [FAS]).  Thus,  all  primary  and  secondary  efficacy  and HRQoL data were summarised and analysed on an intention to treat (ITT) basis.

In addition, subset analyses to the main analyses of PFS, PFS2, OS, and ORR were performed in those patients whose gBRCAm status was confirmed by the Myriad CDx test.

## Sensitivity analyses

The  sensitivity  analyses  included  assessments  of  possible  evaluation  time  bias  (if  scans  were  not performed at the protocol scheduled time points), attrition bias (the possibility that the rate and nature of censoring  resulted  in  bias),  and  ascertainment  bias  (assessing  discrepancies  between  investigator assessed vs BICR assessment of PFS; hereafter referred to as investigator assessment of PFS).

## Multiplicity adjustments

In an effort to control the type I error at 2.5% (1-sided) for key label claims, a multiple testing procedure (MTP) was employed across primary (PFS) and key secondary (PFS2 and OS) endpoints.

Specifically,  PFS2  was tested only after statistical significance was shown  for PFS. OS was tested only after the null hypotheses were rejected for PFS and PFS2. The MTP was to recycle the test mass to the endpoint not yet rejected in the hierarchy.

Interim analysis of OS was carried out at the time of the primary analysis of PFS, and final OS was tested again when 64% of deaths occurred, given that significant PFS and PFS2 results were observed at the primary analysis.

## Primary analysis of progression-free survival

The primary analysis of PFS was based on the BICR of the radiological scans. A sensitivity analysis of PFS based on Investigator-recorded assessments was also to be carried out. Progression-free survival was to be analysed when approximately 230 progression events had occurred, based on the BICR data. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST version 1.1 assessment.

Progression-free survival was analysed using a log-rank test stratified by whether a patient had received prior  chemotherapy regimens for metastatic breast cancer (yes/no), ER and/or PgR positive versus ER and PgR negative, and prior platinum for breast cancer (yes/no), for generation of the p-value and using the Breslow approach for handling ties.

Although it was expected that there would be enough PFS events in each strata to allow a meaningful analysis, if a stratum for either treatment arm contains less than 5 events, then a pooling strategy had to

<div style=\"page-break-after: always\"></div>

be employed to remove one or more stratification factors from the primary analysis. Stratification factors were  to  be  removed  in  the  following  order  until  were  at  least  5  events  in  each  stratum  for  either treatment  arm:  prior  platinum  for  breast  cancer  (yes/no),  ER  and/or  PgR  positive  versus  ER  and  PgR negative, prior chemotherapy regimens for metastatic breast cancer (yes/no).

The HR (olaparib versus chemotherapy), 95% CI and p-value were to be presented (an HR of less than 1 favoured olaparib). A Kaplan-Meier plot of PFS was to be presented by treatment arm. Summaries of the number and percentage of patients experiencing a PFS event and the type of event (RECIST or death) were to be provided along with median PFS for each treatment arm. The assumption of proportionality was  assessed.  Proportionality  was  to  be  tested  firstly  by  producing  plots  of  complementary  log-log (survival  function)  versus  log  (time)  and  if  these  raised  concerns,  a  Cox  proportional  hazards  model including  a  time-dependent  covariate  would  be  fitted  to  assess  the  extent  to  which  this  represents random variation.

The estimated PFS rates at 6 months and 12 months were to be summarised (using the Kaplan-Meier curve) and presented by treatment arm.

## Patient reported outcome (PRO)

PRO endpoints in this open-label trial were not included in the multiplicity adjustment hierarchy so there is no hypothesis specified.

The  primary  assessment  of  HRQoL  focused  on  comparing  mean  changes  from  baseline  in  the  global quality of life (QoL) score (EORTC QLQ-C30) between the treatment arms in the FAS (ITT) set.  A visit response of deterioration was defined as a decrease of 10 points or more from baseline, or where the patient was too heavily affected by symptoms of the disease under investigation to complete the HRQoL at the visit. Data were descriptive and plots were used to visualise the adjusted mean global QoL/health status  score  over  time  for  each  treatment  arm.    95%  CI  and  p-value  were  presented  for  the  overall adjusted mean estimate.

A supportive analysis of time to deterioration of HRQoL was also performed, using the same methodology and model as for the analysis of the primary endpoint (PFS) A Kaplan-Meier plot of time to deterioration of HRQoL and a summary of median time to deterioration of HRQoL were presented by treatment arm.

To support the primary assessment of HRQoL other items of interest, data from the CTSQ-16 scores of treatment satisfaction (as measured by the 'Satisfaction with Therapy' scale and the other sub-scales and items of the CTSQ-16) and well as overall compliance rate were summarised.

For  each  subscale,  if  less  than  50%  of  the  subscale  items  were  missing,  then  the  subscale  score  was divided by the number of non-missing items and multiplied by the total number of items on the subscales (Fayers et al 1999). If at least 50% of the items were missing, then that subscale was treated as missing. Missing  single  items  were  treated  as  missing.  If  there  was  evidence  that  the  missing  data  were systematic, missing values were handled to ensure that any possible bias was minimised.

## Results

## Participant flow

This study included a 2-part screening. In Part 1, 1918 patients with unknown BRCA status were screened using the Myriad test to determine their BRCA status prior to enrolment. In Part 2, all other patients who had known BRCA status underwent a confirmatory test post-randomisation.

<div style=\"page-break-after: always\"></div>

At the time of DCO for the primary analysis (9 December 2016), 36 (17.6%) and 3 (3.3%) patients in the olaparib  arm  and  physician's  choice  of  chemotherapy  arm,  respectively,  were  still  receiving  study treatment.

In the FAS, the majority of patients who discontinued study treatment did so due to disease progression. A small proportion of patients discontinued treatment due to an AE (4.9% on the olaparib arm versus 7.7% on the physician's choice of chemotherapy arm).

Table 6: Patient disposition (all patients) (DCO 9 December 2016)

|                                                                        | Number(%o)ofpatients   | Number(%o)ofpatients            | Number(%o)ofpatients   |
|------------------------------------------------------------------------|------------------------|---------------------------------|------------------------|
|                                                                        | Olaparib 300 mg bd     | Physician's choice chemotherapy | Total                  |
| Patientsenrolleda                                                      |                        |                                 | 344                    |
| Patientsrandomised                                                     | 205 (100)              | 97 (100)                        | 302 (100)              |
| Patients who were not randomisedb                                      |                        |                                 | 42                     |
| Patient decision                                                       |                        |                                 | 2 (4.8)                |
| Eligibility criterianotfulfilled                                       |                        |                                 | 38 (90.5)              |
| Other                                                                  |                        |                                 | 2 (4.8)                |
| Full analysis sete                                                     | 205 (100)              | 97 (100)                        | 302 (100)              |
| Patientswhoreceivedstudytreatnent                                      | 205 (100)              | 91 (93.8)                       | 296 (98.0)             |
| Numberwhoreceived olaparib (AZD2281)                                   | 205 (100)              | 0                               | 205 (67.9)             |
| Number who received capecitabine                                       | 0                      | 41 (42.3)                       | 41 (13.6)              |
| Numberwhoreceivedvinorelbine                                           | 0                      | 16 (16.5)                       | 16 (5.3)               |
| Number whoreceived eribulin                                            | 0                      | 34 (35.1)                       | 34 (11.3)              |
| Patientswhodidnotreceivestudytreatnent                                 | 0                      | 6 (6.2)                         | 6 (2.0)                |
| Patients ongoing study treatnent at data cut-offd                      | 36 (17.6)              | 3 (3.3)                         | 39 (13.2)              |
|                                                                        | 169 (82.4)             | 88 (96.7)                       | 257 (86.8)             |
| Patient decision                                                       | 7 (3.4)                | (6:6) 6                         | 16 (5.4)               |
| Adverse event                                                          | 10 (4.9)               | 6 (6.6)                         | 16 (5.4)               |
| Objective disease progression                                          | 149 (72.7)             | 68 (74.7)                       | 217 (73.3)             |
| Other                                                                  | 3 (1.5)                | 5 (5.5)                         | 8 (2.7)                |
| Patients continuing study off treatment at data cut-off.               | 68 (33.2)              | 41 (42.3)                       | 109 (36.1)             |
| Patients who prematurely withdrew from the study before data cut-off.e | 101 (49.3)             | 53 (54.6)                       | 154 (51.0)             |
| Patient decision                                                       | 5 (2.4)                | 7 (7.2)                         | 12 (4.0)               |
| Death                                                                  | 94 (45.9)              | 46 (47.4)                       | 140 (46.4)             |
| Patient lost to follow-up                                              | 1 (0.5)                | 0                               | 1 (0.3)                |
| Other                                                                  | 1 (0.5)                | 0                               | 1 (0.3)                |

b Percentages for reasons patients were not randomised are calculated from the number of patients who were not randomised.

Main infomed consentreceived.

Percentages were calculated from number of patients randomised.

Mayhave includedpatientswhoneverreceived study treatment.

Percentages were calculated from number of patients who received treatment.

Included patients who withdrew consent from the study as well as patients who stopped study treatment but continued to be followed for progression and overall survival.

hd tuice dailv

<div style=\"page-break-after: always\"></div>

Figure  4:  Patient  disposition  at  data  cut-off  for  final  OS  analysis  (all  patients)  (DCO  25 September 2017)

<!-- image -->

## Recruitment

The study was open for enrolment at 206 study centres in 19 countries: Bulgaria (8 centres), China (15 centres), Czech Republic (3 centres), France (5 centres), Hungary (7 centres), Italy (7 centres), Japan (9 centres), South Korea (8 centres), Mexico (7 centres), Peru (8 centres), Poland (10 centres), Romania (6 centres), Russia (12 centres), Spain (10 centres), Switzerland (3 centres), Taiwan (6 centres), Turkey (11 centres), United Kingdom (7 centres), United States (64 centres).

The first patient was enrolled into the study on 27 March 2014 and the last patient was enrolled into the study on 30 October 2015.

## Conduct of the study

## Protocol amendments

The original CSP was dated 8 November 2013. Important amendments to the original CSP, including their effective date with respect to patient recruitment, are shown in Table 3 with other significant changes to study conduct.

<div style=\"page-break-after: always\"></div>

Table 7: Protocol amendments and other significant changes to study conduct

| Number (date of internal approval)                     | Key details of amendment (Section of this report affected)                                                                                                                                     | Reason for amendment                                                                                                                                                                                                                                                                                           |
|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendments made after the start of patient recruitment | Amendments made after the start of patient recruitment                                                                                                                                         | Amendments made after the start of patient recruitment                                                                                                                                                                                                                                                         |
| Protocol .Amendmenr I:Substawtive changes              | Protocol .Amendmenr I:Substawtive changes                                                                                                                                                      | Protocol .Amendmenr I:Substawtive changes                                                                                                                                                                                                                                                                      |
| Amendment 1 (12 August 2014)                           | Text descnbing patient survival procedures was revised (Section 5.1; Table 2).                                                                                                                 | To specify time points when patients should be contacted for survival data.                                                                                                                                                                                                                                    |
|                                                        | Text was revised to update the number of PFS events required for the interim and final analyses (Section 5.1)                                                                                  | To update the number of progression events that will define the timing of PFS analyses.                                                                                                                                                                                                                        |
|                                                        | Family history of cancer added to the study schedule (Table 2).                                                                                                                                | To collect data to potentially infom and refine future recommendations for tailoring genetic testing.                                                                                                                                                                                                          |
|                                                        | Revision of inclusion cnitenion mumber 10 to specify the requirenent for serum or plasma creatinine (Section 5.3.1).                                                                           | Extension of creatinine analysis and to meet loeal laboratories* routine requirements.                                                                                                                                                                                                                         |
|                                                        | Secondary objective number 4 was added, to include the exposure lo olapanib in patients receiving ohpanb monotherapy (Section 4.2).                                                            | Collection of PK samples to allow concentration-effect modelling.                                                                                                                                                                                                                                              |
|                                                        | Text added to descnibe collection of PK samples (Section 5.1; Table 2; Section 5.3).                                                                                                           | Collection of PK samples to allow concentration-effect modelling.                                                                                                                                                                                                                                              |
|                                                        | Text was added to include PK blood sampling collection procedures (Section 5.5.4).                                                                                                             | Collection of PK samples to allow concentration-effect modelling.                                                                                                                                                                                                                                              |
|                                                        | Text added to clarify analysis of plasma concentration-time data (Section 5.7.4.6).                                                                                                            | Collection of PK samples to allow concentration-effect modelling.                                                                                                                                                                                                                                              |
|                                                        | The number ofrequired progression events Was updaied and clanification of the timings of the interim and final analyses of OS and PFS2 was made (Section 5.7.3: Section 5.7.7; Section 5.7.8). | To update the number of progression events required to have 90% power to detect a                                                                                                                                                                                                                              |
|                                                        | Text was revised to allow repeat olipanb intemuptions and dose reductions under certain conditions.                                                                                            | Clarifieation of dose management.                                                                                                                                                                                                                                                                              |
|                                                        | The definition of best overall RECIST response Was revised (Section 5.7.3; Section 5.7.4.3)                                                                                                    | Clarifieation that RECIST responses that occured on subsequent cancer therapy should be excluded from the derivation of best overall response.                                                                                                                                                                 |
|                                                        | Text desenbing multiplicity strategy for primary and key secondary endpoints was revised.                                                                                                      | To clarify the multiple testing procedure and to allow for the inclusion of an interim PFS analysis. To specify the significance levels to test PFS, PFS2 and OS against at the intenm and final PFS analysis time points to ensure that the overall type I error was controlled at a 2.59%6 1-sided level.    |
|                                                        | Revision of text descnibing analysis of the primary endpoint (Section 5.7.3).                                                                                                                  | To update the number of progression events that defined the timing of the PFS amalyses.                                                                                                                                                                                                                        |
|                                                        | Revision of text describing analysis of the PFS2 endpoint (Section 5.7.4.1).                                                                                                                   | To specify that PFS2 would be analysed at both interim and final PFS analysis time points, to give fiurther detail regarding the presentation of PFS2 data and to refer to the supportive endpoint by its recognised name, TSST.                                                                               |
|                                                        | Revision of text deseribing analysis of the OS endpoint                                                                                                                                        | stseuestd reuy pue u oqre psfeueaq pomsoeoads o points.                                                                                                                                                                                                                                                        |
|                                                        | Text desenbing interim analysis methods Was revised                                                                                                                                            | An interim amnlysis with low p-alue allocationWas added to allow an earlier temmination of the study in case the treatment differential was much larger than anticipated. An Independent Data Monitoring Committee was set to perform this analysis and to momitor safety and emicacy data on a regular basis. |
|                                                        | Text descnbing the detemination of sample size was revised (Section 5.7.7).                                                                                                                    | To update the number of progression events required to have 90% power to detect a PFS amalysis.                                                                                                                                                                                                                |
|                                                        | Text describing the role of the Independent Data Monitoring Commilfee was revised (Section 5.7.9)                                                                                              | An Independent Data Monitoring Conumitiee was to perfom the interim analysis and to monitor safety and efficacy data on a regular basis.                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| ProtocolAmendment 2:Substantivechanges   | ProtocolAmendment 2:Substantivechanges                                                                                                                       |                                                                                                                                                                                                                                                                                                       |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 2 (21 August 2015)             | Theplannedinterimanalysiswasremovedfromthestudy (Section 5.7.8).                                                                                             | Interim analysis was not to be performed in recognition of the regulatory landscape, to ensurerobust event rates and addressissueswith crossover (tooff-label drugin light of commercial availability of olaparib) which would dilute a potential effect on the secondary endpoints, particularly OS. |
|                                          | Textdescribingthemanagementofolaparibtoxicitywas revised.                                                                                                    | Revised guidelines for the management of olaparib toxicity.                                                                                                                                                                                                                                           |
|                                          | Text describing the management of haematological toxicity was revised.                                                                                       | Revisedguidelinesforthemanagementofhaematologicaltoxicity and anaemia.                                                                                                                                                                                                                                |
|                                          | Text describing reasons for study withdrawal was revised (Section 5.3.4.2).                                                                                  | Added a Sponsor decision as a reason for patient withdrawal from the study.                                                                                                                                                                                                                           |
|                                          | Text describing patient survival procedures was revised.                                                                                                     | Removedinterim analysisandadded awindowforsurvivalcontact.                                                                                                                                                                                                                                            |
|                                          | Text was revised to include the evaluable for response (EFR) analysis set (Section 5.7.2.3).                                                                 | To define an additional analysis set used for the objective response rate, in line with the SAP.                                                                                                                                                                                                      |
|                                          | Formalstatisticalanalysestobeconducted andpre-planned sensitivity analyses, was revised to include QoL assessments (Section 5.7.4.5).                        | To specify that QoL data were to be formally analysed.                                                                                                                                                                                                                                                |
|                                          | Text describing the multiplicity strategy for primary and key secondary endpoints was revised.                                                               | Toremove theindicationsof theinterim analysisfromtheprotocol text and touse O'Brien-Fleming boundaries to preserve the type I error.                                                                                                                                                                  |
|                                          | Text describing analysis of the primary endpoint was revised toinclude status of progressive disease at time of randomisation as a subgroup (Section 5.7.3). | To specify an additional subgroup analysis.                                                                                                                                                                                                                                                           |
| ProtocolAmendment3:Substantivechanges    | ProtocolAmendment3:Substantivechanges                                                                                                                        | ProtocolAmendment3:Substantivechanges                                                                                                                                                                                                                                                                 |
| Amendment3 (10 September 2015)           | Text describing the analysis of PFS was revised to remove the first analysis of PFS (Section 5.7.3).                                                         | To specify that PFS would only be analysed when approximately 230 progression eventshadoccurred                                                                                                                                                                                                       |

All protocol amendments were approved by AstraZeneca before being submitted to a regulatory authority and/or an Institutional Review Board/Independent ethics committee.

Abbreviations:AE,adverse event;BRCA,breast cancer susceptibility gene;CYP3A,cytochrome P4503A;ECG,electrocardiogram;eCRF,electronic case report form; OS, overall survival; PFS, progression free survival; PFS2, time from randomisation to second progression or death; PK, pharmacokinetic; PRO, patient reported outcomes; QoL,quality oflife;RECIST,ResponseEvaluation Criteria inSolidTumors version1.1;SAP,statistical analysis plan;SPC,SummaryofProduct Characteristics;TSST,time to start of second subsequent cancer therapy or death.

<div style=\"page-break-after: always\"></div>

## Changes to planned analyses

Table 8: Changes to planned analysis

| Key details of change (section of this report affected)                                                                                                                                                       | Reason for change                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Additional summaries of duration of response, time to onset of response and disease control rate were added. (see CSP Sections 11.1.2.3 and 12.2.3.3 and SAP Section 6)                                       | To support the analysis                                                                                          |
| An additional supportive analysis of time to HRQoL deterioration was added.                                                                                                                                   | To provide details and analyses of the PRO endpoints                                                             |
| The formula for calculating the log-rank statistic was corrected to the formula for the stratified log-rank statistic. (see CSP Section 12.2.2 and SAP Section 6)                                             | To update the formula to be appropriate for the primary analysis                                                 |
| A novel mutation subgroup analysis was added. (see CSP Section 12.2.2 and SAP Section 6)                                                                                                                      | To support the PMA submission                                                                                    |
| The model used to analyse change from baseline in HRQoL score was updated to include an interaction term for baseline global QoL score and visit. (see CSP Section 12.2.3.4 and SAP Section 6)                | To have a data cut-off at a point when most of the patients had discontinued and no longer had HRQoL assessments |
| An additional category ‘no evidence of disease' was added for best objective response in case of any BICR reviewers concluding no disease at baseline. (CSP Sections 11.1.2.3 and 12.2.3.3 and SAP Section 6) | To provide a category for BICR reviewers concluding no disease at baseline                                       |
| Potential exploratory analyses of Os to adjust for the impact of receiving a subsequent PARP inhibitor were extended to PFS2. (CSP Section 12.2.4 and SAP Section 6)                                          | To further understand the potential impact of receiving a subsequent PARP inhibitor                              |

Abbreviations: CSP, clinical study protocol; HRQoL, health-related quality of life; PMA, pre-marketing approval; QoL, quality of life; SAP, statistical analysis plan.

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Overall, the proportion of patients with at least 1 important protocol deviation was 4.0%, and balanced between the treatment arms: 3.9% on olaparib and 4.1% on physician's choice of chemotherapy. In total, 14 important protocol deviations were reported (9 and 5 in the olaparib arm and physician's choice of chemotherapy arm, respectively). The most common important deviation observed in both treatment arms was exclusion criteria met: 5 patients (2.4%) in the olaparib arm and 4 (4.1%) in the physician's choice of chemotherapy arm.

Table 9: Important protocol deviations (FAS)

|                                                                                                                                                                                                                              | Number (%6) of patients    | Number (%6) of patients                | Number (%6) of patients   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------------------|---------------------------|
| Importantprotocol deviation                                                                                                                                                                                                  | Olaparib 300 mg bd (N=205) | Physician's choiee chemotherapy (N=97) | (N=302)                   |
| Number of patients with at least 1 important deviation                                                                                                                                                                       | 8 (3.9)                    | 4 (4.1)                                | 12 (4.0)                  |
| Exclusion criteria met: Cytotoxic chemotherapy. non-hormonal targeted or endocrine therapy. palliative radiotherapy. bisphosphonates or denosumab for bone metastases within a disallowed time from start of study treatment | 5 (2.4)                    | 4 (4.1)                                | 9 (3.0)                   |
| Inclusion criteria not met: Patients must have nomal organ and bone marrow function measured  2 (1.0) within 28 days of randomisation                                                                                        |                            | 0                                      | 2 (0.7)                   |
| Inclusion critenia not met: Patients must have received treatment with an anthracyeline (eg. doxonubicin, epinubicin) and a taxane (eg. paclitaxel, docetaxel) in either a neoadjuvant/adjuvant or metastatic setting        | 1 (0.5)                    | 0                                      | 1 (0.3)                   |
| Inclusion criteria not met: Patients who received platinum (cisplatin or carboplatin) for advanced breast cancer are eligible if there was no evidence of disease progression during the platinum chemotherapy               |                            | 1 (1.0)                                | 1 (0.3)                   |
| Patients must not receive any other concurrent anti- cancer therapy, including investigational agents, while on study treatment                                                                                              | 1 (0.5)                    | 0                                      | 1 (0.3)                   |

Note: The same patient may have had more than 1 inportant protocol deviation.

Important deviations before the start of treatment and during treatment.

bd, twice daily: N, mumber of patients.

None of the important protocol deviations were considered to have the potential to influence the overall study conclusions in a relevant way. The study conclusions are considered robust and representative of the overall study data.

## Baseline data

The demographic and key baseline characteristics of study patients are summarised below.

<div style=\"page-break-after: always\"></div>

Table 10: OlympiAD: Summary of selected demographic and patient characteristics at baseline (FAS and Myriad CDx gBRCAm subgroup)

|                                | FAS                        | FAS                         | Myriad CDx gBRCAm          | Myriad CDx gBRCAm           |
|--------------------------------|----------------------------|-----------------------------|----------------------------|-----------------------------|
|                                | Olaparib 300 mg bd (n=205) | Physician's choice a (n=97) | Olaparib 300 mg bd (n=202) | Physician's choice a (n=95) |
| Demographics                   |                            |                             |                            |                             |
| Age (years)                    |                            |                             |                            |                             |
| Mean (SD)                      | 45.0 (10.9)                | 45.9 (10.3)                 | 45.2 (10.9)                | 46.0 (10.4)                 |
| Median (range)                 | 44.0 (22 - 76)             | 45.0 (24 - 68)              | 44.0 (22 - 76)             | 45.0 (24 - 68)              |
| Age arm (years), n (%)         |                            |                             |                            |                             |
| <50                            | 138 (67.3)                 | 63 (64.9)                   | 136 (67.3)                 | 62 (65.3)                   |
| ≥50 to <65                     | 56 (27.3)                  | 30 (30.9)                   | 55 (27.2)                  | 29 (30.5)                   |
| ≥65                            | 11 (5.4)                   | 4 (4.1)                     | 11 (5.4)                   | 4 (4.2)                     |
| Sex, n (%)                     |                            |                             |                            |                             |
| Female                         | 200 (97.6)                 | 95 (97.9)                   | 197 (97.5)                 | 93 (97.9)                   |
| Male                           | 5 (2.4)                    | 2 (2.1)                     | 5 (2.5)                    | 2 (2.1)                     |
| Race, n (%)                    |                            |                             |                            |                             |
| White                          | 134 (65.4)                 | 63 (64.9)                   | 132 (65.3)                 | 61 (64.2)                   |
| Asian                          | 66 (32.2)                  | 28 (28.9)                   | 65 (32.2)                  | 28 (29.5)                   |
| Black/African American         | 1 (0.5)                    | 4 (4.1)                     | 1 (0.5)                    | 4 (4.2)                     |
| Other                          | 4 (2.0)                    | 2 (2.1)                     | 4 (2.0)                    | 2 (2.1)                     |
| Ethnicity, n (%)               |                            |                             |                            |                             |
| Hispanic or Latino             | 11 (5.4)                   | 6 (6.2)                     | 11 (5.4)                   | 6 (6.3)                     |
| Not Hispanic or Latino         | 194 (94.6)                 | 91 (93.8)                   | 191 (94.6)                 | 89 (93.7)                   |
| Disease characteristics        |                            |                             |                            |                             |
| ECOG performance status, n (%) |                            |                             |                            |                             |
| (0) Normal activity            | 148 (72.2)                 | 62 (63.9)                   | 146 (72.3)                 | 60 (63.2)                   |
| (1) Restricted activity        | 57 (27.8)                  | 35 (36.1)                   | 56 (27.7)                  | 35 (36.8)                   |
| Myriad germline BRCA status    |                            |                             |                            |                             |
| BRCA1                          | 114 (55.6)                 | 50 (51.5)                   | 114 (56.4)                 | 50 (52.6)                   |
| BRCA2                          | 84 (41.0)                  | 45 (46.4)                   | 84 (41.6)                  | 45 (47.4)                   |
| BRCA1 and BRCA2                | 4 (2.0)                    | 0                           | 4 (2.0)                    | 0                           |
| Missing b                      | 3 (1.5)                    | 2 (2.1)                     | NA                         | NA                          |
| Tumour characteristics         |                            |                             |                            |                             |
| Tumour grade at diagnosis      |                            |                             |                            |                             |
| Well Differentiated (G1)       | 5 (2.4)                    | 2 (2.1)                     | 5 (2.5)                    | 2 (2.1)                     |
| Moderately Differentiated (G2) | 52 (25.4)                  | 23 (23.7)                   | 52 (25.7)                  | 22 (23.2)                   |
| Poorly Differentiated (G3)     | 108 (52.7)                 | 55 (56.7)                   | 106 (52.5)                 | 54 (56.8)                   |
| Undifferentiated (G4)          | 4 (2.0)                    | 0                           | 4 (2.0)                    | 0                           |
| Unassessable (GX)              | 27 (13.2)                  | 15 (15.5)                   | 26 (12.9)                  | 15 (15.8)                   |
| Missing                        | 9 (4.4)                    | 2 (2.1)                     | 9 (4.5)                    | 2 (2.1)                     |

<div style=\"page-break-after: always\"></div>

|                                                                             | FAS                        | FAS                         | Myriad CDx gBRCAm          | Myriad CDx gBRCAm           |
|-----------------------------------------------------------------------------|----------------------------|-----------------------------|----------------------------|-----------------------------|
|                                                                             | Olaparib 300 mg bd (n=205) | Physician's choice a (n=97) | Olaparib 300 mg bd (n=202) | Physician's choice a (n=95) |
| At the time of randomisation, was the patient's breast cancer progressing?  |                            |                             |                            |                             |
| Yes                                                                         | 159 (77.6)                 | 73 (75.3)                   | 157 (77.7)                 | 71 (74.7)                   |
| Overall disease classification                                              |                            |                             |                            |                             |
| Locally advanced                                                            | 0                          | 0                           | 0                          | 0                           |
| Metastatic                                                                  | 205 (100)                  | 97 (100)                    | 205 (100)                  | 97 (100)                    |
| De Novo Metastatic Disease c                                                |                            |                             |                            |                             |
| Yes                                                                         | 26 (12.7)                  | 12 (12.4)                   | NC                         | NC                          |
| Prior endocrine therapy                                                     |                            |                             |                            |                             |
| For metastatic disease                                                      | 68 (33.2)                  | 30 (30.9)                   | NC                         | NC                          |
| For localised disease (adjuvant and/or neoadjuvant)                         | 80 (39.0)                  | 36 (37.1)                   | NC                         | NC                          |
| Stratification factors (IVRS data)                                          |                            |                             |                            |                             |
| Received prior chemotherapy regimens for metastatic breast cancer d , n (%) |                            |                             |                            |                             |
| No                                                                          | 59 (28.8)                  | 28 (28.9)                   | NC                         | NC                          |
| Yes                                                                         | 146 (71.2)                 | 69 (71.1)                   | NC                         | NC                          |
| ER and PgR status e , n (%)                                                 |                            |                             |                            |                             |
| ER and/or PgR positive                                                      | 103 (50.2)                 | 49 (50.5)                   | 103 (51.0)                 | 48 (50.5)                   |
| ER and PgR negative                                                         | 102 (49.8)                 | 48 (49.5)                   | 99 (49.0)                  | 47 (49.5)                   |
| Prior use of platinum for breast cancer, n (%) f                            |                            |                             |                            |                             |
| Yes                                                                         | 60 (29.3)                  | 26 (26.8)                   | NC                         | NC                          |

a Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine.

b Patients with Missing status were not confirmed as gBRCAm using the Myriad CDx gBRCA test. Within the olaparib arm all 3 cases were determined as BRCA1 by local or CLIA testing and within the physician's choice of chemotherapy arm 1 patient was BRCA1 and 1 patient was BRCA2 .

c Metastatic disease at time of initial diagnosis of breast cancer.

d According to the electronic case report form data, 68 patients in the olaparib arm and 31 patients in the physician's choice of chemotherapy arm had not received prior chemotherapy regimens for metastatic breast cancer.

e According to the electronic case report form data, 102 patients in the olaparib arm and 47 patients in the physician's choice of chemotherapy arm were ER and/or PgR positive.  Patient E2806008 did not have PgR status assessed but was stratified to the ER negative and PgR negative subgroup for randomisation.  The patient was excluded from summaries of eCRF data.

f According to the electronic case report form data, 55 patients in the olaparib arm and 21 patients in the physician's choice of chemotherapy arm had prior use of platinum for breast cancer.

bd  Twice daily; BRCA Breast cancer susceptibility gene; CDx  Companion diagnostic; CLIA  Clinical laboratory improvement amendments; ECOG  Eastern cooperative oncology arm; eCRF  electronic case report form; ER  Estrogen receptor; FAS  Full analysis set; gBRCA Germline BRCA ; IVRS  Interactive Voice Response System; NA  Not applicable; NC  Not calculated; PgR  Progesterone receptor; SD  Standard deviation.

Source: Table 11.1.4, Table 11.1.4m, Table 11.1.6, Table 11.1.8, Table 11.1.8m, Table 11.1.10.2, Table 11.1.10.4, Table 11.1.10.4m, and Table 11.1.11, OlympiAD CSR, Module 5.3.5.1.

<div style=\"page-break-after: always\"></div>

## Previous disease-related treatment modalities

Table 11: Previous disease-related treatment modalities (FAS)

|                    |                         |                                  | Number (%) of patients     | Number (%) of patients   | Number (%) of patients   |
|--------------------|-------------------------|----------------------------------|----------------------------|--------------------------|--------------------------|
|                    | Previous Regimen Number | Previous treatment modalities    | 0laparib 300 mg bd (N=205) | Chemotherapy (N=97)      | Total (N=302)            |
| Metastatic Disease | Any                     |                                  | 153 (74.6)                 | 68 (70.1)                | 221 (73.2)               |
|                    |                         | Anthracyclines                   | 41 (20.0)                  | 16 (16.5)                | 57 (18.9)                |
|                    |                         | Taxanes                          | 107 (52.2)                 | 41 (42.3)                | 148 (49.0)               |
|                    |                         | Platinum containing chemotherapy | 43 (21.0)                  | 14 (14.4)                | 57 (18.9)                |
|                    |                         | Other cytotoxic chemotherapy     | 94 (45.9)                  | 43 (44.3)                | 137 (45.4)               |
|                    |                         | Bevacizumab or everolimus        | 31 (15.1)                  | 6 (9.3)                  | 40 (13.2)                |
|                    |                         | Endocrine therapy                | 68 (33.2)                  | 30 (30.9)                | 98 (32.5)                |
|                    |                         | Other systemic therapies         | 6 (2.9)                    | (6.2)                    | 12 (4.0)                 |
|                    | 1st [a]                 | Anthracyclines                   | 36 (17.6)                  | 15 (15.5)                | 51 (16.9)                |
|                    |                         | Taxanes                          | 90 (43.9)                  | 32 (33.0)                | 122 (40.4)               |
|                    |                         | Platinum containing chemotherapy | 31 (15.1)                  | 11 (11.3)                | 42 (13.9)                |
|                    |                         | Other cytotoxic                  | 76 (37.1)                  | 39 (40.2)                | 115 (38.1)               |

chemotherapy

Patients may appear under more than one previous treatment modality.

Patients who received disease related previous therapy will be counted at least once under the category of Any and

[al Only cytotoxic chemotherapies are summarised under an individual regimen number.

at least once under the relevant regimen number.

Datacut-off:09DEc2016

|                                                 |                         |                                  | Number(%)of patients       | Number(%)of patients   | Number(%)of patients   |
|-------------------------------------------------|-------------------------|----------------------------------|----------------------------|------------------------|------------------------|
|                                                 | Previous Regimen Number | Previous treatment modalities    | 0laparib 300 mg bd (N=205) | Chemotherapy (N=97)    | Total (N=302)          |
|                                                 | 2nd [a]                 | Anthracyclines                   | 7(3.4)                     | 1 (1.0)                | 8(2.6)                 |
|                                                 |                         | Taxanes                          | 24 (11.7)                  | 11 (11.3)              | 35 (11.6)              |
|                                                 |                         | Platinum containing chemotherapy | 16 (7.8)                   | 4 (4.1)                | 20 (6.6)               |
|                                                 |                         | Other cytotoxic chemotherapy     | 36 (17.6)                  | 13 (13.4)              | 49 (16.2)              |
| Localized Disease (adjuvant and/or neoadjuvant) | Any                     |                                  | 180 (87.8)                 | 80 (82.5)              | 260 (86.1)             |
|                                                 |                         | Anthracyclines                   | 169 (82.4)                 | 76 (78.4)              | 245 (81.1)             |
|                                                 |                         | Taxanes                          | 146 (71.2)                 | 66 (68.0)              | 212 (70.2)             |
|                                                 |                         | Platinum containing chemotherapy | 15 (7.3)                   | 7 (7.2)                | 22(7.3)                |
|                                                 |                         | Other cytotoxic chemotherapy     | 156 (76.1)                 | 73 (75.3)              | 229 (75.8)             |
|                                                 |                         | Bevacizumab or everolimus        | (0.5)                      | 2 (2.1)                | 3 3(1.0)               |
|                                                 |                         | Endocrine therapy                | 80 (39.0)                  | 36 (37.1)              | 116 (38.4)             |
|                                                 |                         | Other systemic                   | 3 (1.5)                    | 1 (1.0)                | 4 (1.3)                |

therapies

Patients may appear under more than one previous treatment modality.

Patients who received disease related previous therapy will be counted at least once under the category of Any and at least once under the relevant regimen number.

[al only cytotoxic chemotherapies are summarised under an individual regimen number.

Data cut-off:09DEC2016

<div style=\"page-break-after: always\"></div>

## Prior endocrine therapy in patients with HR+ breast cancer

Table 12: OlympiAD: Prior endocrine therapy in patients with HR+ breast cancer (FAS)

|                                                                          | Olaparib 300 mg bd N=205   | Physician's choice of chemotherapy N=97   |
|--------------------------------------------------------------------------|----------------------------|-------------------------------------------|
| Patients who were HR+, n (%)                                             | 103 (50.2)                 | 49 (50.5)                                 |
| Patients who received endocrine therapy in the adjuvant setting, n (%)   | 71 (68.9 a )               | 36 (73.5 a )                              |
| Patients who received endocrine therapy in the metastatic setting, n (%) | 66 (64.1 a )               | 28 (57.1 a )                              |

Percentage value based on the number of patients who were hormone receptor positive.

bd  Twice daily; HR+  Hormone receptor positive

Note: Patient numbers are not mutually exclusive, and patient could have received prior endocrine treatment in both the adjuvant and metastatic settings.

Six (5.8%) patients in olaparib arm and 4 (8.2%) in chemotherapy arm did not receive prior endocrine therapy while they were HR+. Among these patients, 4 were mis-stratified as HR+ instead of TNBC, 5 were considered to have a disease inappropriate for endocrine therapy by the investigator (not specified for 1 patient, progressive breast cancer during the neoadjuvant therapy for 1 patient, low HR expression for 2 patients, luminal B for 1 patient), 1 were not justified.

## Previous disease-related cytotoxic chemotherapy

The  taxanes  (docetaxel  and  paclitaxel)  were  the  most  commonly  used  followed  by  capecitabine  or gemcitabine for metastatic disease. Regarding prior platinum therapy, 43 (21.0%) patients in the olaparib arm and 14 (14.4%) in the physician's choice of chemotherapy arm had received platinum for metastatic disease; 15 (7.3%) patients in the olaparib arm and 7 (7.2%) in the physician's choice of chemotherapy arm had received platinum for localised disease. The median number of regimens of previous diseaserelated chemotherapy at baseline was 1.0 in both treatment arms. The number of regimens of previous disease-related chemotherapy at baseline (FAS) is summarized Table 13.

Table 13: Number of regimens of previous disease-related chemotherapy at baseline (FAS)

|                    | Number (9b) of patients    | Number (9b) of patients                | Number (9b) of patients   |
|--------------------|----------------------------|----------------------------------------|---------------------------|
| Number of regimens | Olaparib 300 mg bd (N=205) | Physician's choice chemotherapy (L6-ND | Total (N=302)             |
| 0                  | 68 (33.2)                  | 31 (32.0)                              | 99 (32.8)                 |
|                    | 80 (39.0)                  | 42 (43.3)                              | 122 (40.4)                |
| 2                  | 57 (27.8)                  | 24 (24.7)                              | 81 (26.8)                 |
|                    | 205                        | L6                                     | 302                       |
| Mean               | 0.9                        | 0.9                                    | 60                        |
| Sundard deviatlon  | 0.78                       | 0.75                                   | 0.77                      |
| Median             | 1.0                        | 1.0                                    | 1.0                       |

bd wice dkiny: N, mumbar of ptient in tetmnt proup. n number of prients

Only cyiolodic chamothenples formetnshtic disease are inchded

<div style=\"page-break-after: always\"></div>

Table 14: Previous disease-related cytotoxic chemotherapy treatments in localised disease (FAS)

|                                                                |                                      | Number (&)of patients      | Number (&)of patients   | Number (&)of patients   | Number (&)of patients   |
|----------------------------------------------------------------|--------------------------------------|----------------------------|-------------------------|-------------------------|-------------------------|
| Group                                                          | Previous treatment                   | 0laparib 300 mg bd (N=205) | Chemotherapy (N=97)     | Total (N=302)           |                         |
| Localized Disease (adjuvant CAPECITABINE and/or neoadjuvant)   |                                      | 8(3.9)                     | 0                       | 8 (2.6)                 |                         |
|                                                                | CARBOPLATIN                          | 7 (3.4)                    | 5 (5.2)                 | 12 (4.0)                |                         |
|                                                                | CISPLATIN                            | 8 (3.9)                    | 2 2 (2.1)               | 10 (3.3)                |                         |
|                                                                | CYCLOPHOSPHAMIDE                     | 154 (75.1)                 | 72 (74.2)               | 226 (74.8)              |                         |
|                                                                | DOCETAXEL                            | 93 (45.4)                  | 38 (39.2)               | 131 (43.4)              |                         |
|                                                                | DOXORUBICIN                          | 92 (44.9)                  | 33 (34.0)               | 125 (41.4)              |                         |
|                                                                | DOXORUBICIN HYDROCHLORIDE            | 2 (1.0)                    | 2 (2.1)                 | (1.3)                   |                         |
|                                                                | EPIRUBICIN                           | 64 (31.2)                  | 36 (37.1)               | 100 (33.1)              |                         |
|                                                                | EPIRUBICIN HYDROCHLORIDE             | 5 (2.4)                    | (4.1)                   | 6 (3.0)                 |                         |
|                                                                | FLUOROURACIL                         | 59 (28.8)                  | 36 (37.1)               | 95 (31.5)               |                         |
|                                                                | GEMCITABINE                          | 2 (1.0)                    | 2 (2.1)                 | (1.3)                   |                         |
|                                                                | GIMERACIL+OTERACIL POTASSIUM+TEGAFUR | 0                          | 1 (1.0)                 | 1 (0.3)                 |                         |
|                                                                | LOBAPLATIN                           | 0                          | 1 (1.0)                 | 1 (0.3)                 |                         |
|                                                                | METHOTREXATE                         | 9 (4.4)                    | 6 (6.2)                 | 15 ( 5.0)               |                         |
|                                                                | MITOXANTRONE                         | 0                          | 1 (1.0)                 | 1 (0.3)                 |                         |
| Localized Disease (adjuvant NAB-PACLITAXEL and/or neoadjuvant) |                                      | (2.0)                      | 3 (3.1)                 | 7 (2.3)                 |                         |
|                                                                | PACLITAXEL                           | 65 (31.7)                  | 31 (32.0)               | 96 (31.8)               |                         |
|                                                                | PIRARUBICIN                          | 6 (4.4)                    | 1 (1.0)                 | 10 (3.3)                |                         |
|                                                                | TEGAFUR                              | 0                          | 1 (1.0)                 | 1 0.3)                  |                         |
|                                                                | VINCRISTINE                          | 3 (1.5)                    | 0                       | 3 1.0)                  |                         |
|                                                                | VINORELBINE                          | 1 (0.5)                    | 1 (1.0)                 | 2 0.7)                  |                         |
|                                                                | VINORELBINE DITARTRATE               | 1 (0.5)                    | 0                       | 1 (0.3)                 |                         |

Table 15: Previous disease-related cytotoxic chemotherapy treatments in the metastatic setting according to line of therapy (FAS)

|                         |                           | Number of patients         | Number of patients   | Number of patients   |
|-------------------------|---------------------------|----------------------------|----------------------|----------------------|
| Previous regimen number | Previous treatment        | Olaparib 300 mg bd (N=205) | Chemotherapy (N=97)  | Total (N=302)        |
| 1                       | Paclitaxel                | 56 (27.3)                  | 24 (24.7)            | 80 (26.5)            |
|                         | Capecitabine              | 25 (12.2)                  | 7 (17.5)             | 42 (13.9)            |
|                         | Docetaxel                 | 30 (14.6)                  | 9 (9.3)              | 39 (12.9)            |
|                         | Cyclophosphamide          | 23 (11.2)                  | 11 (11.3)            | 34 (11.3)            |
|                         | Gemcitabine               | 23 (11.2)                  | 8 (8.2)              | 31 (10.3)            |
|                         | Doxorubicin               | 18 (8.8)                   | 10 (10.3)            | 28 (9.3)             |
|                         | Carboplatin               | 18 (8.8)                   | 7 (7.2)              | 25 (8.3)             |
|                         | Epirubicin                | 14 (6.8)                   | 3 (3.1)              | 17 (5.6)             |
|                         | Cisplatin                 | 10 (4.9)                   | 4 (4.1)              | 14 (4.6)             |
|                         | Vinorelbine               | 5 (2.4)                    | 3 (3.1)              | 8 (2.6)              |
|                         | Gemcitabine hydrochloride | 6 (2.9)                    | 1 (1.0)              | 7 (2.3)              |
|                         | Nab-paclitaxel            | 5 (2.4)                    | 2 (2.1)              | 7 (2.3)              |
|                         | Fluorouracil              | 4 (2.0)                    | 2 (2.1)              | 6 (2.0)              |
|                         | Doxorubicin hydrochloride | 3 (1.5)                    | 1 (1.0)              | 4 (1.3)              |
|                         | Eribulin                  | 1 (0.5)                    | 3 (3.1)              | 4 (1.3)              |

<div style=\"page-break-after: always\"></div>

| Lobaplatin                           | 3 (1.5)   | 1 (1.0)   | 4 (1.3)   |
|--------------------------------------|-----------|-----------|-----------|
| Investigational drug                 | 3 (1.5)   | 0         | 3 (1.0)   |
| Gimeracil+oteracil potassium+tegafur | 0         | 2 (2.1)   | 2 (0.7)   |
| Ixabepilone                          | 2 (1.0)   | 0         | 2 (0.7)   |
| Nedaplatin                           | 2 (1.0)   | 0         | 2 (0.7)   |
| Methotrexate                         | 1 (0.5)   | 0         | 1 (0.3)   |
| Antineoplastic agents                | 0         | 1 (1.0)   | 1 (0.3)   |
| Daunorubicin                         | 0         | 1 (1.0)   | 1 (0.3)   |
| Pirarubicin                          | 1 (0.5)   | 0         | 1 (0.3)   |
| Lobaplatin                           | 3 (1.5)   | 1 (1.0)   | 4 (1.3)   |
| Investigational drug                 | 3 (1.5)   | 0         | 3 (1.0)   |
| Gimeracil+oteracil potassium+tegafur | 0         | 2 (2.1)   | 2 (0.7)   |
| Paclitaxel                           | 13 (6.3)  | 7 (7.2)   | 20 (6.6)  |
| Capecitabine                         | 12 (5.9)  | 3 (3.1)   | 15 (5.0)  |
| Docetaxel                            | 9 (4.4)   | 3 (3.1)   | 12 (4.0)  |
| Carboplatin                          | 8 (3.9)   | 2 (2.1)   | 10 (3.3)  |
| Gemcitabine                          | 5 (2.4)   | 4 (4.1)   | 9 (3.0)   |
| Cisplatin                            | 7 (3.4)   | 2 (2.1)   | 9 (3.0)   |
| Cyclophosphamide                     | 9 (4.4)   | 0         | 9 (3.0)   |
| Eribulin                             | 4 (2.0)   | 3 (3.1)   | 7 (2.3)   |
| Vinorelbine                          | 4 (2.0)   | 2 (2.1)   | 6 (2.0)   |
| Vinorelbine ditartrate               | 4 (2.0)   | 1 (1.0)   | 5 (1.7)   |
| Epirubicin                           | 4 (2.0)   | 0         | 4 (1.3)   |
| Doxorubicin                          | 2 (1.0)   | 1 (1.0)   | 3 (1.0)   |
| Fluorouracil                         | 2 (1.0)   | 1 (1.0)   | 3 (1.0)   |
| Nab-paclitaxel                       | 2 (1.0)   | 1 (1.0)   | 3 (1.0)   |
| Methotrexate                         | 2 (1.0)   | 0         | 2 (0.7)   |
| Nedaplatin                           | 2 (1.0)   | 0         | 2 (0.7)   |
| Antineoplastic agents                | 1 (0.5)   | 0         | 1 (0.3)   |
| Doxorubicin hydrochloride            | 1 (0.5)   | 0         | 1 (0.3)   |
| Etoposide                            | 1 (0.5)   | 0         | 1 (0.3)   |
| Gemcitabine hydrochloride            | 1 (0.5)   | 0         | 1 (0.3)   |
| Investigational drug                 | 1 (0.5)   | 0         | 1 (0.3)   |
| Ixabepilone                          | 1 (0.5)   | 0         | 1 (0.3)   |
| Lobaplatin                           | 0         | 1 (1.0)   | 1 (0.3)   |
| Mitomycin                            | 0         | 1 (1.0)   | 1 (0.3)   |
| Vinflunine                           | 1 (0.5)   | 0         | 1 (0.3)   |

bd  Twice daily.

Patients can contribute to multiple categories.

Source data: Table 1531.1; Data cut-off: 09 December 2016

<div style=\"page-break-after: always\"></div>

Table 16: Stratification factors (FAS)

|                                                           |                 |                                  | Nunber (%o) of patients   | Nunber (%o) of patients                | Nunber (%o) of patients   |
|-----------------------------------------------------------|-----------------|----------------------------------|---------------------------|----------------------------------------|---------------------------|
| Receivedprevious chemotherapyfor metastaticbreast cancer' | Receptor status | Prior platinun for breast cancer | Olaparib 300mg bd (N=205) | Physician's choice chemotherapy (N=97) | Total (N=302)             |
| As randomised (IVRS)                                      |                 |                                  |                           |                                        |                           |
| Yes                                                       | ER+ and/or PgR+ | Yes                              | 24 (11.7)                 | 10 (10.3)                              | 34 (11.3)                 |
|                                                           |                 | No                               | 56 (27.3)                 | 27 (27.8)                              | 83 (27.5)                 |
|                                                           | ER- and PgR-    | Yes                              | 32 (15.6)                 | 14 (14.4)                              | 46 (15.2)                 |
|                                                           |                 | No                               | 34 (16.6)                 | 18 (18.6)                              | 52 (17.2)                 |
| No                                                        | ER+ and/or PgR+ | Yes                              | 0                         | 1 (1.0)                                | 1 (0.3)                   |
|                                                           |                 | No                               | 23 (11.2)                 | 11 (11.3)                              | 34 (11.3)                 |
|                                                           | ER- and PgR-    | Yes                              | 4 (2.0)                   | 1 (1.0)                                | 5 (1.7)                   |
|                                                           |                 | No                               | 32 (15.6)                 | 15 (15.5)                              | 47 (15.6)                 |

ER, oestrogenreceptor;IVRS,interactive voice response system; PgR,progesterone receptor.

Source:Table11.1.6.

## Numbers analysed

The analysis sets and the number of patients in each analysis set are summarised in Table 17.

Table 17: Analysis sets

|                                                                                        | Number (%o) of patients   | Number (%o) of patients         | Number (%o) of patients   |
|----------------------------------------------------------------------------------------|---------------------------|---------------------------------|---------------------------|
|                                                                                        | Olaparib 300 mg bd        | Physician's choice chemotherapy | Total                     |
| Patients randomised                                                                    | 205                       | 97                              | 302                       |
| Patients included in full analysis set                                                 | 205                       | 97                              | 302                       |
| Patients included in safety analysis set                                               | 205                       | 91                              | 296                       |
| Patients excluded from safety analysis set                                             | 0                         | 6                               | 6                         |
| Did not receive treatment                                                              | 0                         | 6                               | 6                         |
| Patients selected for PK assessments                                                   | 41                        | NA                              | 41                        |
| Patients included in PK analysis set                                                   | 41                        | NA                              | 41                        |
| Patients excluded from PK analysis set                                                 |                           | NA                              |                           |
| Important protocol deviation                                                           |                           | NA                              |                           |
| Patients included in the evaluable for response analysis set (BICR)                    | 167                       | 66                              | 233                       |
| Patients included in the evaluable for response analysis set (Investigator assessment) | 165                       | 72                              | 237                       |

An individual patient could have been excluded for more than 1 reason.

Note: Full analysis set: all randomised patients analysed on an ITT basis. Safety analysis set: all patients who received at least 1 dose of study treatment. PK analysis set: all randomised patients who had PK assessment samples taken at pre-agreed sites,received olaparib as per protocol and did not violate or deviate from the protocol in ways that would significantly affect the PK analyses. Evaluable for response analysis set (BICR): all randomised patients who had measurable disease at baseline as per the RECIST version 1.1 criteria using BICR data. Evaluable for response analysis set (investigator assessment): all randomised patients who had measuuable disease at baseline as per the RECISI version 1.1 criteria using investigator assessment data.

bd, twice daily; BICR, blinded independent central review; NA, not applicable; PK, pharmacokinetic; RECIST, Response Furaluation Criteria in Snlid Tumnrs

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Primary variable: PFS by BICR (FAS, DCO 9 December 2016, 77.5% maturity)

Table 18: Progression status at time of PFS analysis (DCO 9 December 2016)

|                    |                                      | Number(%o)ofpatients     | Number(%o)ofpatients                 |
|--------------------|--------------------------------------|--------------------------|--------------------------------------|
| Progression status | Type of event                        | Olaparib300mg bd (N=205) | Physician'schoicechemotherapy (N=97) |
| Progression        | Total                                | 163 (79.5)               | 71 (73.2)                            |
|                    | RECIST progression*                  | 161 (78.5)               | 68 (70.1)                            |
|                    | Target lesionsb                      | 59 (28.8)                | 23 (23.7)                            |
|                    | Non-target lesions                   | 51 (24.9)                | 30 (30.9)                            |
|                    | New lesionsb                         | 77 (37.6)                | 28 (28.9)                            |
|                    | Deathe                               | 2 (1.0)                  | 3 (3.1)                              |
| No progression     | Total                                | 42 (20.5)                | 26 (26.8)                            |
|                    | Censored RECIST progressiond         | 1 (0.5)                  | 1 (1.0)                              |
|                    | Censored death                       | 2 (1.0)                  | 3 (3.1)                              |
|                    | Progression free at time of analysis | 36 (17.6)                | 16 (16.5)                            |
|                    | Lost to follow-up                    | 1 (0.5)                  | 0                                    |
|                    | Withdrawn consent                    | 2 (1.0)                  | 6 (6.2)                              |
|                    | Discontinued studys                  | 0                        | 0                                    |

Targetlesions,non-targetlesions and newlesions are notnecessarilymutually exclusive categories.

Only includes progression events that occured within 2 visits of the last evaluable assessment (excludes censored progressions that occured after two or more missed visits).

Deathin the absence of RECIST progression.Does notinclude deaths that occured after 2 or more missed visits.

Death occured after 2ormore missed visits inthe absence of RECISTprogression.

d RECISTprogressioneventoccuured after2ormoremissedvisits.

Patients knowm to be alive and without RECIST progression, or with no evaluable baseline assessment.

Note:This analysiswas based onindependent central review ofradiological scans.Modified RECISTversion 1.1 was used forindependent central review assessments.

B Patients who discontinued the study without consent withdrawal eg, due to site closure.

Although patients were required to enter the study with at least one lesion (measurable and/or non-measurable) based on investigator assessment, independent reviewers may conclude NED at baseline.

bd twice daily; N, number of patients in treatment group; NED, no evidence of disease;RECIST, Response EvaluationCriteria in Solid Tumors version 1.1. Source:Table11.2.1.1.

Table 19: Progression-free survival, stratified log-rank test (DCO 9 December 2016)

|                               |     | Treatmenteffect Comparisonbetweengroups   | Treatmenteffect Comparisonbetweengroups   | Treatmenteffect Comparisonbetweengroups   | Treatmenteffect Comparisonbetweengroups   |
|-------------------------------|-----|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Group                         |     | Number (%)of patientswith events\"         | Hazard ratio                              | 95%6CI                                    | 2-sidedp-value                            |
| Olaparib300mgbd               | 205 | 163 (79.5)                                | 0.58                                      | 0.43,0.80                                 | 0.0009                                    |
| Physician'schoicechemotherapy | 97  | 71 (73.2)                                 |                                           |                                           |                                           |

a Progression-free survival was defined as the time from randomisation until date of RECIST progression or death.

Patients who had not progressed or died at the time of analysis, or who progressed or died after 2 or more missed visits, were censored at the latest evaluable RECIST assessment, or Day 1 if the patient had no evaluable visits or no baseline assessment (unless they died within 2 visits of baseline).

Note: A hazard ratio of &lt;1 favours olaparib 300 mg bd. The p-value was determined using log-rank test stratified by received previous chemotherapy regimens for metastatic breast cancer (yes/no), and ER and/or PgR positive versus ER and PgR negative. The hazard ratio  and  CI  were  estimated  from  the  stratified  log-rank  test  statistics.  This  analysis  was  based  on  independent  central  review  of radiological scans. Modified RECIST version 1.1 as per Section 5.1. Although patients were required to enter the study with at least one lesion (measurable and/or non-measurable) based on investigator assessment, independent reviewers may conclude NED at baseline. bd, twice daily; CI, confidence interval; ER estrogen receptor; N, number of patients in treatment group; NED, no evidence of disease; PgR, progesterone receptor; RECIST, Response Evaluation Criteria in Solid Tumors.

<div style=\"page-break-after: always\"></div>

Table 20: Median progression-free survival (DCO 9 December 2016)

|                                                      | Olaparib 300 mg bd (N=205)   | Physician's choice chemotherapy (N=97)   |
|------------------------------------------------------|------------------------------|------------------------------------------|
| Total number of eventsa                              | 163                          | 71                                       |
| Median progression-free survival (months)b           | 7.03                         | 4.17                                     |
| 95% CI for median progression-free survival          | 5.68, 8.31                   | 2.79,4.27                                |
| Progression-free at 6 months (%)b                    | 54.1                         | 32.9                                     |
| Progression-free at 12 months (%)b                   | 25.9                         | 15.0                                     |
| Median time from randomisation to censoring (months) | 13.62                        | 4.29                                     |

were censored at the latest evaluable RECIST assessment, or Day1if the patient hadno evaluable visits or nobaseline assessment (unless they died within 2 visits of baseline).

Censored patients only.

Calculated using theKaplan-Meier technique.

Note: Progression included deaths in the absence of RECIST progression. Progression-free included patients who had not progressed or died. This analysis was based on independent central review of radiological scans. RECIST version 1.1. investigator assessment,independent reviewersmay concludeNED at baseline.

bd, twice daily; CI, confidence interval; N, number of patients in treatment group; NED, no evidence of disease; RECIST, ResponseEvaluation Criteria inSolid Tumors.

The Kaplan-Meier plot for the BICR-assessed PFS by modified RECIST version 1.1 is presented in Figure 5 for the FAS.

Figure 5: Progression-free survival, Kaplan-Meier plot (FAS) (DCO 9 December 2016)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Supportive and sensitivity analyses of progression-free survival (FAS)

Table 21: Progression-free survival sensitivity analyses (DCO 9 December 2016)

|                                                    |                                 |     |                                    | Treatmenteffect Comparisonbetveengroups   | Treatmenteffect Comparisonbetveengroups   | Treatmenteffect Comparisonbetveengroups   |
|----------------------------------------------------|---------------------------------|-----|------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Analysis                                           | Group                           | N   | Number (%) of patients with events | Hazard ratio                              | 10 %56                                    | 2-sided p-value                           |
| Removing stratificationaf                          | Olaparib 300 mg bd              | 205 | 163 (79.5)                         | 0.59                                      | 0.43, 0.80                                | 0.0009                                    |
|                                                    | Physician’s choice chemotherapy | 97  | 71 (73.2)                          |                                           |                                           |                                           |
| Ascertainment biasb,?                              | Olaparib 300 mg bd              | 205 | 165 (80.5)                         | 0.50                                      | 0.36, 0.68                                | <0.0001                                   |
|                                                    | Physician's choice chemotherapy | 97  | 80 (82.5)                          |                                           |                                           |                                           |
| Evaluation time biasdbf                            | Olaparib 300 mg bd              | 205 | 163 (79.5)                         | 0.59                                      | 0.43, 0.81                                | 0.0012                                    |
|                                                    | Physician’s choice chemotherapy | 97  | 71 (73.2)                          |                                           |                                           |                                           |
| Attrition biassb,f                                 | Olaparib 300 mg bd              | 205 | 154 (75.1)                         | 0.53                                      | 0.38, 0.74                                | 0.0002                                    |
| Attrition biassb,f                                 | Physician’s choice chemotherapy | 97  | 66 (68.0)                          |                                           |                                           |                                           |
| Adjusted for progressive disease at randomisationf | Olaparib 300 mg bd              | 205 | 163 (79.5)                         | 0.59                                      | 0.45, 0.79                                | 0.0004                                    |
| Adjusted for progressive disease at randomisationf | Physician’s choice chemotherapy | 97  | 71 (73.2)                          |                                           |                                           |                                           |
| UsingeCRF data to define stratification factors    | Olaparib 300 mg bd              | 205 | 163 (79.5)                         | 0.58                                      | 0.42, 0.79                                | 0.0007                                    |
| UsingeCRF data to define stratification factors    | Physician's choice chemotherapy | 96  | 71 (74.0)                          |                                           |                                           |                                           |

Thep-valuewas determined using unstratifiedlogrank test.

Thep-valuewas determined usinglog-rank teststratifiedby receivedprevious chemotherapyregimensformetastaticbreast cancer(yes/no),ER-and/orPgR-positive

Patients who progressed or died after 2 or more missed visits were not censored. Patients who took subsequent therapy prior to progression or death were censored at their last evaluable RECIST assessment prior to taking the subsequent therapy.

P Progression-freesurvival wastaken asthemidpoint between thetime ofprogression andpreviousevaluableRECISTassessment.

The p-value was determined using a Cox proportional hazards model containing factors for treatment, received previous chemotherapy regimens for metastatic breast cancer (yes/no) and progressive disease at the time of randomisation (yes/no), ER and/or PgR positive versus ER and PgR negative, prior platinum for breast cancer (yes/no). The HR was estimated from the model and CI calculated using a profile likelihood approach.

This analysis is based on investigator assessment of radiological scans.

This analysis is based on independent central review ofradiological scans.

positiveversusER andPgRnegative,defined according to eCRFdata.TheHR and CI were estimatedfrom the stratified1og-rank test statistics.

Patient E2806008was ER negative, did not have PgR status assessed andis excluded from analysis

<div style=\"page-break-after: always\"></div>

Table 22: Concordance between investigator and central reviews of RECIST progression (DCO 9 December 2016)

|                                                                          | Number (%o) of patients    | Number (%o) of patients                | Difference Olaparib   |
|--------------------------------------------------------------------------|----------------------------|----------------------------------------|-----------------------|
| Progression                                                              | Olaparib 300 mg bd (N=205) | Physieian's choice chemotherapy (N=97) | 300 mg bd- Placebo    |
| RECIST progression declared by                                           |                            |                                        |                       |
| Investigator and central review                                          | 156 (76.1)                 | 70 (72.2)                              | NA                    |
| Progression date agreement (within 2 weeks)                              | 92 (44.9)                  | 40 (41.2)                              | NA                    |
| Progression date ≥2 wecks carlier by central review than by investigator | 46 (22.4)                  | 23 (23.7)                              | NA                    |
| Progression date 22 weeks earlier by investigator than by central review | 18 (8.8)                   | 7 (7.2)                                | NA                    |
| Investigator but not central review                                      | 9 (4.4)                    | 10 (10.3)                              | NA                    |
| Central reviewbut not imvestigator                                       | 7 (3.4)                    | 1 (1.0)                                | NA                    |
| No progression by both                                                   | 33 (16.1)                  | 16 (16.5)                              | NA                    |
| Early diserepaney rate %                                                 | 16.36                      | 21.25                                  | -4.89                 |
| Late discrepancy rate %°                                                 | 66.25                      | 58.54                                  | 7.71                  |

Progression events that occur after two or more missed visits, are censored at the latest evaluable RECIST assessment. or Day 1 if the patient has no evaluable visits or no baseline assessment (unless they die within 2 visits of baseline).

and inchuding progressions declared by investigator but not BICR) as a proportion of all investigator review progressions.

Late discrepancy rate is the firequency of investigator review progressions declared after the BICR (22 weeks later and including progressions declared by BICR but not investigator) as a proportion of all discrepancies (including early and late discrepancies)

Modified RECIST version 1.1 was used for independent central review assessments. RECIST version 1.1 for investigator assessment.

bd, twice daily: BICR, blinded independent central review; NA, not applicable; RECIST Response Evaluation Criteria in Solid Tumors.

## Secondary variables

## Time to second progression or death (PFS2; FAS)

In both treatment arms, of the patients who had a second progression or died, the majority were based on investigator-assessed radiological assessment. At the time of the primary analysis, 32.7% of olaparibtreated patients and 24.7% of comparator-treated patients had no second progression or death event.

Table 23: Time to second progression or death (PFS2), stratified log-rank test (DCO: 09 December 2016)

|                                 |     | Treatment effect                                               | Treatment effect   | Treatment effect   | Treatment effect   |
|---------------------------------|-----|----------------------------------------------------------------|--------------------|--------------------|--------------------|
| Group                           | N   | Coinparison between groups Number (%) of patients with events\" | Hazard ratio       | 95%CI              | 2-sided p-value    |
| Olaparib 300 mg bd              | 205 | 104 (50.7)                                                     | 0.57               | 0.40,0.83          | 0.0033             |
| Physician's choice chemotherapy | 97  | 53 (54.6)                                                      |                    |                    |                    |

Patients who have not had a second disease progression or died at the time of analysis, or who have second progression or die after two or more missed visits, are censored at the latest evaluable assessment where they are known to be alive and without a second disease progression.

A hazard ratio &lt;1 favours Olaparib 300 mg bd.

The p-value was determined using log-rank test stratified by received previous chemotherapy regimens for metastatic breast cancer (yes/no), and ER and/or PgR positive versus ER and PgR negative. The hazard ratio (HR) and confidence

<div style=\"page-break-after: always\"></div>

interval (CI) were estimated from the stratified log-rank test statistics. The analysis is based on the investigator assessment of second progression. PROGRAM: AZD0819C00003\\Trunk\\TLF\\T11020302.SAS Executed: 09MAR2017:23:57 Extracted: 10FEB2017. Data cut-off: 09DEC2016

Figure 6: Time to second progression or death (PFS2), Kaplan-Meier plot (DCO: 09 December 2016)

<!-- image -->

Table 24: Median time to second progression or death (PFS2) (DCO: 09 December 2016)

| Analysis                                                       | Olaparib 300 mg bd (N=205)   | Physician's choice chemotherapy (N=97)   |
|----------------------------------------------------------------|------------------------------|------------------------------------------|
| Total number of eventsa                                        | 104                          | 53                                       |
| Median second progression-free survival (months)b              | 13.17                        | 9.26                                     |
| 95% CI for median second progression-free survival             | 10.94, 15.34                 | 7.29, 10.35                              |
| Second progression free at 6 months (%)b                       | 85.3                         | 68.4                                     |
| Second progression free at 12 months (%)b                      | 54.7                         | 32.6                                     |
| Median follow-up for second progression-free survival (months) | 11.79                        | 9.71                                     |

Patients who had not had a second disease progression or died at the time of analysis, or who had second progression of died after 2 or more missed visits, were censored at the latest evaluable assessment where they were kmown to be alive and without a second disease progression.

Calculated using the Kaplan-Meier technique.

Censored patients only.

Note: This analysis is based on investigator assessment of second progression.

bd, twice daily; CI, confidence interval; N, number of patients in treatment group.

<div style=\"page-break-after: always\"></div>

Table 25: Summary of PFS2 at 25 September 2017 DCO (Full Analysis Set)

|                           | Olaparib 300 mg bd (N=205)   | Physician's choice of chemotherapy a (N=97)   |
|---------------------------|------------------------------|-----------------------------------------------|
| Number of events (%)      | 130 (63.4)                   | 66 (67.0)                                     |
| Median PFS2 (months)      | 12.8                         | 9.4                                           |
| Hazard ratio (95% CI) b   | 0.55 (0.39, 0.77)            | 0.55 (0.39, 0.77)                             |
| Nominal p-value (2-sided) | 0.0005                       | 0.0005                                        |

a Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine

b A hazard ratio &lt;1 favours olaparib

CI Confidence interval; DCO Data cut-off date; PFS2 Time to second progression or death Data cut-off date: 25 September 2017

<!-- image -->

205200187 157 129 106 92 74 66 58 47 35 24 13 7 9 2 2 0 Qlaparib300mgbd 97 86 71 53 44 33 24 20 14 12 8 5 4 2 0 Chemotherapy

Figure 7: Time to second progression or death (PFS2), Kaplan-Meier plot (DCO 25 September 2017)

<div style=\"page-break-after: always\"></div>

Table 26: OS, stratified log-rank test (FAS, DCO 9 December 2016, 46% maturity)

|                                 |     |                                     | Treatment effect Comparison between groups   | Treatment effect Comparison between groups   | Treatment effect Comparison between groups   |
|---------------------------------|-----|-------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Group                           | N   | Number (%) of patients with eventsa | Hazard ratio                                 | 95% CI                                       | 2-sided p-value                              |
| Olaparib 300 mg bd              | 205 | 94 (45.9)                           | 0.90                                         | 0.63, 1.29                                   | 0.5665                                       |
| Physician's choice chemotherapy | 97  | 46 (47.4)                           |                                              |                                              |                                              |

Overall survival was defined as the time from the date of randomisation until death due to any cause. Patients not known to have died at the time of analysis were censored at the last recorded date on which the patient was known to be alive.

Note: A HR &lt;1 favours olaparib 300 mg bd. The p-value was determined using log-rank test stratified by received previous chemotherapy regimens for metastatic breast cancer (yes/no), ER and/or PgR positive versus ER and PgR negative. The HR and CI were estimated from the stratified log-rank test statistics.

bd, twice daily; CI, confidence interval; ER, oestrogen receptor; HR, hazard ratio; N, number of patients in treatment group: PgR, progesterone receptor.

Figure 8: OS, Kaplan-Meier plot (FAS, 1st DCO 9 December 2016)

<!-- image -->

A final analysis of OS was performed when the OS data were approximately 60% mature (approximately 190 events) and thus based on a DCO of 25 September 2017. At this time, 26 patients were still receiving study treatment (all 26 were in the olaparib arm), and an additional 67 patients were ongoing in the study, off treatment (39 in the olaparib arm, and 28 in the physician's choice of chemotherapy arm).

<div style=\"page-break-after: always\"></div>

Table 27: Overall survival, stratified log-rank test, secondary analysis (FAS) (DCO: 25 September 2017)

| Treatment arm                   | N   | Number (%) of patients with events   | Treatment effect Comparison between groups   | Treatment effect Comparison between groups   | Treatment effect Comparison between groups   |
|---------------------------------|-----|--------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                 |     |                                      | Hazard ratio                                 | 95% CI                                       | 2-sided p-value                              |
| Olaparib 300 mg bd              | 205 | 130 (63.4)                           | 0.90                                         | (0.66, 1.23)                                 | 0.5131                                       |
| Physician's choice chemotherapy | 97  | 62 (63.9)                            |                                              |                                              |                                              |

a Overall survival was defined as the time from the date of randomisation until death due to any cause. Patients not known to have died at the time of analysis were censored at the last recorded date on which the patient was known to be alive.

The p-value was determined using log-rank test stratified by received previous chemotherapy regimens for metastatic breast cancer (yes/no), ER and/or PgR positive versus ER and PgR negative. The HR and CI were estimated from the stratified log-rank test statistics.

bd, twice daily; CI, confidence interval; ER, oestrogen receptor; HR, hazard ratio; N, number of patients in treatment group; PgR, progesterone receptor.

<!-- image -->

Patients not known to have died at the time of analysis were censored at the latest recorded date on which the patient was known to be alive.

Data cut-off date: 25 September 2017.

bd, twice daily; N, number of patients in treatment group.

Figure 9: Overall survival, Kaplan-Meier plot (FAS) (DCO: 25 September 2017)

<div style=\"page-break-after: always\"></div>

Table 28: Median overall survival (FAS) (DCO: 25 September 2017)

| Analysis                                                             | Olaparib 300 mg bd (N=205)   | Physician's choice chemotherapy (N=97)   |
|----------------------------------------------------------------------|------------------------------|------------------------------------------|
| Totalnumberofdeaths                                                  | 130                          | 62                                       |
| Median overall survival (months)*                                    | 19.25                        | 17.12                                    |
| 95% CI for median overall survival                                   | 17.15, 21.55                 | 13.86, 21.85                             |
| Survival at 6 months (%)a                                            | 93.1                         | 85.8                                     |
| Survival at 12 months (%)a                                           | 72.7                         | 69.2                                     |
| Survival at 18 months(%)a                                            | 54.1                         | 48.0                                     |
| Median follow-up for overall survival (months) in all patientsb      | 18.92                        | 15.54                                    |
| Median follow-up for overall survival (months) in censored patientsc | 25.30                        | 26.25                                    |

CalculatedusingtheKaplan-Meiertechnique.

b Timefromrandomisation todateof death or todateofcensoringforcensoredpatients.

Timefrom randomisation todate of censoring(date last known tobe alive) forpatients who had not died at the time of analysis.

The results of the sensitivity analyses (unstratified log rank test and stratified log-rank test in confirmed Myriad gBRCAm subset) were consistent with the main OS analysis.

The  final  OS  outcome  in  the  confirmed  Myriad  gBRCAm  patients  (HR  0.87;  95%  CI:  0.63,  1.18; p=0.3658) was consistent with the overall population (FAS).

## Time to first subsequent cancer therapy (TFST; FAS)

Table 29: Summary analysis of TFST (DCO 9 December 2016)

|                                 |     |                       | Treatment effect   | Treatment effect   | Treatment effect   |
|---------------------------------|-----|-----------------------|--------------------|--------------------|--------------------|
| Group                           | N   | Number (%) of eventsd | Hazard ratio       | 95% CI             | 2-sided p-value    |
| Olaparib 300 mg bd              | 205 | 154 (75.1)            | 0.34               | 0.24,0.47          | <0.0001            |
| Physician's choice chemotherapy | 97  | 85 (87.6)             |                    |                    |                    |

Time to first subsequent cancer therapy was the time from randomisation to the earlier of the second subsequent therapy start date following study treatment discontinuation, or death. Any patient not lmowm to have died at the time of the analysis and not kmowm to have had a further intervention of this type was censored at the last kmowm time to have not received second subsequent therapy, ie, the last follow-up visit where this was confirmed.

Note: A HR &lt;1 favours olaparib 300 mg bd. The p-value was determined using log-rank test stratified by received previous chemotherapy regimens for metastatic breast cancer (yes/no) and ER and/or PgR positive versus ER and PgR negative. The HR and CI were estimated from the stratified log-rank test statistics.

bd, twice daily; CI, confidence interval; ER, oestrogen receptor; HR, hazard ratio; N, number of patients in treatment group: PgR, progesterone receptor.

<div style=\"page-break-after: always\"></div>

Figure 10: TFST, Kaplan-Meier plot (DCO 9 December 2016)

<!-- image -->

Time to second subsequent cancer therapy (TSST; FAS)

Table 30: Summary of analysis of TSST (DCO 9 December 2016)

|                                 |     |                       | Treatnent effect   | Treatnent effect   | Treatnent effect   |
|---------------------------------|-----|-----------------------|--------------------|--------------------|--------------------|
| Group                           | N   | Number (%) of events\" | Hazard ratio       | 95% CI             | 2-sided p-value    |
| Olaparib 300 mg bd              | 205 | 122 (59.5)            | 0.53               | 0.38,0.74          | 0.0002             |
| Physician's choice chemotherapy | 97  | 69 (71.1)             |                    |                    |                    |

Time to second subsequent cancer therapy is the time from randomisation to the earlier of the second subsequent therapy start date following study treatment discontinuation, or death.Any patient not knowm to have died at the time of the analysis and not knowm to have had a fiuther intervention of this type was censored at the last knowm time to have not received second subsequent therapy, ie, the last follow-up visit where this was confinmed.

Note: A HR =1 favouus olapanib 300 mg bd.The p-value was determined using log-rank test stratified by received previous chemotherapy regimens for metastatic breast cancer (yes/no) and ER and/or PgR positive versus ER and PgR. negative. The HR amd CI were estimated from the shratifiedlog-rank test statistics.

bd, twice daily; CI, confidence interval; ER, oestrogen receptor; HR, hazard ratio; N, mumber of patients in treatment group: PgR, progesterone receptor.

Souwce: Table 11.2.6.1.

<div style=\"page-break-after: always\"></div>

Figure 11: TSST, Kaplan-Meier plot (DCO 9 December 2016)

<!-- image -->

Objective response rate (ORR = complete or partial response)

Table 31: Non-confirmed ORR based on independent central review (in patients with measurable disease) (DCO 9 December 2016)

|                    |   N | Number (%o) ofpatients with response   | qI0 %56     |
|--------------------|-----|----------------------------------------|-------------|
| O1aparib 300 mg bd | 167 | 100 (59.9)                             | 52.03.67.38 |
| Chemotherapy       |  66 | 19 (28.8)                              | 18.30.41.25 |

Response does not require confimation.

Modified RECIST version 1.1 was used for independent cenhral review assessments. Although patients Were required to enter the stdy with at least one lesion (measuuable amd/or non-measurable)based on investigator assessment,independent reviewersmay conchudeNED atbaseline.

The CIs for response rate were calculated using the Clopper-Pearson exact method for bimomial proportions.

bd, twice daily; CI, confidence interval; N, mumber of patients in treatment group; NED, no evidence of disease; RECIST: ResponseEvaluation Cniteriain Solid Tumors.

Table 32: Confirmed ORR (DCO 9 December 2016)

| Confirmed ORR - DCO 09 December 2016                                                 | Confirmed ORR - DCO 09 December 2016   | Confirmed ORR - DCO 09 December 2016   |
|--------------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|
|                                                                                      | Olaparib 300 mg bd                     | Chemotherapy                           |
| Number of objective responders: Total number of patients with measurable disease (%) | 87: 167 (52) d                         | 15:66 (23)                             |
| 95% CI                                                                               | 44.2-59.9                              | 13.3-34.7                              |

Note: Confirmed responses (by BICR) were defined as a recorded response of either CR/PR, confirmed by repeat imaging not less than 4 weeks after the visit when the response was first observed. In the olaparib arm 8% with measurable disease had a complete response versus 1.5% of patients in the comparator arm; 74/167 (44%) of patients in the olaparib arm had a partial response versus 14/66 (21%) of patients in  the  chemotherapy  arm.  In  the  TNBC  patient  subgroup  the  confirmed  ORR  was  48%  (41/86)  in  the olaparib arm and 12% (4/33) in the comparator arm. In the HR+ patient subgroup the confirmed ORR was 57% (46/81) in the olaparib arm and 33% (11/33) in the comparator arm.

<div style=\"page-break-after: always\"></div>

Table 33: Onset and duration of objective response in patients with objective response (patients with objective response) (DCO 9 December 2016)

|                                                          | Olaparib 300 mg bd (N=102)   | Physician's choice chemotherapy (N=21)   |
|----------------------------------------------------------|------------------------------|------------------------------------------|
| Number of responders who subsequently progressed or died | 78                           | 15                                       |
| Duration of response form onset of response (days)a b    |                              |                                          |
| 25\" percentile                                           | 86.0                         | 98.0                                     |
| Median (95% CI)                                          | 196.0 (151.0, 218.0)         | 216.0 (98.0, 372.0)                      |
| 75\" percentile                                           | 296.0                        | 372.0                                    |
| Time to onset of response from randomisation (days)      |                              |                                          |
| 25 percentile                                            | 42.0                         | 39.0                                     |
| Median (95% C1)                                          | 47.0                         | 45.0                                     |
| 75 percentile                                            | 86.0                         | 85.0                                     |

Duration of response was the time from the first documentation of CR/PR until the date of progression, or the last evaluable RECIST assessment for patients that did not progress or progressed after two or more missed visits.

Caleulated usingKaplan-Meier technique.

Note: This analysis was based on independent central review of radiological scans.RECIST version 1.1. Although patients Were required to enter the shudy with at least one lesion (measurable and/or non-measurable) based on investigator assessment, independent reviewers may conclude NED at baseline.

bd, twice daily: CI, confidence interval; CR, complete response; N, number of patients in treatment group: NED, no evidence of disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.

## Patient reported outcomes/health-related quality of life (FAS)

The  EORTC  QLQ-C30 questionnaires  were  completed  at  baseline  (prior  to  randomisation)  and  every  6 weeks  until  disease  progression.  Baseline  compliance  rate  (99.0%  for  olaparib;  95.9%  for  physician's choice of chemotherapy) and overall compliance rate (93.2% for olaparib; 77.3% for physician's choice of chemotherapy) of the EORTC QLQ-C30 questionnaire were &gt;75%.

Change from baseline global health status/QoL score (average across all visits) was nominally statistically significant  in  favour  of  olaparib  treated  patients  compared  to  the  physician's  choice  of  chemotherapy patients.  The  differences  in  changes  from  baseline  were  observed  across  all  visits  with  the  maximum difference  at  Visit  12  of  12.7  (95%  CI  5.45,  19.95).  The  overall  estimated  mean  difference  in  change from  baseline  global  health  status/QoL  score  was  7.5  measured  on  a  100-point  scale  (95%  CI  2.48, 12.44; p=0.0035).

<div style=\"page-break-after: always\"></div>

Table 34: Global HRQoL score - best overall QoL response (DCO 9 December 2016)

|                   |                                           | Number (&) of patients     | Number (&) of patients   |
|-------------------|-------------------------------------------|----------------------------|--------------------------|
| Best QoL Response |                                           | 0laparib 300 mg bd (N=205) | Chemotherapy (N=97)      |
| Improved [a]      |                                           | 69(33.7)                   | 13 (13.4)                |
| No change [b]     |                                           | 85 (41.5)                  | 25 (25.8)                |
| Deterioration (e) |                                           | 24 (11.7)                  | 19 (19.6)                |
| Non-evaluable     | Cannot demonstrate                        | 10 (4.9)                   | 17 (17.5)                |
| Missing           | improvement/deterioration/no change Total | 13 (6.3)                   | 19 (19.6)                |
|                   | Nofollowupdata                            | 13 (6.3)                   | 19 (19.6)                |

The denominator is the full analysis set; however best overall QoL response is only determined for patients who have abaseline globalHRQoL score≥l0.

[al Two visit responses of 'improved' a minimum of 2l days apart without an intervening visit response of 'deterioration'.

[bl Does not qualify for overall score response of 'improved'. Two visit response of either 'no change' or 'improved'

[cl Does not qualify for overall score response of 'improved'. A visit response of 'deterioration' without a response

for Improved, No change or Deterioration.

There  was  a  nominally  statistically  significant  difference  in  the  time  to  global  health  status/QoL deterioration in the olaparib arm compared with the physician's choice of chemotherapy arm (HR 0.44; 95%CI: 0.25, 0.77; p=0.0043).

Table 35: Analysis of time to HRQoL deterioration in patients whose baseline Global HRQoL score ≥10 (DCO 9 December 2016)

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Treatmenteffect Comparisonbetiveengroups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Treatmenteffect Comparisonbetiveengroups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Treatmenteffect Comparisonbetiveengroups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Treatmenteffect Comparisonbetiveengroups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Number(%)of patientswithevents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Hazardratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 2-sided p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Olaparib 300 mg bd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 201                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 49 (24.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.25,0.77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.0043                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Physician's choice chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25 (26.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Time todeteriorationofHRQoLwasdefinedasthetimefrom dateofrandomisation to thedate ofa clinicallyimportant deterioration(decrease in 10 points or more in global HRQoL score or reason for not completing fonm was‘Subject too heavily affected by symptoms of disease uwderinvestigation)sustained at the next scheduledvisit.Patients whose global HRQoL score hadnot showm a clinically impoitant deterioration andwho were alive at the time of analysis,or whoexperiencedHRQoLdeteriorationordeathafter 2ormoremissedassessments,werecensoredatthelatest evaluableEORTCQLQ-C30assessment. | Time todeteriorationofHRQoLwasdefinedasthetimefrom dateofrandomisation to thedate ofa clinicallyimportant deterioration(decrease in 10 points or more in global HRQoL score or reason for not completing fonm was‘Subject too heavily affected by symptoms of disease uwderinvestigation)sustained at the next scheduledvisit.Patients whose global HRQoL score hadnot showm a clinically impoitant deterioration andwho were alive at the time of analysis,or whoexperiencedHRQoLdeteriorationordeathafter 2ormoremissedassessments,werecensoredatthelatest evaluableEORTCQLQ-C30assessment. | Time todeteriorationofHRQoLwasdefinedasthetimefrom dateofrandomisation to thedate ofa clinicallyimportant deterioration(decrease in 10 points or more in global HRQoL score or reason for not completing fonm was‘Subject too heavily affected by symptoms of disease uwderinvestigation)sustained at the next scheduledvisit.Patients whose global HRQoL score hadnot showm a clinically impoitant deterioration andwho were alive at the time of analysis,or whoexperiencedHRQoLdeteriorationordeathafter 2ormoremissedassessments,werecensoredatthelatest evaluableEORTCQLQ-C30assessment. | Time todeteriorationofHRQoLwasdefinedasthetimefrom dateofrandomisation to thedate ofa clinicallyimportant deterioration(decrease in 10 points or more in global HRQoL score or reason for not completing fonm was‘Subject too heavily affected by symptoms of disease uwderinvestigation)sustained at the next scheduledvisit.Patients whose global HRQoL score hadnot showm a clinically impoitant deterioration andwho were alive at the time of analysis,or whoexperiencedHRQoLdeteriorationordeathafter 2ormoremissedassessments,werecensoredatthelatest evaluableEORTCQLQ-C30assessment. | Time todeteriorationofHRQoLwasdefinedasthetimefrom dateofrandomisation to thedate ofa clinicallyimportant deterioration(decrease in 10 points or more in global HRQoL score or reason for not completing fonm was‘Subject too heavily affected by symptoms of disease uwderinvestigation)sustained at the next scheduledvisit.Patients whose global HRQoL score hadnot showm a clinically impoitant deterioration andwho were alive at the time of analysis,or whoexperiencedHRQoLdeteriorationordeathafter 2ormoremissedassessments,werecensoredatthelatest evaluableEORTCQLQ-C30assessment. | Time todeteriorationofHRQoLwasdefinedasthetimefrom dateofrandomisation to thedate ofa clinicallyimportant deterioration(decrease in 10 points or more in global HRQoL score or reason for not completing fonm was‘Subject too heavily affected by symptoms of disease uwderinvestigation)sustained at the next scheduledvisit.Patients whose global HRQoL score hadnot showm a clinically impoitant deterioration andwho were alive at the time of analysis,or whoexperiencedHRQoLdeteriorationordeathafter 2ormoremissedassessments,werecensoredatthelatest evaluableEORTCQLQ-C30assessment. |

Figure 12: Time to HRQoL deterioration, Kaplan Meier plot (DCO 9 December 2016)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Cancer therapy satisfaction questionnaire

The primary objective of the CTSQ-16 was to assess satisfaction with the therapy and the questionnaire was administered every 6 weeks from baseline and at treatment discontinuation. The compliance rates were relatively high throughout the study and never fell below 50%.

The CTSQ-16 is scored on 0-100 scale and higher scores are associated with better therapy expectations, feeling  less  impact  of  side  effects,  and  greater  satisfaction  with  therapy.  Across  the  majority  of  visits, satisfaction  with  therapy mean scores were higher in the olaparib arm (range 71.6 to 89.3) compared with the physician's choice of chemotherapy arm (range 62.5 to 77.8). Similar patterns of higher mean scores for therapy expectations and feeling less impact of side effects were observed for olaparib patients compared with physician's choice of chemotherapy patients.

## Ancillary analyses

## Subgroup analyses of progression-free survival

Results of the subgroup analyses of PFS are presented in Figure 13 as a forest plot. The global interaction test  of  PFS  showed  no  evidence  of  treatment  effect  being  different  across  all  pre-specified  subgroups (p=0.1933).

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 13: PFS, forest plot, by subgroup (FAS, DCO 09 December 2016)

## Subgroup analyses of overall survival

<!-- image -->

0.2

0.4

0.6

0.8

1.2

1.8

2

2.2

Figure 14: Overall survival, Forest plot by subgroup (FAS) (DCO 09 December 2016)

Size of circle is proportional to the number of events. Estimated from a Cox proportional hazards model including treatment, subgroup and treatment by subgroup interaction. Grey band represents the 95% CI for the overall (all patients) HR. HRs and 95% CIs are not presented for subgroups with &lt;20 events. bd, twice daily; CI, confidence interval; ER, oestrogen receptor; HR, hazard ratio; NC, not calculated; PgR, progesterone receptor. Source: Figure 11.2.5.

## Subsequent cancer therapies (FAS)

Switch over to olaparib was not permitted within the study design. Patients could, however, receive a PARP inhibitor as a subsequent therapy outside of the study.

<div style=\"page-break-after: always\"></div>

Table 36: Subsequent cancer therapies (FAS) (DCO 25 September 2017)

|                                            | Number (%) of patients     | Number (%) of patients                 |
|--------------------------------------------|----------------------------|----------------------------------------|
|                                            | Olaparib 300 mg bd (N=205) | Physician's choice chemotherapy (N=97) |
| Continuing study treatment at data cut-off | 26 (12.7)                  | 0                                      |
| No subsequent therapy                      | 32 (15.6)                  | 18 (18.6)                              |
| PARPinhibitors                             | 2 (1.0)                    | 8 (8.2)                                |
| Platinum chemotherapy                      | 77 (37.6)                  | 44 (45.4)                              |
| Other cytotoxic chemotherapy               | 125 (61.0)                 | 70 (72.2)                              |
| Hormonal therapy                           | 33 (16.1)                  | 24 (24.7)                              |
| Targeted/Biologics                         | 30 (14.6)                  | 19 (19.6)                              |
| Other                                      | 8 (3.9)                    | 2 (2.1)                                |

Data cut-off date: 25September 2017.

bd, twice daily; PARP, polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerase.

<div style=\"page-break-after: always\"></div>

## Efficacy of olaparib in Myriad CDx gBRCAm patients

## Table 37: Summary of key efficacy outcome variables for confirmed Myriad gBRCAm patients (FAS) (DCO 09 December 2016)

|                                                                     | Olaparib 300 mg bd (N=202)   | Physician's choice chemotherapy (N=95)   |
|---------------------------------------------------------------------|------------------------------|------------------------------------------|
| Progression-free survivala.b                                        |                              |                                          |
| Number (%) of patients with events                                  | 160 (79.2)                   | 71 (74.7)                                |
| HR (95% CI)                                                         |                              | 0.57 (0.41, 0.78)                        |
| 2-sided p-value                                                     |                              | p=0.0005                                 |
| Median PFS (months)                                                 | 7.39                         | 4.17                                     |
| Sensitivity analyses of PFS:                                        |                              |                                          |
| Evaluation time biasa.b.d                                           |                              |                                          |
| Number (%) of patients with events                                  | 160 (79.2)                   | 71 (74.7)                                |
| HR (95% CI)                                                         |                              | 0.58 (0.42, 0.80)                        |
| 2-sided p-value                                                     |                              | p=0.0008                                 |
| Attrition biasae                                                    |                              |                                          |
| Number (%) of patients with events                                  | 151 (74.8)                   | 66 (69.5)                                |
| 2-sided p-value                                                     |                              | p=0.0001                                 |
| Ascertainment biasb,f                                               |                              |                                          |
| Number (%) of patients with events                                  | 162 (80.2)                   | 80 (84.2)                                |
| HR (95% CI)                                                         |                              | 0.48 (0.35, 0.66)                        |
| 2-sided p-value                                                     |                              | p<0.0001                                 |
| Time to second progression or death (PFS2)hi                        |                              |                                          |
| Number (%) of patients with events                                  | 102 (50.5)                   | 53 (55.8)                                |
| HR (95% CI)                                                         |                              | 0.56 (0.39, 0.82)                        |
| 2-sided p-value                                                     |                              | p=0.0024                                 |
| Median second progression-free survival (months)b                   | 13.24                        | 9.24                                     |
| Overall survival                                                    |                              |                                          |
| Number (%) of patients with events                                  | 91 (45.0)                    | 46 (48.4)                                |
| HR (95% CI)                                                         |                              | 0.86 (0.60, 1.25)                        |
| 2-sided p-value                                                     |                              | p=0.4348                                 |
| Median OS (months)                                                  | 19.38                        | 19.61                                    |
| Time to first subsequent cancer therapy or death?                   |                              |                                          |
| Number (%) ofpatients with events                                   | 151 (74.8)                   | 85 (89.5)                                |
| HR (95% CI)                                                         |                              | 0.33 (0.23, 0.45)                        |
| 2-sided p-value                                                     |                              | p<0.0001                                 |
| Median time to first subsequent therapyfrom randomisation(months)   | 9.40                         | 4.21                                     |
| Time to second subsequent therapy or deathk                         |                              |                                          |
| Number (%) of patients with events                                  | 119 (58.9)                   | 69 (72.6)                                |
| HR (95% CI)                                                         |                              | 0.52 (0.37, 0.72)                        |
| 2-sided p-value                                                     |                              | p=0.0001                                 |
| Median time to second subsequent therapyfrom randomisation (months) | 14.26                        | 10.51                                    |

This analysis was based on independent central review of radiological scans.

Calculated using the Kaplan-Meier technique.

PFSdefinedasthetimefromrandomisationuntildateof RECISTprogressionordeath.Patientswhohadnot progressed or died at the time of analysis, or who progressed or died after 2 or more missed visits, were censored at the latest evaluable RECIST assessment,orDay1ifthe patient hadno evaluablevisits ornobaseline assessment (unless they died within 2 visits of baseline).

PFS was taken as the midpoint between the time of progression and previous evaluable RECIST assessment.

<div style=\"page-break-after: always\"></div>

- PFSdefinedasthetimefromrandomisationuntildateofRECISTprogressionordeath.Patientswhohadnot progressed ordied at thetimeof analysiswere censored at thelatest evaluableRECIST assessment orDay1if the patient hadno evaluablevisits or nobaseline assessment (unless they died within 2visits of baseline).Patients who takingthesubsequent therapy,orDay1iftherewerenoevaluablevisits.Patientswhoprogressedordiedafter2or moremissedvisitswerenotcensored.
- This analysiswasbased oninvestigator assessment ofradiologicalscans.
- 官 OSwasdefinedasthetimefromthedateofrandomisationuntildeathdueto anycause.Patientsnotknowntohave died at thetimeof analysiswerecensoredatthelastrecordeddateonwhich thepatientwasknowntobe alive.
- h Patientswhohadnothadaseconddiseaseprogressionordiedat thetimeofanalysis,orwhohadsecondprogressionor died after2ormoremissedvisits,werecensoredat thelatestevaluable assessmentwhere theywereknowntobe alive andwithout aseconddiseaseprogression.
- Thisanalysiswasbasedoninvestigatorassessment ofsecondprogression.
- Timetofirstsubsequentcancertherapywasthetimefromrandomisationtothe earlieroffirst tosubsequent therapy analysisandnotknowntohavehadafurtherinterventionof thistypewascensored at thelastknowntimetohave receivedsubsequent therapy,ie,thelastfollow-upvisitwhere thiswasconfirmed.
- Timetosecondsubsequentcancertherapywasthetimefromrandomisationtotheearlierofthesecondsubsequent therapystart datefollowingstudytreatment discontinuation,ordeath.Anypatientnotknowntohavedied atthetime of theanalysisandnotknowntohavehadafurtherinterventionofthistypewascensored atthelastknowntimeto have notreceived second subsequent therapy, ie, the last follow-up visit where this was confimmed.

bd,twice daily;CI,confidenceinterval;ERoestrogenreceptor;gBRCAm,germlinebreastcancersusceptibilitygene mutated;HRhazardratio;N,numberofpatients intreatmentgroup;OS,overall survival;PFS,progression-freesurvival; PgR,progesterone receptor; RECIST,Response Evaluation Criteria inSolid Tumors.

## Additional efficacy results by line of therapy

Exploratory subgroup analyses were conducted to evaluate PFS by prior lines of chemotherapy, results are summarised below.

Table 38: Summary statistics of PFS by BICR for olaparib vs. physician's choice of chemotherapy by line of therapy (Full analysis set) (DCO 09 December 2016)

|                                                                                                       | Olaparib 300 mg bd (N=205)   | Physician's choice of chemotherapy a (N=97)   |
|-------------------------------------------------------------------------------------------------------|------------------------------|-----------------------------------------------|
| Number of patients with no prior lines of chemotherapy for mBC (n) (olaparib as 1 st line treatment)  | 68                           | 31                                            |
| Number of events (%)                                                                                  | 51 (75)                      | 22 (71)                                       |
| Median PFS (months) (95% CI) b                                                                        | 7.4 (5.6, 8.5)               | 3.0 (1.5, 5.8)                                |
| Hazard Ratio (95% CI) c                                                                               | 0.50 (0.30, 0.84)            | 0.50 (0.30, 0.84)                             |
| Number of patients with one prior line of chemotherapy for mBC (n) (olaparib as 2 nd line treatment)  | 80                           | 42                                            |
| Number of events (%)                                                                                  | 62 (77.5)                    | 35 (83.3)                                     |
| Median PFS (months) (95% CI) b                                                                        | 8.3 (5.8, 11.0)              | 4.1 (2.6, 4.6)                                |
| Hazard Ratio (95% CI) c                                                                               | 0.50 (0.33, 0.76)            | 0.50 (0.33, 0.76)                             |
| Number of patients with two prior lines of chemotherapy for mBC (n) (olaparib as 3 rd line treatment) | 57                           | 24                                            |
| Number of events (%)                                                                                  | 50 (87.7)                    | 14 (58.3)                                     |
| Median PFS (months) (95% CI) b                                                                        | 5.7 (4.2, 8.2)               | 5.1 (2.9, 9.0)                                |
| Hazard Ratio (95% CI) c                                                                               | 1.21 (0.69, 2.27)            | 1.21 (0.69, 2.27)                             |
| Number of patients with any prior chemotherapy for mBC (n) (olaparib as 2 nd /3 rd line treatment)    | 137                          | 66                                            |
| Number of events (%)                                                                                  | 112 (81.8)                   | 49 (74.2)                                     |
| Median PFS (months) (95% CI) b                                                                        | 7.0 (5.6, 8.3)               | 4.2 (2.9 ,4.7)                                |
| Hazard Ratio (95% CI) c                                                                               | 0.69 (0.49, 0.97)            | 0.69 (0.49, 0.97)                             |

a

Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine Calculated using the Kaplan-Meier technique.

b

c Each  subgroup  analysis  was  performed  using  a  single  Cox  proportional  hazards  model  containing  the  treatment  term, subgroup and the treatment by subgroup interaction. A hazard ratio of &lt;1 favours olaparib. CI: confidence interval; mBC Metastatic breast cancer; PFS Progression free survival Data derived from Table 895.1; Table 901.4.

<div style=\"page-break-after: always\"></div>

Table 39: Summary statistics of OS for olaparib vs. physician's choice of chemotherapy by line of therapy (Full analysis set) (Data cut-off 25 September 2017)

|                                                                                                       | Olaparib 300 (N=205)   | mg   | bd   | Physician's chemotherapy a (N=97)   | choice   | of   |
|-------------------------------------------------------------------------------------------------------|------------------------|------|------|-------------------------------------|----------|------|
| Number of patients with no prior lines of chemotherapy for mBC (n) (olaparib as 1 st line treatment)  | 68                     |      |      | 31                                  |          |      |
| Number of events (%)                                                                                  | 35 (51.5)              |      |      | 24 (77.4)                           |          |      |
| Median OS (months) (95% CI) b                                                                         | 22.60 (19.1, NC)       |      |      | 13.86 (10.4, 18.2)                  |          |      |
| Hazard Ratio (95% CI) c                                                                               | 0.45 (0.27, 0.77)      |      |      |                                     |          |      |
| Number of patients with one prior line of chemotherapy for mBC (n) (olaparib as 2 nd line treatment)  | 80                     |      |      | 42                                  |          |      |
| Number of events (%)                                                                                  | 49 (61.3)              |      |      | 24 (57.1)                           |          |      |
| Median OS (months) (95% CI) b                                                                         | 18.92 (14.9, 26.0)     |      |      | 24.74 (13.3, NC)                    |          |      |
| Hazard Ratio (95% CI) c                                                                               | 1.17 (0.72, 1.93)      |      |      |                                     |          |      |
| Number of patients with two prior lines of chemotherapy for mBC (n) (olaparib as 3 rd line treatment) | 57                     |      |      | 24                                  |          |      |
| Number of events (%)                                                                                  | 46 (80.7)              |      |      | 14 (58.3)                           |          |      |
| Median OS (months) (95% CI) b                                                                         | 17.02 (12.4, 20.4)     |      |      | 16.76 (10.9, 27.2)                  |          |      |
| Hazard Ratio (95% CI) c                                                                               | 1.24 (0.70, 2.35)      |      |      |                                     |          |      |
| Number of patients with any prior chemotherapy for mBC (n) (olaparib as 2 nd /3 rd line treatment)    | 137                    |      |      | 66                                  |          |      |
| Number of events (%)                                                                                  | 95 (69.3)              |      |      | 38 (57.6)                           |          |      |
| Median OS (months) (95% CI) b                                                                         | 17.71 (15.3, 20.4)     |      |      | 21.13 (15.2, 27.4)                  |          |      |
| Hazard Ratio (95% CI) c                                                                               | 1.25 (0.86, 1.84)      |      |      |                                     |          |      |

a Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine Calculated using the Kaplan-Meier technique.

b

c Each  subgroup  analysis  was  performed  using  a  single  Cox  proportional  hazards  model  containing  the  treatment  term, subgroup and the treatment by subgroup interaction.  A hazard ratio of &lt;1 favours olaparib.

CI: confidence interval; mBC Metastatic breast cancer; PFS Progression free survival Data derived from Table 1144.1. Data cut-off 25 September 2017.

<div style=\"page-break-after: always\"></div>

Figure 15: Overall survival, Kaplan-Meier plot comparing olaparib to physician's choice of chemotherapy in patients with no prior chemotherapy (i.e. olaparib as 1 st  line treatment) in metastatic setting (Full analysis set) (Data cut-off date: 25 September 2017)

<!-- image -->

Figure 16: Overall survival, Kaplan-Meier plot comparing olaparib to physician's choice of chemotherapy in patients with one prior chemotherapy (i.e. olaparib as 2nd line treatment) in metastatic setting (Full analysis set) (Data cut-off date: 25 September 2017)

<!-- image -->

<div style=\"page-break-after: always\"></div>

B

Figure 17: Overall survival, Kaplan-Meier plot comparing olaparib to physician's choice of chemotherapy in patients with two prior chemotherapy (i.e. olaparib as 3 rd  line treatment) in metastatic setting (Full analysis set) (Data cut-off date: 25 September 2017)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Additional efficacy results for ER and/or PgR positive and ER and PgR negative breast cancer subgroups

Table 40: Summary of exploratory efficacy results in the ER and/or PgR positive and ER and PgR negative breast cancer subgroups (DCO 9 December 2016)

| Efficacy endpoints                                                                             | ER and/or PgR positive N=152   | ER and PgR negative N=150   | FAS N=302         |
|------------------------------------------------------------------------------------------------|--------------------------------|-----------------------------|-------------------|
| PFS by BICR (DCO 09 December 2016)                                                             |                                |                             |                   |
| HR (95% CI)                                                                                    | 0.82 (0.55, 1.26)              | 0.43 (0.29, 0.63)           | 0.58 (0.43, 0.80) |
| Median PFS (months) with olaparib vs physician’s choice of chemotherapy (difference in median) | 8.3 vs 5.1 (43.2)              | 5.6 vs 2.9 (42.7)           | 7.0 vs 4.2 (42.8) |
| PFS by investigator (DCO 09 December 2016)                                                     |                                |                             |                   |
| HR (95% CI)                                                                                    | 0.57 (0.39, 0.84)              | 0.49 (0.34, 0.72)           | 0.50 (0.36, 0.68) |
| Median PFS (months) with olaparib vs physician's choice of chemotherapy                        | 9.9 vs 4.2                     | 5.6 vs 2.9                  | 7.8 vs 3.8        |
| PFS2(DC009December 2016)                                                                       |                                |                             |                   |
| HR (95% CI)                                                                                    | 0.54 (0.33, 0.89)              | 0.69 (0.44, 1.10)           | 0.57 (0.40, 0.83) |
| Median PFS2 (months) with olaparib vs physician's choice of chemotherapy                       | 15.3 vs 9.6                    | 9.9 vs 8.3                  | 13.2 vs 9.3       |
| OS (DC0 25 September 2017)                                                                     |                                |                             |                   |
| HR (95% CI)                                                                                    | 0.86 (0.55, 1.36)              | 0.93 (0.62, 1.43)           | 0.90 (0.66, 1.23) |
| Median OS (months) with olaparib vs physician's choice of chemotherapy                         | 21.8 vs 21.3                   | 17.4 vs 14.9                | 19.3 vs 17.1      |
| TFST (DCO 09 December 2016)                                                                    |                                |                             |                   |
| HR (95% CI)                                                                                    | 0.44 (0.30, 0.65)              | 0.37 (0.26, 0.55)           | 0.34 (0.24, 0.47) |
| Median time (months) with olaparib vs physician's choice of chemotherapy                       | 10.7 vs 4.9                    | 7.8 vs 4.2                  | 9.4 vs 4.2        |
| TSST (DCO 09 December 2016)                                                                    |                                |                             |                   |
| HR (95% CI)                                                                                    | 0.56 (0.37, 0.87)              | 0.59 (0.39, 0.89)           | 0.53 (0.38, 0.74) |
| Median time (months) with olaparib vs physician's choice of chemotherapy                       | 15.3 vs 10.5                   | 12.0 vs 10.5                | 14.3 vs 10.5      |
| ORR by BICR (DCO 09 December 2016)                                                             | 65.4 vs 36.4                   | 54.7 vs 21.2                | 59.9 vs 28.8      |

(%) olaparib vs physician's choice of chemotherapy (Evaluable for response analysis set)

<div style=\"page-break-after: always\"></div>

Table 41: OlympiAD: Confirmed response rate according to hormone receptor status (by BICR): Evaluable for response set (DCO 9 December 2016)

| Hormone receptor status   | Treatment group                 |   N | Number (%) of patients with response a   | 95% CI     |
|---------------------------|---------------------------------|-----|------------------------------------------|------------|
| ER and/or PgR positive    | Olaparib 300 mg bd              |  81 | 46 (56.8)                                | 45.3, 67.8 |
| ER and/or PgR positive    | Physician's choice chemotherapy |  33 | 11 (33.3)                                | 18.0, 51.8 |
| ER and PgR negative       | Olaparib 300 mg bd              |  86 | 41 (47.7)                                | 36.8, 58.7 |
| ER and PgR negative       | Physician's choice chemotherapy |  33 | 4 (12.1)                                 | 3.4, 28.2  |

A confirmed response of CR/PR means that a response of CR/PR is recorded at 1 visit and confirmed by repeat imaging not less than 4 weeks after the visit when the response was first observed with no evidence of progression between the initial and CR/PR confirmation visit. Both visits contributing to a response must be prior to subsequent anti-cancer therapy for the patient to be considered as a responder.

c

bd  Twice daily; BICR  Blinded independent central review; CI confidence interval; CR  Complete response; ER  Oestrogen receptor; PgR Progesterone receptor; PR  Partial response; NC  Not calculable.

Source data: Table 1138.3. Data cut-off date: 09 December 2016..

## Additional efficacy results in patients with prior platinum therapy

Table 42: OlympiAD: PFS by prior platinum therapy (Data cut-off 09 December 2016)

| Prior platinum therapy   | Treatment Group                             |   Total number of events | Median (95%CI) PFS (months)   | Hazard ratio (95%CI) a   |   Total number of censored patients |   Median time to censoring (months) |
|--------------------------|---------------------------------------------|--------------------------|-------------------------------|--------------------------|-------------------------------------|-------------------------------------|
| Yes                      | Olaparib 300 mg bd (N=60)                   |                       50 | 4.17 (2.79, 5.75)             | 0.67 (0.41, 1.14)        |                                  10 |                               11.19 |
| Yes                      | Physician's choice of chemotherapy b (N=26) |                       21 | 4.17 (1.51, 4.21)             | 0.67 (0.41, 1.14)        |                                   5 |                                1.38 |
| No                       | Olaparib 300 mg bd (N=145)                  |                      113 | 8.31 (6.93, 9.00)             | 0.60 (0.43, 0.84)        |                                  32 |                               13.75 |
| No                       | Physician's choice of chemotherapy b (N=71) |                       50 | 4.17 (2.76, 7.20)             | 0.60 (0.43, 0.84)        |                                  21 |                                5.49 |

d Cox proportional hazards model; a hazard ratio &lt;1 favours olaparib

e Physician's choice of chemotherapy consisting of either: capecitabine, eribulin or vinorelbine.

bd  Twice daily; BRCA breast cancer susceptibility gene; CI  Confidence interval; PFS  Progression free survival.

Source:  Table 11.2.1.6 and Table 11.2.1.7. OlympiAD CSR, Module 5.3.5.1 (Data cut-off 09 December 2016).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source data:  Figure 11.2.1.3.5, OlympiAD CSR, Module 5.3.5.1.  Data cut-off 09 December 2016

Figure 18: OlympiAD: Progression-free survival; Kaplan-Meier plot of subset of patients who received prior platinum (Data cut-off 09 December 2016)

Figure 19: Kaplan-Meier plot for PFS in patients who received prior platinum in the metastatic setting (DCO 9 December 2016)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source data:  Figure 11.2.4.3.5, OlympiAD CSR Addendum, Module 5.3.5.1.  Data cut-off 25 September 2017.

Figure 20: OlympiAD: Overall survival; Kaplan-Meier plot of subset patients of who received prior platinum (DCO 25 September 2017)

<!-- image -->

Chemotherapy

Figure 21: Kaplan-Meier plot for OS in patients who received prior platinum in the metastatic setting (FAS) (DCO 25 September 2017)

<div style=\"page-break-after: always\"></div>

## Additional efficacy results in patients with non-progressive disease

There  were  70  (46  olaparib,  24  chemotherapy)  patients  enrolled  in  OlympiAD  with  non-progressive disease at randomisation of which, 38 patients received chemotherapy other than platinum.  In the 32 patients (24 olaparib, 8 chemotherapy) with non-progressive disease at randomisation who had received a prior platinum, 20 of the 24 olaparib-treated patients had received a prior platinum in the metastatic setting and were a subset of the patients that were heavily pre-treated.

Table 43: OlympiAD: Response rate and duration of response (by BICR) by prior therapy: Evaluable for response analysis set (patients with non-progressive disease at randomisation)(DCO 09 December 2016)

| Patients with non-progressive disease at randomisation     | Treatment group                    |   N | Number (%) of patients with response a   | 95% CI       | Median (95% CI) duration of response from onset of response (months)   |   Median time to onset of response from randomisation (days) |
|------------------------------------------------------------|------------------------------------|-----|------------------------------------------|--------------|------------------------------------------------------------------------|--------------------------------------------------------------|
| All patients                                               | Olaparib 300 mg bd                 |  38 | 17 (44.7)                                | 28.62, 61.70 | 6.9 (5.6, 12.6)                                                        |                                                          1.6 |
| All patients                                               | Physician's choice of chemotherapy |  15 | 6 (40.0)                                 | 16.34, 67.71 | 5.0 (1.4, NC)                                                          |                                                          2.1 |
| Patients who received prior chemotherapy (except platinum) | Olaparib 300 mg bd                 |  17 | 7 (41.2)                                 | 18.44, 67.08 | 10.4 (6.7, NC)                                                         |                                                          1.3 |
| Patients who received prior chemotherapy (except platinum) | Physician's choice of chemotherapy |  11 | 3 (27.3)                                 | 6.02, 60.97  | 7.1 (1.4, NC)                                                          |                                                          2.8 |

Response does not require confirmation.

f

bd  Twice daily; BICR  Blinded Independent Central Review; BRCA Breast cancer susceptibility gene; CI  Confidence interval; NC  Not calculable.

Source data: Table 1427.1 and Table 1427.2. Data cut-off date: 09 December 2016.

Table 44: OlympiAD: Summary of exploratory efficacy results in patients with non-progressive disease (DCO 09 December 2016)

| Efficacy endpoints                                                         | Patients with randomisation   | non-progressive disease at        | non-progressive disease at      | Full Analysis Set (N=302)   |
|----------------------------------------------------------------------------|-------------------------------|-----------------------------------|---------------------------------|-----------------------------|
|                                                                            | All patients (N=70)           | Patients who prior (except (N=38) | received chemotherapy platinum) |                             |
| PFS by BICR (DCO 9 December 2016)                                          |                               |                                   |                                 |                             |
| Hazard Ratio a (95% CI)                                                    | 0.72 (0.39, 1.33)             | 0.54 (0.24,                       | 1.23)                           | 0.58 (0.43, 0.80)           |
| Median PFS (months) with olaparib vs physician's choice of chemotherapy b  | 5.4 vs 4.1                    | 8.3 vs                            | 2.8                             | 7.0 vs 4.2                  |
| PFS2 (DCO 9 December 2016)                                                 |                               |                                   |                                 |                             |
| Hazard Ratio a (95% CI)                                                    | 0.79 (0.40, 1.54)             | 0.69 (0.28,                       | 1.69)                           | 0.57 (0.40, 0.83)           |
| Median PFS2 (months) with olaparib vs physician's choice of chemotherapy b | 12.2 vs 7.4                   | 18.2 vs                           | 7.4                             | 13.2 vs 9.3                 |
| OS (DCO 25 September 2017)                                                 |                               |                                   |                                 |                             |
| Hazard Ratio a (95% CI)                                                    | 1.08 (0.57, 2.03)             | 0.76 (0.31,                       | 1.87)                           | 0.90 (0.66, 1.23)           |
| Median OS (months) with olaparib vs physician's choice of chemotherapy b   | 19.4 vs 16.9                  | 26.4 vs                           | 19.0                            | 19.3 vs 17.1                |

g Cox proportional hazards model; a hazard ratio &lt;1 favours olaparib

Physician's choice of chemotherapy consisting of either: capecitabine, eribulin or vinorelbine.

<div style=\"page-break-after: always\"></div>

## Post-hoc analysis in patients with history of treated CNS metastases

Table 45: Progression-free survival, Cox proportional hazards model, additional subgroup analysis  (DCO 09 December 2016)

| Subgroup   |                                    | Olaparib 300 mg bd   | Physician's choice of chemotherapy   |
|------------|------------------------------------|----------------------|--------------------------------------|
| Brain/CNS  | n                                  | 18                   | 8                                    |
| Brain/CNS  | Total number of events, (%)        | 14 (77.8)            | 5 (62.5)                             |
| Brain/CNS  | Median follow-up for PFS, (months) | 15.2                 | 0                                    |
| Brain/CNS  | Median PFS (95% CI), (months)      | 8.3 (4.2, 11.3)      | 2.8 (1.4, 8.0)                       |
| Brain/CNS  | Hazard ratio (95% CI)              | 0.51 (0.19, 1.58)    | 0.51 (0.19, 1.58)                    |

bd  twice daily; CI Confidence interval; CNS  Central nervous system; PFS  Progression free survival.

Table 46: Objective response rate, Cox proportional hazards model, additional subgroup analysis (EFR set) (DCO 09 December 2016)

| Subgroup   |                                 | Olaparib 300 mg bd   | Physician's choice of chemotherapy   |
|------------|---------------------------------|----------------------|--------------------------------------|
| Brain/CNS  | N                               | 17                   | 5                                    |
|            | Patients with a response, n (%) | 11 (64.7)            | 1 (20.0)                             |
|            | 95% CI                          | 38.33, 85.79         | 0.51, 71.64                          |
| Other a    | N                               | 150                  | 61                                   |
|            | Patients with a response, n (%) | 89 (59.3)            | 18 (29.5)                            |
|            | 95% CI                          | 51.02, 67.27         | 18.52, 42.57                         |

h Other group includes patients without brain/CNS metastases: Visceral , bone/locomotor, nonclassified sites (not bone, not visceral).

bd  twice daily; CI Confidence interval; CNS  Central nervous system; EFR  Evaluable for response.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 47: Summary of Efficacy for trial D0819C00003

| Study identifier                                      | D0819C00003                                           | D0819C00003                                      | D0819C00003                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                                                | a Phase III, open-label, randomised, controlled,      | a Phase III, open-label, randomised, controlled, | a Phase III, open-label, randomised, controlled,                                                                                                                                                                                                                                                                                                                                                         |
| Design                                                |                                                       | of main phase: of Run-in phase:                  | Treatment until progression of the underlying disease, discontinuation of study drug, death, loss to follow up or withdrawal of consent to all study related procedures and follow up. not applicable not applicable                                                                                                                                                                                     |
| Hypothesis                                            | Duration of Extension phase: Superiority              | Duration of Extension phase: Superiority         | Duration of Extension phase: Superiority                                                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                                     | Olaparib                                              | Olaparib                                         | 300 mg (2 x 150 mg tablets) orally bd continuous N=205                                                                                                                                                                                                                                                                                                                                                   |
| Treatments groups                                     | Physician's choice of chemotherapy                    | Physician's choice of chemotherapy               | -Oral capecitabine 2500 mg/m 2 to be taken daily (divided in 2 doses) for 14 days, repeated every 21 days or, -Intravenous (IV) vinorelbine 30 mg/m 2 on Day 1 and Day 8, repeated every 21 days or, -Intravenous eribulin mesylate 1.4 mg/m 2 eribulin (active substance) 1.23 mg/m 2 on Day 1 and Day 8, repeated every 21 days                                                                        |
| Endpoints and definitions                             | Primary endpoint                                      | PFS (Progression Free Survival)                  | N=97 PFS: the time from randomisation until the date of objective radiological disease progression according to RECIST version 1.1, or to death (by any cause in the absence of disease progression), regardless of whether the patient withdraws from randomised therapy or receives another cancer therapy prior to disease progression. This was supported by time to first subsequent therapy (TFST) |
| Endpoints and definitions                             | Primary endpoint                                      | OS (Overall Survival)                            | OS: the time from the date of randomisation until death due to any cause.                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                             | Primary endpoint                                      | PFS2                                             | PFS2: the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death. This was supported by time to second subsequent therapy (TSST).                                                                                                                                                                                    |
| Secondary endpoint Database lock 09 December 2016 (33 | Secondary endpoint Database lock 09 December 2016 (33 | ORR (Objective Response Rate)                    | ORR: the number of responders (CR or PR) divided by the number of patients in the treatment group in the EFR analysis set (ITT population with measurable disease at baseline)                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Results and Analysis                            | Results and Analysis                                                                                                                                                                      | Results and Analysis                                                                                                                                                                      | Results and Analysis                                                                                                                                                                      |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                            | Primary Analysis                                                                                                                                                                          | Primary Analysis                                                                                                                                                                          | Primary Analysis                                                                                                                                                                          |
| Analysis population and time point description  | FAS (Full analysis set): FAS or ITT includes all randomised patients and treatment arms are compared on the basis of randomised treatment, regardless of the treatment actually received. | FAS (Full analysis set): FAS or ITT includes all randomised patients and treatment arms are compared on the basis of randomised treatment, regardless of the treatment actually received. | FAS (Full analysis set): FAS or ITT includes all randomised patients and treatment arms are compared on the basis of randomised treatment, regardless of the treatment actually received. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                           | Olaparib                                                                                                                                                                                  | Physician's choice of chemotherapy                                                                                                                                                        |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                         | 205                                                                                                                                                                                       | 97                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Median PFS (months)                                                                                                                                                                       | 7.03                                                                                                                                                                                      | 4.17                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                    | 5.68-8.31                                                                                                                                                                                 | 2.79-4.27                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Median TFST (months)                                                                                                                                                                      | 9.36                                                                                                                                                                                      | 4.21                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                    | 8.28-10.64                                                                                                                                                                                | 3.32- 5.19                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Median PFS2 (months)                                                                                                                                                                      | 13.17                                                                                                                                                                                     | 9.26                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                    | 10.94-15.34                                                                                                                                                                               | 7.29-10.35                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Median TSST (months)                                                                                                                                                                      | 14.26                                                                                                                                                                                     | 10.51                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                    | 12.16-15.47                                                                                                                                                                               | 8.41-11.3                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Median OS (months)                                                                                                                                                                        | 19.25                                                                                                                                                                                     | 19.61                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                    | 16.66-21.82                                                                                                                                                                               | 14.09-24.18                                                                                                                                                                               |
| Descriptive statistics and estimate variability | ORR (%)                                                                                                                                                                                   | 59.9                                                                                                                                                                                      | 28.8                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                    | 52.03-67.38                                                                                                                                                                               | 18.3-41.25                                                                                                                                                                                |
| Effect estimate per comparison                  | Primary endpoint                                                                                                                                                                          | Comparison groups                                                                                                                                                                         | Olaparib versus physician's choice of chemotherapy                                                                                                                                        |
| Effect estimate per comparison                  | PFS                                                                                                                                                                                       | Hazard ratio                                                                                                                                                                              | 0.58                                                                                                                                                                                      |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 95% CI                                                                                                                                                                                    | 0.43-0.80                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 2 sided P-value                                                                                                                                                                           | 0.0009                                                                                                                                                                                    |
| Effect estimate per comparison                  | Secondary endpoint TFST                                                                                                                                                                   | Comparison groups                                                                                                                                                                         | Olaparib versus physician's choice of chemotherapy                                                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                                                                                           | Hazard ratio                                                                                                                                                                              | 0.34                                                                                                                                                                                      |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 95% CI                                                                                                                                                                                    | 0.24-0.47                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 2 sided P-value                                                                                                                                                                           | <0.0001                                                                                                                                                                                   |
| Effect estimate per comparison                  | Secondary endpoint PFS2 (DCO 25 Sept 2017)                                                                                                                                                | Comparison groups                                                                                                                                                                         | Olaparib versus physician's choice of chemotherapy                                                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                                                                                           | Hazard ratio                                                                                                                                                                              | 0.55                                                                                                                                                                                      |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 95% CI 2 sided P-value                                                                                                                                                                    | 0.39-0.77 0.0005                                                                                                                                                                          |
| Effect estimate per comparison                  | Secondary endpoint TSST                                                                                                                                                                   | Comparison groups                                                                                                                                                                         | Olaparib versus physician's choice of chemotherapy                                                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                                                                                           | Hazard ratio                                                                                                                                                                              | 0.53                                                                                                                                                                                      |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 95% CI                                                                                                                                                                                    | 0.38-0.74                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 2 sided P-value                                                                                                                                                                           | 0.0002                                                                                                                                                                                    |
| Effect estimate per comparison                  | Secondary endpoint OS (final, DCO                                                                                                                                                         | Comparison groups                                                                                                                                                                         | Olaparib versus physician's choice of chemotherapy                                                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                                                                                           | Hazard ratio                                                                                                                                                                              |                                                                                                                                                                                           |
| Effect estimate per comparison                  | 25 Sept 2017)                                                                                                                                                                             |                                                                                                                                                                                           | 0.90                                                                                                                                                                                      |
| Effect estimate per comparison                  |                                                                                                                                                                                           | 2 sided P-value                                                                                                                                                                           | 0.5131                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

## Supportive studies

Supportive data were provided from three Phase II studies (Studies 20, 42 and D0810C00008) and two Phase I studies (Studies 24 and 02) in advanced cancer (one Phase II study only included patients with gBRCAm advanced breast cancer [Study D0810C00008], and the other 4 studies included patients with breast cancer as well as other solid tumours) (see Table 2). Some of the supportive studies investigated different doses and formulations of olaparib and none included comparators. The majority of patients in the supportive studies were more heavily pre-treated compared with those in OlympiAD.

## PFS

PFS was a secondary or exploratory efficacy outcome in Study D0810C00008, Study 24, Study 20, Study 42 and time to progression (TTP) was a secondary efficacy outcome in Study 02. In Study D0810C00008, in patients with gBRCAm breast cancer, median PFS was 6.5 months with the 400 mg bd capsule dose (Table  9),  which  compared  favourably  to  the  results  in  the  literature  for  an  unselected  population.  In Study 42, in the subgroup of patients with gBRCAm breast cancer, the median PFS was 3.7 months. In Study 20 and Study 02, median PFS and median TTP, respectively were longer with olaparib in patients with  gBRCAm breast cancer compared with unselected breast cancer. In Study 24, approximately one third  of  patients  had  gBRCAm  breast  cancer  and  median  PFS  was  between  5  and  7  months.  Thus, accounting  for  the  different  degrees  of  pre-treatment  and  considering  the  limitations  of  cross-study comparisons in general, the PFS on olaparib, as observed in the Phase II studies, supports the results observed in OlympiAD.

## OS

OS  was  a  secondary  endpoint  in  Study  42.  Median  OS  in  Study  42  was  11.01  months  (Table  9)  on olaparib,  which  is  shorter  than  the  median  OS  observed  in  OlympiAD.  Subsequent  therapy  use  was documented for 38/62 (61.3%) of patients with gBRCAm breast cancer in Study 42 and 179/298 (60.1%) overall.

## Other efficacy endpoints - ORR and DoR

Results for ORR for olaparib appeared generally consistent between the Phase II studies and OlympiAD when  accounting  for  differences  in  study  populations,  such  as  different  degrees  of  pre-treatment.  As shown  in  Table  48,  the  majority  of  these  studies  showed  that  olaparib  had  activity  in  patients  with gBRCAm breast cancer and other solid tumours. In Study D0810C00008, in patients with gBRCAm breast cancer,  the  ORR  was  42.3%  with  the  400  mg  bd capsule  dose.  Although  no  breast  cancer  patients  in Study 20 had an objective response, a decrease in target lesion size was observed in 6/8 patients with gBRCAm breast cancer and only 1/14 patients with non-gBRCAm breast cancer.

<div style=\"page-break-after: always\"></div>

Table 48: Summary of efficacy across olaparib studies: other supportive studies

|                                                    | Study 20 Phase II relapsed ovarian and breast cancer study (evaluable for RECIST response)   | Study 42 Phase IⅡ advanced gBRC.Am tumour's (Full analysis set) 400 mgbd   | StudyD0810C00008 Phase II advanced gBRCAmbreastcancer (Per-protocol population)   | StudyD0810C00008 Phase II advanced gBRCAmbreastcancer (Per-protocol population)   | Study24 PhaseIformulationcomparison studyinpatientswith advancedsolid tumours (Full analysis set)   | Study24 PhaseIformulationcomparison studyinpatientswith advancedsolid tumours (Full analysis set)   | Study24 PhaseIformulationcomparison studyinpatientswith advancedsolid tumours (Full analysis set)   | Study 02 Phase IFTIM study in advanced tumour's (Intent-to-treat Population)   |
|----------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                                                    | 400 mg bd capsule                                                                            | capsule                                                                    | 400 mg bd capsule                                                                 | 100 mgbd capsulea                                                                 | Group1- 400 mg bd capsule                                                                           | Group 6- 400 mg bd capsule                                                                          | Group 6 - 300 mgbd tablet                                                                           | All olaparib doses combined capsule                                            |
| Nunber of patients                                 |                                                                                              |                                                                            |                                                                                   |                                                                                   |                                                                                                     |                                                                                                     |                                                                                                     |                                                                                |
| Overall population if study notjust breast cancer  | 86                                                                                           | 298                                                                        | NA                                                                                | NA                                                                                | 11                                                                                                  | 18                                                                                                  | 18                                                                                                  | 98 (gBRC.Am n=60)                                                              |
| Breast cancer population                           | 23                                                                                           | 62                                                                         | 26                                                                                | 24                                                                                | 4                                                                                                   | 5                                                                                                   | 5                                                                                                   | 13 (gBRCAm n=7)                                                                |
| MedianPFS,months                                   |                                                                                              |                                                                            |                                                                                   |                                                                                   |                                                                                                     |                                                                                                     |                                                                                                     |                                                                                |
| Overall population if study not just breast cancer | NA                                                                                           | NA                                                                         | NA                                                                                | NA                                                                                | 5.5b                                                                                                | 5.7                                                                                                 | 7.1                                                                                                 | 2.8 (TTP) (3.8 for gBRCAm)                                                     |
| Breast cancer population                           | 1.8 (3.6 for gBRCAm [m=10])                                                                  | 3.7 (n=62)                                                                 | 6.5                                                                               | 4.1                                                                               | NR                                                                                                  | NR                                                                                                  | NR                                                                                                  | 5.4 (TTP) for gBRCAm (n=7)                                                     |
| MedianOS,months                                    |                                                                                              |                                                                            |                                                                                   |                                                                                   |                                                                                                     |                                                                                                     |                                                                                                     |                                                                                |
| Breast cancer population                           | NA                                                                                           | 11.01 (8.44, 15.38) (n=62)                                                 | NA                                                                                | NA                                                                                | NA                                                                                                  | NA                                                                                                  | NA                                                                                                  | NA                                                                             |
| ORR % (95% CI)                                     |                                                                                              |                                                                            |                                                                                   |                                                                                   |                                                                                                     |                                                                                                     |                                                                                                     |                                                                                |
| Overall population if study not just breast cancer | NA                                                                                           | 29.3 (23.92, 35.19) (FAS measureable disease n=266)                        | NA                                                                                | NA                                                                                | 18.2c                                                                                               | 38.9                                                                                                | 33.3                                                                                                | 14.3 (8.7, 22.6) (21.7 [13.3, 33.6]for gBRCAm)                                 |
| Breast cancer population                           | 0 (0, 14.31) (0 [0, 32.44] for gBRC.Am [n=8])                                                | 13.8 (6.15, 25.38) (FAS measureable disease n=58)                          | 42.3 (25.5, 61.1)                                                                 | 25.0 (12.0, 44.9)                                                                 | NR                                                                                                  | NR                                                                                                  | NR                                                                                                  | 14.3 (2.6, 51.3) for gBRCAm (n=7)                                              |
| Median DoR (range). days                           |                                                                                              |                                                                            |                                                                                   |                                                                                   |                                                                                                     |                                                                                                     |                                                                                                     |                                                                                |
| Overall population if study not just breast        | NA                                                                                           | 208                                                                        | NA                                                                                | NA                                                                                | NR                                                                                                  | NR                                                                                                  | NR                                                                                                  | 252 (170 for gBRCAm [n=13])                                                    |
| Breast cancer population                           | NA                                                                                           | 204                                                                        | 144 (92-393)                                                                      | 141 (55-175)                                                                      | NR                                                                                                  | NR                                                                                                  | NR                                                                                                  | NE                                                                             |

A total of 23 patients in the 100 mg bd am dose escalated to 400 mg bd following protocol amendment 3.

Two patients in the BRCA cohort had metastatic ovarian cancer in addition to breast cancer and were deemed not evaluable for breast cancer response; howeverthebreast cancercohortresponserateisnot affected by this.

10/11 (90.9%) patients had a gBRCA mutation (see Section 6.5.4, Study 24 CSR).

## 2.4.3. Discussion on clinical efficacy

This application for an extension of indication for the treatment of adult patients with BRCA1/2-mutated HER2-negative  metastatic  breast  cancer  is  based  on  the  results  of  the  pivotal  Phase  III,  randomised, controlled, open-label, multicentre study OlympiAD.

## Design and conduct of clinical studies

The 300 mg bd tablet dose was chosen as the recommended Phase III monotherapy dose based on tolerability and tumour shrinkage data from Study 24 in an advanced gBRCA mutated ovarian cancer population. Study 24 explored the safety data and tumour shrinkage data across a number of different doses and schedules of olaparib tablet or capsule in an advanced gBRCA mutated ovarian cancer population. This exploration resulted in the recommendation of 300 mg bd tablet dose for Phase III studies. This dosing regimen is expected to maintain plasma concentrations above the estimated mouse 90% inhibitory concentration ([IC90]; and its upper 95% CI) for tumour PARP inhibition across the full dosing interval, i.e., 12 hours.  The recommended dose is acceptable. The exposure to olaparib following

<div style=\"page-break-after: always\"></div>

administration of 300mg bd tablet formulation observed in the Phase III study OlympiAD (Olaparib-MS05, N=36) was comparable to that in SOLO2 (Olaparib-MS-03, N=94) and was within the range previously predicted for the capsule formulation at 400mg bd (Olaparib-MS-01). In addition, in the pivotal phase 3 study supporting the breast cancer indication, only the currently approved tablet formulation was used.

This  pivotal  study  OlympiAD  is  a  2:1  randomised,  open-label,  controlled,  multi-centre  phase  III  study evaluating olaparib monotherapy versus Physician's Choice Chemotherapy. The selection of appropriate therapy  for  metastatic  breast  cancer  is  complex  because  of  the  many  treatments  options,  biologic heterogeneity  of  the  disease  and  prior  treatments  received  in  the  neo/adjuvant,  locally  advanced  or metastatic settings. In addition, solid evidence is lacking as regards the most appropriate regimens for the  treatment  of  germline  BRCA  1/2  mutation  positive  breast  cancer.  The  appropriateness  of  a comparison with Physician's Choice Chemotherapy is therefore endorsed.

Physician's Choice Chemotherapy included capecitabine, vinorelbine or eribulin as single-agent regimen used according to their marketing authorisation conditions. In patients who have received a taxane/anthracycline-based  regimen,  either  neo/adjuvant  or  as  first-line  treatment  for  metastatic disease, it is  accepted  from  a  regulatory  perspective  that  a  single-agent  regimen  is  used  as  reference mainly because of the absence of relevant data comparing sequential versus combination therapy.

Patients with platinum resistant tumours were excluded from the study due to expected cross-resistance to PARP inhibitors. The absence of a platinum therapy as a treatment option is questioned as previously discussed  during  the  scientific  advice  procedure.  Although  carboplatin  is  mentioned  in  the  ESMO recommendations for the treatment of BRCA mutation positive and negative mTNBC after taxane/anthracycline, the applicant considered that there were insufficient data to recommend platinum agents  over  standard  chemotherapy  in  advanced  breast  cancer  (Byrski  et  al  2012).  However  the  TNT study (Tutt et al 2014) has shown a superiority of carboplatin compared to 'standard' docetaxel in the subgroup of  patients  with  gBRCA  mutated  TNBC  with  a  significantly  better  toxicity  profile  making  it  a treatment  option  recommended  in  clinical  practice  guidelines  in  this  population  (3rd  ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer). It is also acknowledged that the results of TNT study were not available at the start of the study. Although the absence of platinum agent as a comparator option in OlympiAD study is considered a deficiency in the design of the study, it could be considered as acceptable considering the timing of the study. It is noted that it is not possible to conclude for  the  time  being  whether  platinum  would  be  more  effective  in  first  instance  or  after  PARPi  in  this setting.

The study population is heterogeneous as patients could have received between 0 and 2 prior lines of cytotoxic chemotherapy for metastatic disease. Patients with HER2-positive breast cancer were excluded from the study because of the existing therapeutic options in this population.

Patients with ER and/or PgR positive disease were required to have received and progressed on at least 1 endocrine  therapy  (adjuvant  or  metastatic),  or  had  disease  that  the  treating  physician  believed  to  be inappropriate for endocrine therapy. This inclusion criterion is not aligned with the current clinical practice and  recommendations  since  it  does  not  specify  if  patients  could  have  received  targeted  anticancer therapies such as mTOR inhibitors or CDK4/6 inhibitors. It is acknowledged that CDK4/6 inhibitors were not available at the time of study initiation. However, this would have been important to understand the place  of  olaparib  therapy  in  the  treatment  sequence  of  patients  with  gBRCA  HR+  metastatic  breast cancer.

Patients with ECOG status ≥2 were excluded from the study.  This is a standard selection criterion for all olaparib  studies  to  safeguard  patients  who  are  in  poor  health,  as  the  need  to  attend  repeated  clinic appointments and undergo additional testing associated with study participation may be detrimental to

<div style=\"page-break-after: always\"></div>

their  health.  Low  numbers  of  breast  cancer  patients  with  ECOG  PS2  scores  have  received  olaparib treatment in earlier clinical studies. This is adequately reflected in the section 5.1 of the SmPC.

To  be  enrolled  into  the  OlympiAD  study,  subjects  were  required  to  have  documented  evidence  of  a deleterious or suspected deleterious gBRCA1 or gBRCA2 mutation. The presence of germline BRCA1 or BRCA2 mutations was assumed to result in homologous recombination deficiency (HRD) and sensitivity to olaparib in all the subgroups (independent on histology, hormone receptor status or line of therapy).Evidence of a qualifying BRCA mutation could be from either an existing BRCA mutation result generated by local testing or from prospective testing performed by BGI (Chinese patients) or by Myriad using  either  the  Integrated  BRACAnalysis  (Myriad  CLIA  gBRCA  test)  or  BRACAnalysis  CDx  test  (nonChinese patients).

Although germline BRCA1/2 mutations are neither necessary not sufficient for conferring HR-deficiency in breast cancer patients, for the time being there is no validated biomarker for determining patients with homologous-recombination  deficient  tumours  and  the  development  of  tumours  in  BRCA1/2  carriers  is thought to be due to alterations of the second allele in BRCA1 or 2 locus and consequently a functional deficiency  of  BRCA1  or  BRCA2  proteins  leading  to  homologous  recombination  deficiency  and  genomic instability.  From  this  mechanistic  point  of  view,  the  determining  factor  for  selection  of  patients  is  a particular genotype, namely a presence of germline BRCA mutations.

At the time of study initiation, the inclusion of patients with a somatic mutation was not possible because an appropriate diagnostic test based on tissue analysis was not available. Thus, patients with a somatic mutation  were  excluded  from  this  study  and  there  is  currently  no  clinical  data  available  on  the responsiveness  of  breast  tumours  with  somatic  BRCA  mutation  to  PARPi.  The  difficulty  to  conduct  a clinical  trial  only  in  patient  with  somatic  BRCA  mutated  breast  cancer  is  acknowledged  due  to  low prevalence. Several ongoing clinical trials including TAPUR, VIOLETTE and LUCY studies in patients with either  germline  or  somatic  BRCA1/2  mutations  might  provide  relevant  data  in  this  regard.  The extrapolation  of  results  from  patients  with  germline  BRCA  mutations  that  developed  breast  cancer  to patients  with  sporadic  breast  cancers  that  harbour  somatic  BRCA  mutations  in  their  tumours  is  not justified for the time being in the absence of any clinical data and other data supporting the proposed mechanistic rationale (see also SAG  consultation below  in this regard).  Considering  the  CHMP assessment, the MAH has withdrawn its request for an indication in somatic breast cancer susceptibility genes mutated HER2-negative metastatic breast cancer. Data in patients with somatic BRCA mutations and deficiencies in other homologous recombination related genes are expected to be collected in MAH sponsored and other studies  (TAPUR,  LUCY  and  VIOLETTE  and  new  planned  study  to  be  conducted in patients with only somatic BRCAm). The MAH is recommended to provide the results of these studies.

It  is  agreed  that  double-blind  design  is  not  an  option  due  to  obvious  differences  in  tolerability  and treatment schedules between the therapeutic options in the study. Measures included independent review and conduct of sensitivity analyses (for ascertainment bias, for deviation bias and evaluation time bias if scans are not performed at the protocol scheduled time points) to limit potential bias related to the openlabel nature of the trial.

The primary efficacy endpoint was PFS (supported by TFST). Progression was assessed by the blinded independent central review (BICR) using RECIST 1.1. The primary efficacy endpoint was supported by OS, PFS2 (investigator assessment), TFST, TSST and ORR (by BICR) as secondary efficacy endpoints.

Primary and efficacy endpoints were in line with recommendations from EMA 'Guideline on the evaluation of  anticancer  medicinal  products  in  man'  (EMA/CHMP/205/95/Rev.5)  since  when  PFS  is  the  selected primary endpoint, OS should be reported as a secondary endpoint.

PFS as primary efficacy endpoint instead of OS was discussed during scientific advice and is considered acceptable.  The  study  was  intended  to  be  performed  in  the  1 st ,  2 nd and  3 rd line  in  metastatic  setting

<div style=\"page-break-after: always\"></div>

meaning that time from progression on study therapy to death will vary. Also, next-line therapies may influence OS. In this context, result on PFS2 (supported by TSST) will be useful.

The study was adequately powered to observe a 2.3 months improvement in median PFS assuming 4month median PFS for the control arm taking into account that median PFS for the selected comparators (eribulin,  vinorelbine  and  capecitabine)  varied  depending  on  agents,  line  of  therapy  and  previous treatments received.

Analysis of primary and secondary endpoints were based on the ITT population [= all randomised patients defined as the time from randomisation to the earliest date of assessment of objective progression (per RECIST  criteria)  or  death  by  any  cause  (in  the  absence  of  disease  progression)]  and  included  the stratified  2-sided  log-rank  test  for  PFS,  PFS2  and  OS  analysis,  the  Kaplan-Meier  method  to  estimate median survival and the extended Cox regression model for the estimation of HR. In order to strongly control  the  type  I  error  at  2.5%  1-sided,  a  multiple  testing  procedure  was  also  employed  across  the primary endpoint and secondary endpoints intended for key label claims (i.e. PFS2 and OS).

The proposed analysis methods for the primary and secondary endpoints are standard methods in this fields  in  line  with  recommendations  from  EMA  'Guideline  on  the  evaluation  of  anticancer  medicinal products in man' (EMA/CHMP/205/95/Rev.5) and are therefore considered acceptable.

Cross-over was not allowed in this study as not considered appropriate since there were a number of active compounds available for most patients and it could have a confounding effect on OS and PFS2. However, it is acknowledged that patients were able to access PARPi outside of the study. As subsequent therapy,  0.5%  and  8%  of  patients  have  received  a  subsequent  PARP  inhibitor  in  the  treatment  and comparator arm respectively, whereas 29% and 42% of patients received subsequent platinum therapy, respectively.

Of the 302 patients included in the FAS, the majority were female (97.7%), white (65.2%) with a median age 44 years (range 22 to 76), ECOG PS 0 (69.5%). A slightly higher percentage of patients with an ECOG  PS  1  in  the  physician's  choice  of  chemotherapy  arm  (36.1%)  compared  with  the  olaparib  arm (27.8%) was observed.

All  patients  had  metastatic  disease  as  per  protocol  requirement  with  at  least  2  metastatic  sites  in approximately ¾ of patients. A majority had a poorly differentiated tumour grade (54%).

167 patients (55.3%) had a known locally confirmed gBRCA mutation: 99 BRCA1 mutations (32.8%), 67 BRCA2 (22.2%), 1 BRCA1/2 (0.3%) and not reported for 135 patients (44.7%).

Approximately  half  of  patients  (50.3%)  were  HR+/HER2-  and  half  of  patients  (49.7%)  were  TNBC  at baseline.

The mean time from original diagnosis to randomisation in the study was approximately 5 years and 38 days from the most recent disease progression.

Twenty four (24) patients (11.7%) in the olaparib arm and 6 (6.2%) in the physician's choice of chemotherapy received disallowed concomitant medication, mainly for treatment of bone diseases [19 (9.3%) in the olaparib arm and 5 (5.2%) in the physician's choice of chemotherapy]. The use of disallowed concomitant medication did not raise concerns about the conduct of the study.

The patients randomised in the study were representative of the intended target population of gBRCAm patients with HER2-negative metastatic breast cancer. The demographic and disease characteristics in the FAS population were generally well balanced between the two treatment arms. Stratification factors by receipt of prior chemotherapy, hormone receptor status, and receipt of prior platinum therapy were also well balanced between the treatment arms.

<div style=\"page-break-after: always\"></div>

At DCO for the primary analysis (9 December 2016), there was ~15% reduction risk of discontinuations in  olaparib  arm.  Discontinuations  were  mainly  due to the  disease  progression,  including  deaths.  These discontinuations were rather well balanced between both arms (72.7% vs 74.7% for PD and 45.9% vs 47.4% for deaths). In the contrary, there were 66% and 26% reduction risk of discontinuation due to patients decision and AEs respectively in olaparib arm.

Since  ethnic/physical  characteristics  were  reported  in  the  trial,  it  was  noticed  that  very  few  Black  or African-American included in the trial (1.7%). The mutations rates in this population seem to be similar to other  populations  included  in  the  study.  The  low  recruitment  rate  was  partly  explained  by  a  lack  of recommendation to undergo BRCA1/2 testing in the US. The SmPC mentions in section 4.2 that there are limited data available in non-Caucasian patients.

Overall, the proportion of patients with at least 1 important protocol deviation was 4.0%, and balanced between the treatment arms: 3.9% on olaparib and 4.1% on physician's choice of chemotherapy.

## Efficacy data and additional analyses

OlympiAD met its primary endpoint demonstrating a statistically significant and clinically relevant 3months improvement in PFS based on BICR in the FAS population treated with olaparib compared to physician's choice of chemotherapy (HR 0.58; 95% CI: 0.43, 0.80; p&lt;0.0001; median 7.03 vs 4.17 months) which was supported by sensitivity analysis by investigator assessment (HR 0.50; 95% CI: 0.36, 0.68; p=0.0009; median 7.8 vs 3.8 months).

The improvement in PFS in the olaparib arm compared with the physician's choice of chemotherapy arm was  statistically  significant  and  clinically  relevant,  as  evidenced  by  the  magnitude  of  effect:  a  42% reduction in risk of progression or death. There was clear separation of curves in favour of olaparib. This separation appeared to start with the first radiologic assessment scheduled at 6 weeks.

The robustness of the primary analysis is supported by sensitivities analysis (eg, ascertainment bias, evaluation time bias, attrition bias) demonstrating a consistent and favourable treatment benefit for olaparib. Discordance between BICR and investigator review for progression assessment was relatively low, 9% and not suggestive for major bias. Only 1 patient (0.5%) in the olaparib arm and 2 patients (2.1%) in the comparator arm missed ≥ 2 RECIST assessment with no impact of differential censoring between the 2 treatment groups.

Following the subgroup analyses of PFS, no subgroups derived a differential benefit compared with the overall population. Regarding subgroup analyses of PFS, consistent results were observed across all the pre-specified subgroup.

The design of the OlympiAD study does not allow making definitive conclusions in terms of comparison of efficacy of olaparib in HR+ BC vs TNBC but allows making conclusions in terms of consistency of results. PFS subgroup analysis results in TNBC and HR+ patients have been included in section 5.1 of the SmPC. Consistent  benefit  was  seen  in  both  ER  and/or  PgR  positive  and  ER  and  PgR  negative  patients  in  all efficacy outcomes, including PFS2 and ORR.

gBRCA mutations are found in 10% of male breast cancer patients. Male breast cancer patients generally have gBRCA2 mutation. In study OlympiAD, 7 male patients were randomised (5 olaparib and 2 comparator). At the time of the PFS analysis, 1 patient had a confirmed partial response with a duration of response of 9.7 months in the olaparib arm. There were no confirmed responses in the comparator arm. Three of the male subjects on the olaparib arm had stable disease at the DCO for the primary analysis and 1 male on the olaparib arm had progressive disease. While the proportion of men in the study program is very low, it is still considered possible to extrapolate results to men, based on the common biological and pharmacological rationale.

<div style=\"page-break-after: always\"></div>

At  the  time  of  DCO  for  primary  analysis  (DCO  9  December  2016),  a  statistical  significance  on  PFS2 improvement in the olaparib arm (HR: 0.57, 95% CI 0.40 - 0.87; p=0.0033) with a median second PFS 13.17 months in the olaparib arm and 9.26 months in the comparator arm.

Post-hoc analysis with the DCO 25 September 2017 of PFS2 (65% maturity, DCO 25 September 2017) was consistent (HR 0.55, 95% CI 0.39-0.77) with the results for PFS2 at the primary analysis. PFS2 event rate was 63% (130/205) with a median time of 12.8 months in the olaparib arm and 67% (65/97) with a median time of 9.4 months in the comparator arm. The nominal p value was 0.0005, this test was not pre-specified under the multiplicity testing procedure.

Final  OS  analysis  was  conducted  at  64%  maturity  of  the  FAS  population  (DCO  25  September  2017). There was no suggestion of an OS detriment, with the HR numerically favouring olaparib. The results of the  final  OS  analysis  were  consistent  the  interim  analysis  (46%  maturity  of  FAS  population).  Even  if switch to olaparib was not permitted within the study design OlympiAD, it is acknowledged that patients were able to access PARPi outside of the study. This has the potential to confound interpretation of OS data.  However,  the  number  of  patient  who  received  PARPi  as  subsequent  therapy  is  relatively  low  (2 patient (1%) in the olaparib arm and 8 (8.2%) in the comparator arm). Thus, the impact on OS analysis from  subsequent  PARPi  therapy  would  be  minor  and  did  not  favour  olaparib.  Subsequent  platinum therapy was reported in 29% of patients in the olaparib arm and in 42% of patients in the chemotherapy arm. There is no evidence of a differential subgroup effect on OS.

A statistically and clinically longer TSFT and TSST in the olaparib arm than the comparator arm have been observed. ORR in the olaparib arm (59.9%) was doubled compared with the comparator arm (28.8%).

Efficacy outcomes in the Myriad CDx gBRCAm subgroup (297 patients overall; 202 in the olaparib arm and 97 in the comparator arm) were consistent with the FAS.

The statistically significant improvement of HRQoL (mean difference in change from baseline = 7.5 out of 100 points scale 95%CI 2.5, 12.4; p=0.0035) and difference in time to HRQoL deterioration (HR 0.44; 95% CI 0.5, 0.77; p=0.0043) in favour of olaparib were supported by sensitive analyses. However, the data from this open label are not considered robust enough to be included in the SmPC based on the review of the pre-planned analyses and hypotheses for PROs including the handling of missing data.

Only 32.5% of patients received endocrine therapy in metastatic disease and 38.4% in adjuvant/neoadjuvant setting while 152 patients (50.3%) were HR+ in OlympiAD study. Among the HR+ patients, 103 (50.2%) were treated with olaparib and 49 (50.5%) with physician's choice of chemotherapy. Six (5.8%) patients in olaparib arm and 4 (8.2%) in chemotherapy arm did not receive prior endocrine therapy while they were HR+.

Treatment options for patients with hormone receptor positive (HR+) breast cancer have changed over the last few years, with the introduction of new endocrine therapies (new first line treatment options and combination therapies with CDK4/6 inhibitors) after the start of OlympiAD study. Even if eCRF in the OlympiAD study, did not capture how many patients had progressed on, or after, being treated with hormonal therapy, it is expected that all HR+ patients have a progressive disease at the time of olaparib initiation and HR+ patients with non-progressive disease should be excluded from the indication. Overall, it is considered that the indication should reflect that patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy or be considered unsuitable for endocrine therapy in line with the studied population.

The median of previous chemotherapy received for metastatic disease was 1 for each treatment arm.

As required for eligibility in the study, nearly all patients had received prior treatment with anthracycline (unless contraindicated) and a taxane in either the neoadjuvant, adjuvant or metastatic setting. Patients had  received  prior  treatment  with  anthracycline  (unless  contraindicated)  in  the  localised  (81%)  or

<div style=\"page-break-after: always\"></div>

metastatic (19%) setting and a taxane in the localised (70%) or metastatic setting (49%). Prior therapy with platinum was allowed in the (neo)adjuvant setting provided the last dose was received at least 12 months  prior  to  randomisation  and  in  metastatic  setting  if  there  had  been  no  evidence  of  disease progression during platinum treatment. Patients have received platinum either for localised disease (7% of  patients  in  the  olaparib  arm  and  7%  in  the  chemotherapy  arm)  or  for  metastatic  disease  (21%  of patients  in  the  olaparib  arm  and  14%  in  the  chemotherapy  arm)  with  the  exception  of  3  patients  (2 olaparib and 1 comparator) who had received platinum in both settings.

According to eligibility criteria, patients must have completed previous courses of cytotoxic chemotherapy more than 21 days of randomisation. Absence of progressive disease at the time of randomisation was reported for 46 patients in olaparib arm and 24 patients in chemotherapy arm.

It is expected that median PFS varied depending on line of therapy and the nature of physician's choice chemotherapy. The results for each of the individual chemotherapy regimens are considered as exploratory and showed that the treatment effects observed in individual chemotherapies were similar to that observed in the ITT set, with slight variations.

Additional analyses of PFS were provided in patients who received 0 line, 1 line and 2 lines of previous CT in metastatic setting. HR greatly varied between subgroups of patient who received &lt;2 prior lines of chemotherapy [no prior line: HR 0.50 (0.30, 0.84); one prior line: HR 0.50 (0.33, 0.76)] and subgroup of patients who received 2 prior lines of chemotherapy: HR 1.21 (0.69, 2.27).

Patients who received 2 prior lines of chemotherapy for mBC treated with olaparib (57 patients) experienced more progression or death (87.7%) than in chemotherapy arm (24 patients; number of events: 58.3%) with no numerical difference in median PFS (5.7 months versus 5.1 months). Resistant mechanisms of PARP inhibitors should have been further investigated to better determine the optimal sequence of use for PARP inhibitors and chemotherapy for breast cancer and to elaborate on more effective therapeutic strategies in metastatic BRCAm breast cancer. Given the data indicating a lower response to olaparib treatment after several lines of cytotoxic chemotherapy, the efficacy outcomes in subgroups of patient who received no prior line vs one or 2 prior lines of chemotherapy have been reflected in the SmpC section 5.1.

It is considered that anthracycline and taxane should be specified prior regimens in the indication, based on the proven OS benefit in the breast cancer setting for these drugs and the risk of loss of chance if not included. The study was performed under these conditions and no data have been produced to justify the extrapolation. Therefore, the indication reflects patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see SmPC sections 4.1 and 5.1).

Absence of progressive disease at the time of randomisation was reported for 46 patients in olaparib arm and 24 patients in chemotherapy arm. Of the 70 patients with non-progressive disease at randomisation, 38 patients received chemotherapy other than platinum.  In the provided post-hoc analysis of the subgroup of patients that had not progressed on chemotherapy other than platinum, the median PFS in the olaparib arm (n=22) was 8.3 months (95% CI 3.1-16.7) and 2.8 months (95% CI 1.4-4.2) in the chemotherapy arm (n=16) with a HR of 0.54 (95% CI 0.24-1.23). However, the number of patients is too limited to make meaningful conclusions on the efficacy in this subgroup (see SmPC section 5.1).

The currently available data do not provide sufficient level of evidence whether platinum would be more effective in first instance or after PARPi. Data in patients with prior platinum exposure are limited and it is not known whether olaparib would have activity in platinum-resistant breast cancers since these patients have not been enrolled in the OlympiAD trial. Information on prior and subsequent platinum therapy is considered relevant for the prescribers and has been included in the SmPC section 5.1.

<div style=\"page-break-after: always\"></div>

Other  chemotherapeutic  options  than  platinum  are  suggested  to  have  activity  in  HRD  tumours.  In particular, 'anthracycline-sensitive' tumours might be responsive to PARP inhibitors and/or induce crossresistance diminishing further responsiveness to PARPi. The MAH provided data on type of response to anthracycline in localised disease for patients enrolled in OlympiAD trials in order to estimate the initial responsiveness of tumours to anthracyclines that have a similar mechanism of action as platinum agents and might be considered, similarly to platinum, as potential treatment option to target tumours with HRD (data not shown).

Response  rate  for  patients  who  received  prior  anthracycline  in  localised  setting  was  13.2%  in  the population of patients enrolled and well balanced between arm (13.7% in the olaparib arm and 12.4% in the physician's choice of chemotherapy arm. However, 3 patients (1.5%) on the olaparib arm reported a complete response to prior anthracycline. The response rate and duration of response for patients with a response to prior anthracycline by platinum treatment was also presented (data not shown). Patients who received both prior anthracycline and platinum appear to have numerically worse outcomes than patients without prior exposure to platinum, indicating plausible resistance mechanisms.

Overall, except prior platinum therapy that is known to share a similar mechanism of action supported by clinical  data,  it  is  not  known  whether  other  type  of  prior  chemotherapy  could  have  an  impact  on  the response to PARP inhibitors in progressive BRCAm metastatic breast cancer. Anthracyclines are suggested to have similar mechanism of action but supporting data are still limited and OlympiAD trial results do not allow making conclusions on the role of anthracyclines in predicting HRD in tumours or in inducing crossresistance when used prior to olaparib.

The  Applicant  is  recommended  to  investigate  tumour  heterogeneity  and  mechanisms  of  resistance  to DNA-damaging agents that could impact the efficacy of Lynparza in different lines of therapy in patients with  BRCA1- and BRCA2-mutated tumours and breast tumours of particular histological and molecular subtypes.  The  investigation  of  efficacy  in  platinum-resistant  tumours  and  comparative  efficacy  to platinum agents is recommended.

Patients with locally advanced disease with a generally better prognosis have not been included in the pivotal trial, but the extrapolation to this patient population was considered acceptable by the CHMP given a similar clinical management for locally advanced and metastatic disease and based on a biological and pharmacological rationale.

Despite the relatively small sample size and the more advanced stage of disease of the patients included in the supportive studies, the data collected in patients with gBRCAm breast cancer from these studies is considered supportive.

Results reported in early phase trials with capsule formulation of olaparib appear to be inconsistent in terms of ORR reported in patients with germline BRCA mutations (varying from no response to 42.3% of ORR).

## Additional expert consultation

The SAG Oncology was consulted on the following aspects.

## 1. Can the efficacy of olaparib, demonstrated by selecting patients through gBRCA mutations in blood samples, be extrapolated to patients with tumors exhibiting only sBRCA mutations?

The majority of the SAG agreed that the validity of extrapolating the efficacy associated with PARP inhibitors observed in patients with germline BRCA mutations to patients with tumours with somatic BRCA mutations is only a hypothesis. Clinical data are lacking and extrapolating from the experience

<div style=\"page-break-after: always\"></div>

in ovarian cancer mainly based on the mechanism of action may not be appropriate in view of potential different tumour biology in terms of tumour microenvironment, immune system involvement, etc., between gBRCA- and sBRCA-associated breast cancers, and also considering that previous exposure to platinum differs in ovarian and breast cancer. Even if the BRCA-mutation is likely to be of great biological importance, the BRCA mutations per se may not be a sufficient 'driver' for tumorigenesis in sBRCA-associated breast cancer. Other factors are probably involved, such as the extent of tumour heterogeneity and if somatic BRCA loss is an early or late event, TP53 abnormalities, etc. Thus, the effect of olaparib in tumours harbouring only a somatic mutation, although an effect is biologically plausible, might be qualitatively or quantitatively different from the effect in gBRCA-associated breast cancer. In conclusion, there is uncertainty about both the treatment effect and a potentially differential side effect profile for sBRCA-associated breast cancer in comparison with gBRCA-associated disease.

According to a minority of SAG members, however, although acknowledging the challenges expressed above, given that the effect of somatic mutation is in terms of phenotype is similar to what is seen with a germline mutation, it seems counter-intuitive that the response would be different for somatic v. germline BRCA mutated breast cancer. Safety advantages might also be hypothesized as the drug would act more specifically on cancer cells (albeit not observed in ovarian cancer).

The SAG agreed that further clinical studies, even just looking at response rate and duration in patients with tumours harbouring somatic mutations, are needed in order to support the hypothesis of sBRCA as a treatment predictive factor in patients with breast cancer. Observational studies (registries) might also be useful to explore this hypothesis. Studies should also investigate the incidence of MDS and AML.

The SAG further noted that the control group of the pivotal clinical study excluded the use of a platinum-containing regimen, which is considered more efficacious than the physician's choice monotherapies used in the pivotal trial. Thus, a smaller effect of PARP-inhibition would be expected compared to current standard treatments (although the toxicity profile is likely improved compared to platinum-containing regimen). Furthermore, the compliance in the physician's choice arm indicated problems. Whether a PARP-inhibitor is more efficacious than platinum-containing regimens in the population of gBRCA-associated metastatic breast cancer has not been established.

## 2. Can efficacy be extrapolated from patients with gBRCA mutations to those with tumours displaying germline/somatic mutations in other genes potentially impacting HRD status?

Given the challenges expressed above regarding extrapolation to tumours harbouring somatic mutations and the less clear role for other mutations and other mechanisms causing HRD, further extrapolation is not considered justified.

## 3. What methods for establishing the HRD status of breast cancers are appropriate and available?

Currently, multiple different HRD assays have been explored. No studies of the effect of PARPinhibitors using HRD as a treatment predictive marker has been presented. Thus, no HRD assay can be considered having clinical validity and utility for predicting PARP inhibitor sensitivity.

4. What methods for establishing the BRCA1/2 locus-specific loss of heterozygosity (LOH) are appropriate and available? Is there an established relationship between the extent of LOH and the degree HRD in BRCA1/2 germline mutation-associated and sporadic breast tumours?

<div style=\"page-break-after: always\"></div>

There are methods available in a research setting, to test for BRCA1/2 locus-specific loss of heterozygosity; however, the SAG could not confirm to what extent any particular test is wellestablished. Furthermore, the relationship between LOH and HRD in germline mutation-associated and sporadic breast tumours is unclear, and mechanisms apart from LOH do operate in gBRCAassociated breast cancer as a mechanism for biallelic inactivation of BRCA1 and BRCA2, so the clinical utility of such tests over BRCA testing is not likely to be important in the context of treatment effect with PARP inhibition.

## 5. What is the likelihood of non-HRD tumours in patients with gBRCA mutations and HER2/hormone-receptor positive disease? Does this possibility give rise to further diagnostic considerations?

There are no data to quantify the rate of 'sporadic' cancer in germline mutation carriers, i.e. nonhereditary breast cancers occurring as a consequence of other mechanisms apart from the BCRA mutation in a germ line mutation carrier. Such cancers certainly exist, but in general, this is not considered to be of such clinical importance as to warrant further diagnostic considerations.

6. Could other genotype/phenotype features of breast tumours (e.g. molecular subtype, tumour grade, concomitant mutations, platinum/other chemotherapy sensitivity) indicate HRD, similarly to ovarian cancers?

The SAG was not aware of any patient, tumour, or treatment characteristics that could be used as a present valid indication of HRD; further clinical data are required.

## 2.4.4. Conclusions on the clinical efficacy

The results of the different efficacy outcomes in the pivotal OlympiAD study support efficacy of olaparib for the treatment of adult patients with germline BRCA1/2 -mutations who have HER2 negative metastatic breast cancer. There was a statistically significant improvement in PFS, with supportive data for PFS2, TFST  and  TSST  in  favour  of  olaparib  at  the  time  of  primary  analysis.  There  was  no  indication  on  a detrimental effect on OS at interim and final analysis at 64% maturity, with HR numerically favouring olaparib.

For  the  time  being,  there  is  no  clinical  data  available  on  the  responsiveness  of  breast  tumours  with somatic BRCA mutation to PARPi and the extrapolation is not supported in the context of different types of breast cancer.

## 2.5. Clinical safety

## Patient exposure

Across  the  entire  clinical  programme,  as  of  15  December  2017,  8319  patients  are  estimated  to  have received treatment with olaparib.

The OlympiAD study provides the main safety data for the use of olaparib 300 mg bd therapy in patients with HER2-negative metastatic gBRCAm breast cancer. The OlympiAD data are supported by safety data from patients receiving olaparib monotherapy at 300 mg bd (as a continuous dose) in an additional 10 studies, corresponding to a total of 759 patients with advanced solid tumours.

The majority of patients in the 300 mg bd pool had either ovarian, fallopian tube or primary peritoneal cancer  (335/759  [44.1%]  patients)  or  breast  cancer  (268/759  [35.3%]  patients).  Patients  with  other advanced solid tumours, including colon/colorectal (n=23), pancreas (n=12) or prostate (n=11) cancers

<div style=\"page-break-after: always\"></div>

were also treated in these studies. Patients were also being treated for different stages of their disease. Data are summarised regardless of BRCA mutation status.

Figure 22: Overview of the olaparib clinical programme as of 15 December 2017

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 49: Number of patients exposed to olaparib tablet monotherapy (as of DCO: 25 September 2017)

| Study/pooled dataset                                                           |   Number of patients receiving olaparib 300 mg bd (all tumour types) |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------|
| OlympiAD: Phase II HER2-negative breast cancer patients with gBRCA1/2 mutation |                                                                  205 |
| 300 mg bd pool                                                                 |                                                                  759 |
| OlympiAD: Phase II HER2-negative breast cancer patients with gBRCA1/2 mutation |                                                                  205 |
| Groups 4 and 6)                                                                |                                                                   24 |
| Study 04: Phase I Food interaction & QT                                        |                                                                   57 |
| Study 06: Phase I Renal impairment study                                       |                                                                   43 |
| Study 07: Phase I CYP3A4 inhibition and QT                                     |                                                                   56 |
| Study 08: Phase I CYP induction                                                |                                                                   19 |
| Study D081CC00001: Phase I anti-hormonal PK study                              |                                                                   69 |
| Study D081BC00001: Phase I Japan Monotherapy study                             |                                                                   19 |
| SOLO2: Phase III platinum-sensitive serous ovarian cancer                      |                                                                  195 |
| SOLO2: China cohort                                                            |                                                                   22 |
| D0816C00005: Phase I hepatic impairment study                                  |                                                                   30 |
| D081BC00002: China PK study                                                    |                                                                   20 |

ADME: Absorption, distribution, metabolism and elimination; bd: Twice daily; CYP: Cytochrome P450; gBRCA: Germline breast cancer susceptibility gene; HER2: Human epidermal growth factor receptor-2; PK: Pharmacokinetic(s); SAE: Serious adverse event;

## Overall extent of exposure: OlympiAD

A total of 302 patients were randomised in OlympiAD, 205 were randomised to the olaparib arm and 97 to the physician's choice of chemotherapy arm. All of the 205 patients randomised to olaparib received study treatment. Of the 91 patients who received treatment in the physician's choice of chemotherapy arm, 41 (42.3%) patients received capecitabine, 34 (35.1%) patients received eribulin and 16 (16.5%) patients received vinorelbine. Six patients randomised to the physician's choice of chemotherapy arm did not receive any treatment and were therefore excluded from the SAS.

<div style=\"page-break-after: always\"></div>

Table 50: Overall extent of exposure in OlympiAD (SAS)

|                          | Number (%) of patients   | Number (%) of patients   |
|--------------------------|--------------------------|--------------------------|
| Month (approximate)      | Olaparib 300 mg bd N=205 | Physician's choicea N=91 |
| Day 1                    | 205 (100)                | 91 (100)                 |
| ≥1 month (30.4 days)     | 201 (98.0)               | 87 (95.6)                |
| ≥3 months (91.3 days)    | 176 (85.9)               | 48 (52.7)                |
| ≥6 months (182.6 days)   | 123 (60.0)               | 25 (27.5)                |
| ≥9 months (273.9 days)   | 86 (42.0)                | 15 (16.5)                |
| ≥12 months (365.3 days)  | 57 (27.8)                | 9 (9.9)                  |
| ≥18 months (547.9 days)  | 39 (19.0)                | 2 (2.2)                  |
| ≥24 months (730.5 days)  | 18 (8.8)                 | 1 (1.1)                  |
| ≥30 months (913.1 days)  | 5 (2.4)                  | 0                        |
| ≥36 months (1095.8 days) | 2 (1.0)                  | 0                        |

Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine Rows are cumulative and patients are included if they have taken treatment beyond the treatment day stated in the parenthesis. A month is defined as 365.25/12 = 30.4375 days. Exposure includes treatment interruptions for olaparib and treatment delays for physican's choice of chemotherapy.

bd: Twice daily; CSR: Clinical study report; DCO: Data cut-off; SAS: Safety analysis set.

Data derived from Table 11.3.1.6.1, OlympiAD CSR Addendum, Module 5.3.5.1

(DCO: 25 September 2017).

<div style=\"page-break-after: always\"></div>

## Duration of treatment

Table 51: Duration of treatment in OlympiAD (SAS)

| Treatment duration (days)                             | Treatment duration (days)   | Olaparib300mgbd N=205   | Physician's choice N=91   |
|-------------------------------------------------------|-----------------------------|-------------------------|---------------------------|
| Total treatment duration (days)                       | Mean (sd)                   | 315.8 (249.04)          | 156.3 (150.83)            |
| Total treatment duration (days)                       | Median (range)              | 251.0 (14 - 1165)       | 105.0 (21 - 759)          |
| Total treatment duration (days)                       | Total treatment days        | 64744                   | 14226                     |
| Actual treatment duration (days)                      | Mean (sd)                   | 305.0 (245.48)          | NAb                       |
| Actual treatment duration (days)                      | Median (range)              | 230.0 (14 - 1158)       |                           |
| Actual treatment duration (days)                      | Total treatment days        | 62517                   |                           |
| Actual treatment duration at the assigned dose (days) | Mean (sd)                   | 243.9 (229.25)          | NAb                       |
| Actual treatment duration at the assigned dose (days) | Median (range)              | 162.0 (3 - 1061)        |                           |
| Actual treatment duration at the assigned dose (days) | Total treatment days        | 49502                   |                           |

Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine.

b Actual treatment duration (which excludes treatment interruptions) is not applicable to the physician's choice of chemotherapy arm in OlympiAD due to the complexity of defining the duration of an interruption).

bd: twice daily; CSR: Clinical study report; DCO: Data cut-off; NA: not applicable; SAS: Safety analysis set; sd: standard deviation.

Data derived from Table 11.3.1.1, OlympiAD CSR Addendum, Module 5.3.5.1 (DCO: 25 September 2017).

## Dose intensity

Table 52: Relative and percentage intended doses of study treatment in OlympiAD (SAS)

| Treatment duration (days)             | Treatment duration (days)   | Olaparib300mgbd N=205   | Physician's choicea N=91   |
|---------------------------------------|-----------------------------|-------------------------|----------------------------|
| Relative dose intensity (RDI) (days)  | N                           | 205                     | q06                        |
| Relative dose intensity (RDI) (days)  | Mean (sd)                   | 92.2 (12.81)            | 89.2 (20.88)               |
| Relative dose intensity (RDI) (days)  | Median (range)              | 99.4 (42 -100)          | 92.4 (49 -201)             |
| Percentage intended dose (PID) (days) | N                           | 205                     | 90b                        |
| Percentage intended dose (PID) (days) | Mean (sd)                   | 90.4 (15.30)            | 82.5 (25.31)               |
| Percentage intended dose (PID) (days) | Median (range)              | 99.4 (28 - 100)         | 84.9 (12 - 186)            |

a Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine

b One patient had no height measurement recorded at baseline. As planned dose for planned dose, and therefore not possible to calculate RDI and PID.

The RDI is the percentage of the actual dose delivered relative to the intended dose through to treatment discontinuation. The PID is the percentage of the actual dose delivered relative to the intended dose through to progression

bd: twice daily; CSR: Clinical study report; DCO: Data cut-off; NA: not applicable; PDI percentage intended dose; RDI relative dose intensity; SAS: Safety analysis set; sd: standard deviation.

Data derived from Table 11.3.1.4 OlympiAD CSR Addendum, Module 5.3.5.1 (DCO: 25 September 2017).

<div style=\"page-break-after: always\"></div>

Table 53: Mean daily dose of olaparib by time period in OlympiAD (SAS)

|                          | Number (%o) of patients by time period   | Number (%o) of patients by time period   | Number (%o) of patients by time period   | Number (%o) of patients by time period   | Number (%o) of patients by time period   |
|--------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Olaparib daily dose (mg) | Up to 3 months (N=205)                   | >3 to ≤6 months (N=176)                  | >6 to ≤9 months (N=123)                  | >9 to ≤12 months (N=86)                  | >12 months (N=56)                        |
| >600                     | 1 (0.5)a                                 | 0                                        | 0                                        | 0                                        | 0                                        |
| >500 to ≤600             | 171 (83.4)                               | 132 (75.0)                               | 88 (71.5)                                | 61 (70.9)                                | 36 (64.3)                                |
| >400 to≤500              | 22 (10.7)                                | 18 (10.2)                                | 11 (8.9)                                 | 10 (11.6)                                | 10 (17.9)                                |
| ≤400                     | 11 (5.4)                                 | 26 (14.8)                                | 24 (19.5)                                | 15 (17.4)                                | 10 (17.9)                                |

a This was Patient who took daily dose 900 mg olaparib (3 x 300 mg) for 1 day only, due to

bd: twice daily; CSR: Clinical study report; DCO: Date cut-off; SAS: Safety analysis set. Data derived from Table 11.3.1.7 and Appendix 12.2.10.3,OlympiAD CSR, Module 5.3.5.1 (DCO: 09 December 2016).

<div style=\"page-break-after: always\"></div>

## Dose modification

Table 54: Dose interruptions or delays and reductions in OlympiAD (SAS)

|                                                                    |                                                                    | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------|--------------------------|
| Treatment duration (days)                                          | Treatment duration (days)                                          | Olaparib 300 mg bd N=205 | Physician's choice* N=91 |
| Number of patients with no interruptions/delays                    | Number of patients with no interruptions/delays                    | 101 (49.3)               | 56 (61.5)                |
| Number of patients with an interruption/delay                      | Any                                                                | 104 (50.7)               | 35 (38.5)                |
| Number of patients with an interruption/delay                      | 1                                                                  | 42 (20.5)                | 21 (23.1)                |
| Number of patients with an interruption/delay                      | 2                                                                  | 32 (15.6)                | 7 (7.7)                  |
| Number of patients with an interruption/delay                      | 3                                                                  | 12 (5.9)                 | 2 (2.2)                  |
| Number of patients with an interruption/delay                      | 4                                                                  | 8 (3.9)                  | 2 (2.2)                  |
| Number of patients with an interruption/delay                      | >4                                                                 | 10 (4.9)                 | 3 (3.3)                  |
| Reason for interruption/delay                                      | Adverse event                                                      | 72 (35.1)                | 24 (26.4)                |
| Reason for interruption/delay                                      | Otherb                                                             | 66 (32.2)                | 22 (24.2)                |
| Number of patients with no reductions                              | Number of patients with no reductions                              | 150 (73.2)               | 63 (69.2)                |
| Number of patients with a reduction                                | Any                                                                | 55 (26.8)                | 28 (30.8)                |
| Number of patients with a reduction                                | 1                                                                  | 37 (18.0)                | 24 (26.4)                |
| Number of patients with a reduction                                | 2                                                                  | 17 (8.3)                 | 4 (4.4)                  |
| Number of patients with a reduction                                | 3                                                                  | 1 (0.5)                  | 0                        |
| Reason for reduction                                               | Adverse event                                                      | 52 (25.4)                | 28 (30.8)                |
| Reason for reduction                                               | Laboratory abnormality not reported as an adverse event            | 1 (0.5)                  | 0                        |
| Reason for reduction                                               | Other                                                              | 5 (2.4)                  | 0                        |
| Number of patients with both an interruption/delay and a reduction | Number of patients with both an interruption/delay and a reduction | 51 (24.9)                | 15 (16.5)                |

Note: Dose interruptions were used to manage toxicity in the olaparib arm, dose delays were used to manage toxicity in the physician's choice of chemotherapy arm.

a Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine

Reasons for interruptions are not mutually exclusive for patients with multiple interruptions, although feasons were counted only once per category.

bd: twice daily; CSR: Clinical study report; DCO: Data cut-off; SAS: Safety analysis set. Data derived fromIable 11.3.1.2.1 and Table 11.3.1.3 OlympiADCSRAddendum,Module 5.3.5.1

(DC0: 25 September 2017).

<div style=\"page-break-after: always\"></div>

## Overall extent of exposure: 300 mg bd pool

Table 55: Overall extent of exposure in the 300 mg bd pool

| Month (days)             | Number (%) of patients Olaparib 300mg bd N=759   |
|--------------------------|--------------------------------------------------|
| 0                        | 759 (100.0)                                      |
| ≥1 month (30.4 days)     | 698 (92.0)                                       |
| ≥3 months (91.3 days)    | 526 (69.3)                                       |
| ≥6 months (182.6 days)   | 378 (49.8)                                       |
| ≥9 months (273.9 days)   | 214 (28.2)                                       |
| ≥12 months (365.3 days)  | 144 (19.0)                                       |
| ≥24 months (730.5 days)  | 80 (10.5)                                        |
| ≥30 months (913.1 days)  | 20 (2.6)                                         |
| ≥36 months (1095.8 days) | 2 (0.3)                                          |

Duration of treatment was collected in days. An approximation of treatment duration in months was made by dividing the time points in days by 30.4375 (based on 365.25 days/12 months) and selecting the one that was closest to (but not longer than) the treatment month.

Rows are cumulative and patients are included if they have taken treatment beyond the treatment day stated in the parenthesis bd: Twice daily; DCO: Data cut-off.

Data derived from Iable 2.7.4.1.9.2, 300 mg bd pool, MIodule 5.3.5.3 (DCO: 25 September 2017).

Demographics and other characteristics of patients in OlympiAD study are presented in Table 10 in the section on clinical efficacy.

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 56: Number (%) of patients who had at least 1 AE in any category in OlympiAD (SAS)

|                                                         | Number (%) of patients   | Number (%) of patients   |
|---------------------------------------------------------|--------------------------|--------------------------|
| AE categorya                                            | Olaparib 300 mg bd N=205 | Physician's choiceb N=91 |
| Any AE                                                  | 200 (97.6)               | 87 (95.6)                |
| Any AE causally related to study drug                   | 178 (86.8)               | 74 (81.3)                |
| Any AE of CTCAE Grade 3 or higher                       | 78 (38.0)                | 45 (49.5)                |
| Any AE with outcome = Death                             | 1 (0.5)                  | 0                        |
| Any SAE (including events with outcome = death)         | 34 (16.6)                | 15 (16.5)                |
| Any AE leading to discontinuation of study treatment    | 10 (4.9)                 | 7 (7.7)                  |
| Any AE leading to dose reduction of study treatment     | 52 (25.4)                | 28 (30.8)                |
| Any AE leading to interruption/delay of study treatment | 74 (36.1)                | 26 (28.6)                |

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories

Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine As assessed by the investigator.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE: Adverse event; bd: Twice daily; CSR: Climical study report; CTCAE: Common Terminology Criteria for Adverse Events; DCO: Data cut-off.; N: Total number of patients; SAE: serious adverse event; SAS: Safety analysis set.

Data derived from Table 11.3.2.1.1, Table 11.3.2.9.l and Table 11.3.2.9.2 OlympiAD CSR Addendum, MIodule 5.3.5.1 (DC0: 25 September 2017).

<div style=\"page-break-after: always\"></div>

Table 57: Number (%) of patients who had at least 1 AE in any category (olaparib treatment groups) in OlympiAD and the 300 mg bd pool

|                                                         | Nunber (%o) of patients Olaparib 300 mg bd   | Nunber (%o) of patients Olaparib 300 mg bd   |
|---------------------------------------------------------|----------------------------------------------|----------------------------------------------|
| AE category                                             | OlympiAD SAS N=205                           | 300 mg bd pool N=759                         |
| Any AE                                                  | 200 (97.6)                                   | 741 (97.6)                                   |
| Any AE causally related to study drug                   | 178 (86.8)                                   | 654 (86.2)                                   |
| Any AE of CTCAE Grade 3 or higher                       | 78 (38.0)                                    | 278 (36.6)                                   |
| Any AE with outcome = Death                             | 1 (0.5)                                      | 3 (0.4)                                      |
| Any SAE (including events with outcome = death)         | 34 (16.6)                                    | 143 (18.8)                                   |
| Any AE leading to discontinuation of study treatment    | 10 (4.9)                                     | 50 (6.6)                                     |
| Any AE leading to dose reduction of study treatment     | 52 (25.4)                                    | 134 (17.7)                                   |
| Any AE leading to interruption/delay of study treatment | 74 (36.1)                                    | 239 (31.5)                                   |

Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories

As assessed by the investigator.

300 mg bd pool includes data from OlympiAD

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE: Adverse event; bd: Twice daily; CSR: Clinical study report; CTCAE: Common Terminology Criteria for Adverse Events: DCO: Data cut-off.: N: Total number of patients; SAE: serious adverse event; SAS: Safety analysis set.

Data derived from Table 11.3.2.1.1, Table 11.3.2.9.1 and Iable 11.3.2.9.2 OlympiAD CSR Addendum, MIodule 5.3.5.1 (DC0: 25 September 2017); Iable 2.7.4.1.1.1, 300 mg bd pool, Module 5.3.5.3 (DC0: 25 September 2017).

## Common adverse events: OlympiAD

<div style=\"page-break-after: always\"></div>

Table 58: Most common AEs (reported by ≥10% patients in either arm) and adjusted by patient years' exposure in OlympiAD (SAS)

|                                   | Olaparib 300 mg bd N=205           | Olaparib 300 mg bd N=205            | Physician's choicea N=91           | Physician's choicea N=91            |
|-----------------------------------|------------------------------------|-------------------------------------|------------------------------------|-------------------------------------|
| Preferred term                    | Number (%) of patients with events | Event rate (per 1000 patient years) | Number (%) of patients with events | Event rate (per 1000 patient years) |
| Any AE                            | 200 (97.6)                         | 12722.05                            | 87 (95.6)                          | 23451.48                            |
| Nausea                            | 119 (58.0)                         | 1367.12                             | 32 (35.2)                          | 980.04                              |
| Anaemia                           | 81 (39.5)                          | 575.83                              | 23 (25.3)                          | 674.38                              |
| Vomiting                          | 66 (32.2)                          | 441.23                              | 14 (15.4)                          | 341.40                              |
| Neutropenia                       | 37 (18.0)                          | 234.14                              | 28 (30.8)                          | 862.97                              |
| Fatigue                           | 61 (29.8)                          | 406.96                              | 22 (24.2)                          | 597.97                              |
| Diarrhoea                         | 42 (20.5)                          | 261.52                              | 20 (22.0)                          | 602.72                              |
| PPE syndrome                      | 1 (0.5)                            | 5.21                                | 19 (20.9)                          | 593.85                              |
| WBC count decreased               | 33 (16.1)                          | 192.02                              | 19 (20.9)                          | 504.82                              |
| Headache                          | 42 (20.5)                          | 250.20                              | 14 (15.4)                          | 349.45                              |
| Neutrophil count decreased        | 23 (11.2)                          | 128.04                              | 17 (18.7)                          | 467.25                              |
| Pyrexia                           | 30 (14.6)                          | 172.90                              | 16 (17.6)                          | 440.43                              |
| ALT increased                     | 24 (11.7)                          | 136.31                              | 16 (17.6)                          | 426.23                              |
| Decreased appetite                | 35 (17.1)                          | 208.31                              | 11 (12.1)                          | 265.76                              |
| Cough                             | 35 (17.1)                          | 209.97                              | 6 (6.6)                            | 143.54                              |
| AST increased                     | 20 (9.8)                           | 111.26                              | 15 (16.5)                          | 385.23                              |
| Back pain                         | 30 (14.6)                          | 169.94                              | 8 (8.8)                            | 202.85                              |
| Upper respiratory tract infection | 27 (13.2)                          | 155.87                              | 9 (9.9)                            | 228.87                              |
| Constipation                      | 26 (12.7)                          | 147.35                              | 12 (13.2)                          | 297.72                              |
| Asthenia                          | 19 (9.3)                           | 109.25                              | 12 (13.2)                          | 318.53                              |
| Alopecia                          | 7 (3.4)                            | 37.26                               | 12 (13.2)                          | 300.60                              |
| Arthralgia                        | 23 (11.2)                          | 131.09                              | 9 (9.9)                            | 215.42                              |
| Leukopenia                        | 23 (11.2)                          | 134.70                              | 9 (9.9)                            | 233.11                              |
| Stomatitis                        | 16 (7.8)                           | 89.47                               | 10 (11.0)                          | 244.48                              |

Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine. Table ordered by decreasing incidence in either treatment arm.

AE: Adverse event; ALT alanine aminotransferase; AST aspartate aminotransferase; bd: Twice daily; CSR: Climical study report; CTCAE: Common Terminology Criteria for Adverse Events; DCO: Data cut-off; N: Total number of patients; PPE Palmar-plantar erythrodysaesthesia; SAE: serious adverse event; SAS: safety analysis set.

Data derived from Table 11.3.2.2, OlympiAD CSR Addendum, Module 5.3.5.1 (DCO: 25 September 2017).

<div style=\"page-break-after: always\"></div>

In OlympiAD, the AE preferred terms (PTs) that were reported at a 5% greater frequency in the olaparib 300  mg  tablet  bd  group  compared  with  the  physician's  choice  of  chemotherapy  group  were:  nausea (58.0% of patients on olaparib vs. 35.2% on the physician's choice of chemotherapy), anaemia (39.5% vs.  25.3%),  vomiting  (32.2%  vs.  15.4%),  fatigue  (29.8%  vs.  24.2%),  headache  (20.5%  vs.  15.4%), cough (17.1% vs. 6.6%), decreased appetite (17.1% vs. 12.1%) and back pain (14.6% vs. 8.8%).

Whereas, the AE preferred terms (PTs) that were reported at a 5% greater frequency in the physician's choice  of  chemotherapy  group  compared with the olaparib 300 mg tablet bd group were: neutropenia (30.8% on the physician's choice of chemotherapy vs. 18.0% on olaparib), PPE syndrome (20.9% vs. 0.5%), WBC count decreased (20.9% vs. 16.1%), neutrophil count decreased (18.7% vs. 11.2%), ALT increased (17.6% vs. 11.7%), AST increased (16.5% vs. 9.8%) and alopecia (13.2% vs. 3.4%).

Common adverse events: tablet pool

Table 59: Most common AEs (reported in ≥10%) in the olaparib treatment arm of OlympiAD or the 300 mg bd pool

|                                   | Number (%) of patients Olaparib 300 mg bd   | Number (%) of patients Olaparib 300 mg bd   |
|-----------------------------------|---------------------------------------------|---------------------------------------------|
| Preferred term                    | OlympiAD SAS N=205                          | 300 mg bd pool N=759                        |
| Any AE                            | 200 (97.6)                                  | 741 (97.6)                                  |
| Nausea                            | 119 (58.0)                                  | 455 (59.9)                                  |
| Anaemia                           | 81 (39.5)                                   | 277 (36.5)                                  |
| Vomiting                          | 66 (32.2)                                   | 260 (34.3)                                  |
| Fatigue                           | 61 (29.8)                                   | 297 (39.1)                                  |
| Diarrhoea                         | 42 (20.5)                                   | 187 (24.6)                                  |
| Headache                          | 42 (20.5)                                   | 129 (17.0)                                  |
| Neutropenia                       | 37 (18.0)                                   | 94 (12.4)                                   |
| Cough                             | 35 (17.1)                                   | 110 (14.5)                                  |
| Decreased appetite                | 35 (17.1)                                   | 178 (23.5)                                  |
| WBC count decreased               | 33 (16.1)                                   | 56 (7.4)                                    |
| Pyrexia                           | 30 (14.6)                                   | 89 (11.7)                                   |
| Back pain                         | 30 (14.6)                                   | 86 (11.3)                                   |
| Upper respiratory tract infection | 27 (13.2)                                   | 61 (8.0)                                    |
| Constipation                      | 26 (12.7)                                   | 121 (15.9)                                  |
| ALT increased                     | 24 (11.7)                                   | 51 (6.7)                                    |
| Neutrophil count decreased        | 23 (11.2)                                   | 47 (6.2)                                    |
| Arthralgia                        | 23 (11.2)                                   | 83 (10.9)                                   |
| Leukopenia                        | 23 (11.2)                                   | 61 (8.0)                                    |
| Dysgeusia                         | 19 (9.3)                                    | 116 (15.3)                                  |

<div style=\"page-break-after: always\"></div>

| Asthenia       | 19 (9.3)   | 105 (13.8)   |
|----------------|------------|--------------|
| Dyspnoea       | 18 (8.8)   | 100 (13.2)   |
| Dizziness      | 18 (8.8)   | 77 (10.1)    |
| Abdominal pain | 14 (6.8)   | 107 (14.1)   |

300 mg bd pool includes data from OlympiAD

Table ordered by incidence of events in the OlympiAD study

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE: Adverse event; ALT: Alanine aminotransferase; bd: Twice daily; CSR: Clinical study report; DCO: Data cut-off.; N: Total number of patients; SAS: Safety analysis set; WBC: White blood cell.

Data derived from Table 11.3.2.5,OlympiAD CSR Addendum, Module 5.3.5.1 (DCO: 25 September 2017):

Table 2.7.4.1.1.2 and Iable 11.3.2.1.1, 300 mg bd pool, Module 5.3.5.3 (DCO: 25 September 2017).

<div style=\"page-break-after: always\"></div>

## Adverse events by treatment period: OlympiAD

Table 60: Onset of AE in the first 3 months and 3-6 months of treatment for the most common AEs (reported in ≥10% of patients in either arm) in OlympiAD (SAS)

|                                   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-----------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                   | Onset in 0-3months       | Onset in 0-3months       | Onsetin3-6months         | Onsetin3-6months         |
| System organ class                | Olaparib300 mg bd        | Physician's choicea      | Olaparib300 mg bd        | Physician's choicea      |
| Preferred term                    | N=205                    | N=91                     | N=185                    | N=61                     |
| Nausea                            | 105 (51.2)               | 27 (29.7)                | 15 (8.1)                 | 1 (1.6)                  |
| Anaemia                           | 55 (26.8)                | 19 (20.9)                | 27 (14.6)                | 6 (9.8)                  |
| Neutropenia                       | 23 (11.2)                | 25 (27.5)                | 13 (7.0)                 | 4 (6.6)                  |
| Vomiting                          | 43 (21.0)                | 14 (15.4)                | 13 (7.0)                 | 1 (1.6)                  |
| Fatigue                           | 45 (22.0)                | 20 (22.0)                | 10 (5.4)                 | 0                        |
| Diarrhoea                         | 32 (15.6)                | 20 (22.0)                | 7 (3.8)                  | 4 (6.6)                  |
| PPE syndrome                      | 0                        | 17 (18.7)                | 1 (0.5)                  | 1 (1.6)                  |
| WBC count decreased               | 24 (11.7)                | 16 (17.6)                | 10 (5.4)                 | 5 (8.2)                  |
| Headache                          | 35 (17.1)                | 12 (13.2)                | 4 (2.2)                  | 2 (3.3)                  |
| Neutrophil count decreased        | 17 (8.3)                 | 16 (17.6)                | 9 (4.9)                  | 6 (9.8)                  |
| Pyrexia                           | 17 (8.3)                 | 14 (15.4)                | 6 (3.2)                  | 3 (4.9)                  |
| ALT increased                     | 19 (9.3)                 | 15 (16.5)                | 7 (3.8)                  | 3 (4.9)                  |
| Cough                             | 16 (7.8)                 | 5 (5.5)                  | 14 (7.6)                 | 0                        |
| AST increased                     | 14 (6.8)                 | 12 (13.2)                | 5 (2.7)                  | 2 (3.3)                  |
| Decreased appetite                | 30 (14.6)                | 10 (11.0)                | 3 (1.6)                  | 0                        |
| Constipation                      | 16 (7.8)                 | 11 (12.1)                | 3 (1.6)                  | 1 (1.6)                  |
| Asthenia                          | 13 (6.3)                 | 11 (12.1)                | 5 (2.7)                  | 2 (3.3)                  |
| Alopecia                          | 3 (1.5)                  | 10 (11.0)                | 1 (0.5)                  | 0                        |
| Upper respiratory tract infection | 12 (5.9)                 | 7 (7.7)                  | 6 (3.2)                  | 3 (4.9)                  |
| Back pain                         | 7 (3.4)                  | 8 (8.8)                  | 7 (3.8)                  | 0                        |
| Dyspnoea                          | 6 (2.9)                  | 8 (8.8)                  | 7 (3.8)                  | 1 (1.6)                  |
| Stomatitis                        | 6 (2.9)                  | 9 (9.9)                  | 5 (2.7)                  | 1 (1.6)                  |
| Arthralgia                        | 10 (4.9)                 | 8 (8.8)                  | 4 (2.2)                  | 0                        |
| Leukopenia                        | 11 (5.4)                 | 8 (8.8)                  | 10 (5.4)                 | 2 (3.3)                  |

a Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine

Includes AEs with an onset date between the date of first dose and 30 days following the date oflast dose of study treatment.

AE: Adverse event, ALT: alanine aminotransferase; AST: aspartate aminotransferase; bd: Twice daily; CSR: Clinical study report; CTCAE: Common Terminology Criteria for Adverse Events; DCO: Data cut-off; N: Total number of patients; PPE: Palmar-plantar erythrodysaesthesia; SAE: serious adverse event; SAS: safety analysis set; WBC: White blood cell.

Data derived from Iable 2.7.4.1.7.3, MIodule 5.3.5.3 (DCO: 25 September 2017).

## Causally-related adverse events: OlympiAD

<div style=\"page-break-after: always\"></div>

Table 61: Most common AEs of CTCAE Grade 3 or higher (reported in ≥2% patients in either arm) in OlympiAD (SAS)

|                                                      | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------------------|--------------------------|--------------------------|
| System organ class Preferred term                    | Olaparib 300 mg bd N=205 | Physician's choicea N=91 |
| Any Grade≥3 AE                                       | 78 (38.0)                | 45 (49.5)                |
| Blood and lymphatic system disorders                 | 38 (18.5)                | 18 (19.8)                |
| Anaemia                                              | 32 (15.6)                | 4 (4.4)                  |
| Neutropenia                                          | 11 (5.4)                 | 12 (13.2)                |
| Leukopenia                                           | 5 (2.4)                  | 3 (3.3)                  |
| Febrile neutropenia                                  | 0                        | 3 (3.3)                  |
| Investigations                                       | 23 (11.2)                | 19 (20.9)                |
| Neutrophil count decreased                           | 10 (4.9)                 | 12 (13.2)                |
| WBC count decreased                                  | 7 (3.4)                  | 9 (9.9)                  |
| Platelet count decreased                             | 5 (2.4)                  | 1 (1.1)                  |
| AST increased                                        | 5 (2.4)                  | 0                        |
| GGT increased                                        | 4 (2.0)                  | 1 (1.1)                  |
| Musculoskeletal and connective tissue disorder's     | 9 (4.4)                  | 4 (4.4)                  |
| Back pain                                            | 4 (2.0)                  | 1 (1.1)                  |
| General disorders and administration site conditions | 10 (4.9)                 | 2 (2.2)                  |
| Fatigue                                              | 7 (3.4)                  | 1 (1.1)                  |
| Respiratory, thoracic and mediastinal disorders      | 6 (2.9)                  | 3 (3.3)                  |
| Dyspnoea                                             | 2 (1.0)                  | 2 (2.2)                  |
| Nervous system disorders                             | 6 (2.9)                  | 3 (3.3)                  |
| Headache                                             | 2 (1.0)                  | 2 (2.2)                  |
| Skin and subcutaneous tissue disorders               | 1 (0.5)                  | 3 (3.3)                  |
| PPE syndrome                                         | 0                        | 2 (2.2)                  |

卫 Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment. Table ordered by decreasing incidence im either treatment arm by System Organ Class and Preferred Term.

AE: Adverse event; AST Aspartate aminotransferase; bd: Twice daily; CSR: Clinical study report; CTCAE: Common Terminology Criteria for Adverse Events; DCO: Data cut-off; GGT: Gamma-glutamyltransferase; N: Total number of patients; PPE Palmar-plantar erythrodysaesthesia; SAE: serious adverse event; SAS: safety analysis set; WBC White blood cell count.

Data derived from Table 11.3.2.7, OlympiAD CSR Addendum, MIodule 5.3.5.1 (DCO: 25 September 2017).

<div style=\"page-break-after: always\"></div>

Table 62: Most common AEs of CTCAE Grade 3 or higher (reported in ≥2% patients in olaparib treatment arm of OlympiAD and the 300 mg bd pool

|                                                      | Number (%o) of patients Olaparib 300 mg bd   | Number (%o) of patients Olaparib 300 mg bd   |
|------------------------------------------------------|----------------------------------------------|----------------------------------------------|
| System organ class Preferred term                    | OlympiAD SAS N=205                           | 300 mg bd pool N=759                         |
| Any Grade ≥3 AE                                      | 78 (38.0)                                    | 278 (36.6)                                   |
| Blood and lymphatic system disorders                 | 38 (18.5)                                    | 132 (17.4)                                   |
| Anaemia                                              | 32 (15.6)                                    | 111 (14.6)                                   |
| Neutropenia                                          | 11 (5.4)                                     | 29 (3.8)                                     |
| Leukopenia                                           | 5 (2.4)                                      | 12 (1.6)                                     |
| Investigations                                       | 23 (11.2)                                    | 49 (6.5)                                     |
| Neutrophil count decreased                           | 10 (4.9)                                     | 21 (2.8)                                     |
| WBC count decreased                                  | 7 (3.4)                                      | 13 (1.7)                                     |
| AST increased                                        | 5 (2.4)                                      | 7 (0.9)                                      |
| Platelet count decreased                             | 5 (2.4)                                      | 10 (1.3)                                     |
| GGT increased                                        | 4 (2.0)                                      | 6 (0.8)                                      |
| General disorders and administration site conditions | 10 (4.9)                                     | 46 (6.1)                                     |
| Fatigue                                              | 7 (3.4)                                      | 24 (3.2)                                     |
| MIusculoskeletal and connective tissue disorder's    | 9 (4.4)                                      | 18 (2.4)                                     |
| Back pain                                            | 4 (2.0)                                      | 7 (0.9)                                      |

300 mg bd pool includes data from OlympiAD

Table ordered by incidence of events in the OlympiAD study

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE: Adverse event; bd: Twice daily; CSR: Clinical study report; CTCAE: Common Terminology Criteria for Adverse Events; DCO: Data cut-off.; N: Total number of patients; SAS: Safety analysis set.

Data derived from Table 11.3.2.7, OlympiAD CSR Addendum, Module 5.3.5.1 (DCO: 25 September 2017); Table 2.7.4.1.1.5, 300 mg bd pool, Module 5.3.5.3 (DC0: 25 September 2017).

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Table 63: Patients who died in OlympiAD (FAS)

|                                                                                              | Number (%o) of patients   | Number (%o) of patients   |
|----------------------------------------------------------------------------------------------|---------------------------|---------------------------|
| Category                                                                                     | Olaparib 300 mg bd N=205  | Physician's choicea N=97  |
| Total number of deaths                                                                       | 130 (63.4)                | 62 (63.9)                 |
| Death related to disease under investigation only (death <30 days after last treatment dose) | 3 (1.5)                   | 4 (4.1)                   |
| Death related to disease under investigation only (death >30 days after last treatment dose) | 117 (57.1)                | 57 (58.8)                 |
| AE with outcome = death only                                                                 | 1 (0.5)                   | 0                         |
| Death related to disease and an AE with outcome = death                                      | 0                         | 0                         |
| Deaths >30 days after last treatment dose, unrelated to AE or disease under investigation    | 9 (4.4)                   | 1 (1.0)                   |

Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE: Adverse event; bd: Twice daily; CSR: Clinical study report; DCO: Data cut-off; FAS: full analysis set; N: Total number of patients.

Data derived from Table 11.3.3.1.1 and Table 11.3.3.2.1, OlympiAD CSR Addendum, MIodule 5.3.5.1 (DC0: 25 September 2017).

<div style=\"page-break-after: always\"></div>

Table 64: Patients who died in the olaparib treatment arm of OlympiAD and the 300 mg bd pool

|                                                                                           | Number (%o) of patients Olaparib300mg bd   | Number (%o) of patients Olaparib300mg bd   |
|-------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|
| AE category                                                                               | OlympiAD SAS N=205                         | 300 mg bd pool N=759                       |
| Total number of deaths                                                                    | 130 (63.4)                                 | 205 (27.0)                                 |
| Death related to disease under investigation only                                         | 120 (58.5)                                 | 190 (25.0)                                 |
| AE with outcome = death only                                                              | 1 (0.5)                                    | 1 (0.1)                                    |
| Death related to disease and an AE with outcome = death                                   | 0                                          | 2 (0.3)                                    |
| Deaths >30 days after last treatment dose, umrelated to AE or disease under imvestigation | 9 (4.4)b                                   | 12 (1.6)c                                  |

Patients who died and are not captured in the earlier categories

## Serious adverse events: OlympiAD

Table 65: Most common SAEs (≥2 patients in either treatment arm) in OlympiAD (SAS)

|                                                      | Number (%o) of patients   | Number (%o) of patients   |
|------------------------------------------------------|---------------------------|---------------------------|
| System organ class Preferred term                    | Olaparib 300 mg bd N=205  | Physician'schoicea N=91   |
| PatientswithanySAE                                   | 34 (16.6)                 | 15 (16.5)                 |
| Bloodandlymphaticsystemdisorder's                    | 6 (2.9)                   | 6 (6.6)                   |
| Anaemia                                              | 5 (2.4)                   | 2 (2.2)                   |
| Febrile neutropenia                                  | 0                         | 2 (2.2)                   |
| Respiratory,thoracicandmediastinaldisorders          | 5 (2.4)                   | 2 (2.2)                   |
| Dyspnoea                                             | 3 (1.5)                   | 0                         |
| General disorder's and administrationsite conditions | 3 (1.5)                   | 1 (1.1)                   |
| Pyrexia                                              | 3 (1.5)                   | 0                         |
| Investigations                                       | 3 (1.5)                   | 0                         |
| Neutrophil count decreased                           | 2 (1.0)                   | 0                         |
| Plateletcountdecreased                               | 2 (1.0)                   | 0                         |

The majority of SAEs had resolved with either no action taken or following a temporary dose interruption or delay/dose change, or were recovering. Sixteen patients (9 in the olaparib arm and 7 in the physician's choice of chemotherapy arm) had SAEs that were 'not recovered/not resolved' or 'resolving' at the DCO date for this analysis.

At an event level, the 34 olaparib-treated patients had a total of 46 SAEs and the 15 physician's choice of chemotherapy-treated patients had a total of 23 SAEs.

<div style=\"page-break-after: always\"></div>

Table 66: Most common SAEs (reported by ≥2 patients in the olaparib treatment arm of OlympiAD and/or reported by ≥5 patients in the 300 mg bd pool)

|                                                       | Nunber (%) of patients Olaparib 300 mg bd   | Nunber (%) of patients Olaparib 300 mg bd   |
|-------------------------------------------------------|---------------------------------------------|---------------------------------------------|
| System organ class Preferred term                     | OlympiAD SAS N=205                          | 300 mg bd pool N=759                        |
| Patients with any SAE                                 | 34 (16.6)                                   | 143 (18.8)                                  |
| Blood and lynphatic system disorders                  | 6 (2.9)                                     | 39 (5.1)                                    |
| Anaemia                                               | 5 (2.4)                                     | 31 (4.1)                                    |
| Infections and infestations                           | 6 (2.9)                                     | 32 (4.2)                                    |
| Pneumonia                                             | 1 (0.5)                                     | 7 (0.9)                                     |
| Urinary tract infection                               | 0                                           | 6 (0.8)                                     |
| Gastrointestinal disorder's                           | 0                                           | 22 (2.9)                                    |
| Abdominal pain                                        | 0                                           | 5 (0.7)                                     |
| General disorder's and administration site conditions | 3 (1.5)                                     | 14 (1.8)                                    |
| Pyrexia                                               | 3 (1.5)                                     | 5 (0.7)                                     |
| Respiratory, thoracic and mediastinal disorder's      | 5 (2.4)                                     | 10 (1.3)                                    |
| Dyspnoea                                              | 3 (1.5)                                     | 4 (0.5)                                     |
| Investigations                                        | 3 (1.5)                                     | 6 (0.8)                                     |
| Neutrophil count decreased                            | 2 (1.0)                                     | 3 (0.4)                                     |
| Platelet count decreased                              | 2 (1.0)                                     | 2 (0.3)                                     |

300 mg bd pool includes data from OlympiAD

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

bd: Twice daily; CSR: Clinical study report; DCO: Data cut-off.; N: Total number of patients; SAE: Serious adverse event; SAS: Safety analysis set.

Data derived from Table 11.3.4.1.1.1, OlympiAD CSR Addendum, MIodule 5.3.5.1

(DC0: 25 September 2017): Iable 2.7.4.1.3.1, 300 mg bd pool, Module 5.3.5.3 (DCO: 25 September 2017).

## Other significant events

## Important potential risks

MDS/AML, pneumonitis and new primary malignancies are important potential risks (see RMP).Reports for events of MDS/AML and new primary malignancies continue to be collected beyond 30 days after the last dose of olaparib, by use of targeted safety questionnaire, and can be reported at any point in OS followup.Since MDS/AML, pneumonitis and new primary malignancies occur at low frequency, to improve the sensitivity and precision of estimates to characterise these important potential risks, information has been drawn from larger pools of olaparib studies:

Olaparib  monotherapy  combined  therapeutic  dose  pool  (n=1525  patients)  consists  of  all  patients  who have received  olaparib  as  a  monotherapy  treatment  (tablet  or  capsule  formulation)  at  the  therapeutic dose  (ie,  300  mg  bd  tablet  formulation  or  400  mg  bd  capsule  formulation  as  a  continuous  dose).  All patients from the 300 mg bd pool are included in the olaparib monotherapy combined therapeutic dose pool.

<div style=\"page-break-after: always\"></div>

Olaparib monotherapy all doses pool (n=1957 patients) consists of all patients who have received at least 1 dose of olaparib as a monotherapy treatment (tablet or capsule formulation) at any dose. In addition, 66 patients from Study 41 are included. All patients from the olaparib monotherapy combined therapeutic dose pool are included in the olaparib monotherapy all doses pool.

Entire clinical programme as of 15 December 2017 (n=8319 patients): This pool includes all the studies shown in Table 1, any studies where olaparib is given in combination with other anticancer treatments, investigator-sponsored studies (ISSs) and data from the managed access programme (MAP).

## Myelodysplastic syndrome/acute myeloid leukaemia

The table below shows the AEs of MDS/AML in the olaparib all doses monotherapy pool and across the entire olaparib clinical programme, and provides incidence rates.

Table 67: Summary of AEs of MDS/AML occurring across the olaparib programme

|                                                      | TEAEsa + AEs after 30 day follow-up   | TEAEsa + AEs after 30 day follow-up   | TEAEsa + AEs after 30 day follow-up   | TEAEsa + AEs after 30 day follow-up   |
|------------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                                      | Olaparib                              | Olaparib                              | Physician's choiceb                   | Physician's choiceb                   |
| Data source                                          | Number of cases                       | Incidence                             | Number of cases                       | Incidence                             |
| OlympiAD N=205 olaparib                              | 0                                     | 0                                     | 0                                     | 0                                     |
| Olaparib monotherapy, all doses pool N=1957 olaparib | 23                                    | 1.18%                                 | NA                                    | NA                                    |
| Entire climical programme pool N=8319 olaparib       | 50                                    | 0.60%                                 | NA                                    | NA                                    |

b Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine

TEAEs are events occurring on-study or during 30-day follow-up.

AE: Adverse event; AML: Acute myeloid leukaemia; MDS: Myelodysplastic syndrome; N: Total number of patients; NA: Not applicable; TEAE: Treatment emergent adverse event.

Data derived from Table 11.3.2.2 and Table 11.3.2.4, OlympiAD CSR Addendum, Module 5.3.5.1 (DC0: 25 September 2017)

## New primary malignancies

In the OlympiAD study, there was 1 event of new primary malignancy reported in the olaparib arm (0.5% of  patients)  compared  with  no  event  in  physician's  choice  of  chemotherapy  arm.  The  olaparib-treated patient had an AE of malignant melanoma in situ of CTCAE Grade 1; this was a non-serious event in a patient who had a medical history of melanoma and which was reported as resolved after a duration of one day.

Table 68 shows the AEs of new primary malignancies in OlympiAD compared with other studies in the clinical programme, and provides incidence rates.

<div style=\"page-break-after: always\"></div>

Table 68: Summary of AEs of new primary malignancies occurring across the olaparib programme

|                                                      | TEAEs+ AEs after 30 day follow-up   | TEAEs+ AEs after 30 day follow-up   | TEAEs+ AEs after 30 day follow-up   | TEAEs+ AEs after 30 day follow-up   |
|------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                                      | Olaparib                            | Olaparib                            | Physician's choiceb                 | Physician's choiceb                 |
| Data source                                          | Number of cases                     | Incidence                           | Number of cases                     | Incidence                           |
| OlympiAD N=205 olaparib N=91 physician's choice      | 1                                   | 0.5%                                | 0                                   | 0                                   |
| Olaparib monotherapy, all doses pool N=1957 olaparib | 24                                  | 1.23%                               | NA                                  | NA                                  |
| Entire clinical programme pool N=8319 olaparib       | 59                                  | 0.71%                               | NA                                  | NA                                  |

a TEAEs are events occurring on-study or during 30-day follow-up.

b Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine.

Note that events of tumour pain, and benign malignancies are excluded from this analysis.

AE: Adverse event; N: Total number of patients; NA: Not applicable; TEAE: Treatment emergent adverse event. Data derived from Table 11.3.2.2, OlympiAD CSR, Module 5.3.5.1 (DCO: 25 September 2017).

## Pneumonitis

AEs of pneumonitis are collected on-treatment and during the 30-day follow-up period only; there is no additional follow-up for pneumonitis events beyond the end of the 30-day follow up period.

Table 69: Summary of AEs of pneumonitis occurring across the olaparib program

|                                                                     | TEAEsa          | TEAEsa    | TEAEsa              | TEAEsa              |
|---------------------------------------------------------------------|-----------------|-----------|---------------------|---------------------|
|                                                                     | Olaparib        | Olaparib  | Physician's choiceb | Physician's choiceb |
| Data source                                                         | Number of cases | Incidence | Number of cases     | Incidence           |
| OlympiAD N=205 olaparib N=91 physician's choice                     | 0               | 0         | 0                   | 0                   |
| Olaparib monotherapy combined therapeutic dose pool N=1525 olaparib | 8               | 0.52%     | NA                  | NA                  |
| Entire clinical programme pool N=8319 olaparib                      | 53              | 0.64%     | NA                  | NA                  |

a TEAEs are events occurring on-study or during 30-day follow-up.

b Physician's choice of chemotherapy consisting of either capecitabine, eribulin or vinorelbine

AE: Adverse event; N: Total number of patients; NA: Not applicable; TEAE: Treatment emergent adverse event. Data derived from Iable 11.3.2.2, OlympiAD CSR Addendum, MIodule 5.3.5.1 (DCO: 25 September 2017) and on follow-up of patients post the DCO date.

<div style=\"page-break-after: always\"></div>

## Analysis of other adverse drug reactions (OlympiAD SAS)

## Hematologic toxicities

## Anaemia

AEs of anaemia were reported for a higher percentage of patients in the olaparib arm (40.0%) compared with the physician's choice of chemotherapy arm (26.4%). These events were predominantly Grade 1 or 2 in severity, rarely led to permanent discontinuation of treatment (2.0%), were manageable by standard supportive therapies, and generally resolved whilst on treatment.

CTCAE Grade ≥ 3 anaemia was reported in 33 (16.1%) patients in olaparib arm vs. 4 (4.4%) patients in the physician's choice of chemotherapy arm.

Onset of anaemia was early, generally in the first 3 months of starting olaparib (median time to onset was 1.45 months), although the risk of developing anaemia remained fairly constant throughout exposure with  no  evidence  of  cumulative  effect;  the  majority  (64  of  82  patients)  of  first  events  with  olaparib resolved (median duration of resolution 1.36 months).

In  total,  37  (18.0%)  patients  in  the  olaparib  arm,  and  5  (5.5%)  patients  in  the  physician's  choice  of chemotherapy arm had blood transfusions.

Approximately half of the patients in the olaparib arm with anaemia (38 [46.3%] of 82 patients) were treated  for  the  AE  compared  with  approximately  one  third  of  patients  in  the  physician's  choice  of chemotherapy arm (7 [29.2%] of 24 patients).

## Gastrointestinal toxicity

## Nausea and vomiting

AEs of nausea and vomiting were reported for a higher percentage of patients in the olaparib arm (58.0% and 32.2% respectively) compared with the physician's choice of chemotherapy arm (35.2% and 15.4% respectively) in OlympiAD. These events were predominantly Grade 1 or 2 in severity and none led to permanent discontinuation of treatment in the olaparib arm.

A total of 54 (26.3%) olaparib-treated patients reported both nausea and vomiting. Approximately half of the olaparib-treated patients with nausea (63 [52.9%] of 119 patients) were treated for the AE and one third (22 [33.3%] of 66 patients) with vomiting received treatment.

Events of nausea and vomiting were generally reported early in the treatment period (median time to onset was 0.16 months and 0.87 months, respectively) and the majority (109 of 119 AEs of nausea and 63 of 66 AEs of vomiting) of first events with olaparib resolved (median duration of 1.12 months and 0.07 months, respectively).

## Cough

AEs  of  cough  (grouped  term  consisting  of  cough  and  productive  cough)  were  reported  for  a  higher percentage  of  patients  in  the  olaparib  arm  (18.0%)  than  the  physician's  choice  of  chemotherapy  arm (7.7%).  There  was  no  association  between  the  reporting  of  AEs  of  cough  and  the  length  of  time  on olaparib  treatment.  In  the  OlympiAD  study,  AEs  of  cough  in  the  olaparib-treated  arm  were  reported throughout the study period (median time to first onset was 3.12 months [range 0.20 to 19.45 months]); the majority (28 of 37 patients) of first events with olaparib resolved (median duration of 1.02 months).

<div style=\"page-break-after: always\"></div>

## Adverse drug reactions

The safety profile is based on pooled data from 1,525 patients with solid tumours treated with Lynparza monotherapy in clinical trials at the recommended dose.

Table 70: Frequency of AEs in tablet pool and overall events identified as ADRs associated with olaparib treatment

|                                                      | Tablet monotherapy pool N=759   | Tablet monotherapy pool N=759   | Overall (tablet and capsule) N=1525   | Overall (tablet and capsule) N=1525   | Overall (tablet and capsule) N=1525   |                      |
|------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|----------------------|
| System organ class/PT                                | All CTCAE grades n (%)          | CTCAE grades n (%)              | AlI CTCAE grades n (%)                | Frequency descriptor                  | CTCAE grades ≥3 n (%)                 | Frequency descriptor |
| Blood and lymphatic system disorders                 |                                 |                                 |                                       |                                       |                                       |                      |
| Anaemiaa                                             | 284 (37.4)                      | 113 (14.9)                      | 502 (32.9)                            | Very common                           | 217 (14.2)                            | Very common          |
| Neutropeniaa                                         | 137 (18.1)                      | 48 (6.3)                        | 188 (12.3)                            | Very common                           | 74 (4.9)                              | Common               |
| Thrombocytopeniaa                                    | 85 (11.2)                       | 21 (2.8)                        | 138 (9.0)                             | Common                                | 39 (2.6)                              | Common               |
| Lymphopenia                                          | 36 (4.7)                        | 8 (1.1)                         | 41 (2.7)                              | Common                                | 10 (0.7)                              | Uncommon             |
| Leukopeniaa                                          | 113 (14.9)                      | 24 (3.2)                        | 157 (10.3)                            | Very Common                           | 45 (3.0)                              | Common               |
| Gastrointestinal disorders                           |                                 |                                 |                                       |                                       |                                       |                      |
| Nausea                                               | 455 (59.9)                      | 8 (1.1)                         | 932 (61.1)                            | Very common                           | 29 (1.9)                              | Common               |
| Vomiting                                             | 260 (34.3)                      | 11 (1.4)                        | 540 (35.4)                            | Very common                           | 36 (2.4)                              | Common               |
| Diarrhoea                                            | 187 (24.6)                      | 6 (0.8)                         | 372 (24.4)                            | Very common                           | 19 (1.2)                              | Common               |
| Dyspepsia                                            | 69 (9.1)                        | 0                               | 196 (12.9)                            | Very common                           | 0                                     |                      |
| Upper abdominal pain                                 | 65 (8.6)                        | 1(0.1)                          | 140 (9.2)                             | Common                                | 3 (0.2)                               | Uncommon             |
| Stomatitis                                           | 47 (6.2)                        | 3 (0.4)                         | 83 (5.4)                              | Common                                | 6 (0.4)                               | Uncommon             |
| General disorders and administration site conditions |                                 |                                 |                                       |                                       |                                       |                      |
| Fatigue (including asthenia)                         | 388 (51.1)                      | 37 (4.9)                        | 859 (56.3)                            | Very common                           | 94 (6.2)                              | Common               |
| Investigations                                       |                                 |                                 |                                       |                                       |                                       |                      |
| Increase in creatinine                               | 34 (4.5)                        | 0                               | 77 (5.0)                              | Common                                | 2 (0.1)                               | Uncommon             |
| Mean corpuscular volume elevation                    | 2 (0.3)                         | 0                               | 2 (0.1)                               | Uncommon                              | 0                                     |                      |
| Metabolism andnutritiondisorders                     |                                 |                                 |                                       |                                       |                                       |                      |
| Decreased appetite                                   | 178 (23.5)                      | 6 (0.8)                         | 349 (22.9)                            | Very common                           | 11 (0.7)                              | Uncommon             |
| Nervous system disorders                             |                                 |                                 |                                       |                                       |                                       |                      |
| Headache                                             | 129 (17.0)                      | 3 (0.4)                         | 263 (17.2)                            | Very common                           | 5 (0.3)                               | Uncommon             |
| Dysgeusia                                            | 116 (15.3)                      | 0                               | 223 (14.6)                            | Very common                           | 0                                     |                      |
| Dizziness                                            | 77 (10.1)                       | 1 (0.1)                         | 180 (11.8)                            | Very common                           | 4 (0.3)                               | Uncommon             |
| Immune system disorders                              |                                 |                                 |                                       |                                       |                                       |                      |
| Hypersensitivitya                                    | 2 (0.3)                         | 0                               | 9 (0.6)                               | Uncommon                              | 0                                     |                      |
| Rasha                                                | 46 (6.1)                        | 0                               | 129 (8.5)                             | Common                                | 0                                     |                      |
| Dermatitisa                                          | 4 (0.5)                         | 0                               | 8 (0.5)                               | Uncommon                              | 0                                     |                      |
| Respiratory, thoracic and mediastinal disorders      |                                 |                                 |                                       |                                       |                                       |                      |
| Cougha                                               | 121 (15.9)                      | 2 (0.3)                         | 246 (16.1)                            | Very common                           | 3 (0.2)                               | Uncommon             |

Frequencies of occurrence of adverse reactions are defined as: very common (≥1/10); common (≥1/100 to &lt;1/10); uncommon (≥1/1,000 to &lt;1/100); rare (≥1/10,000 to &lt;1/1000); and very rare (&lt;1/10,000) including isolated reports

Anaemia includes PTs of anaemia, erythropenia, haemoglobin decreased, red blood cell count decreased, and haematocrit decreased; Neutropenia includes PTs of neutropenia, granulocytopenia, granulocyte count decreased, neutrophil count decreased, febrile neutropenia, neutropenic infection, and neutropenic sepsis; Thrombocytopenia includes PTs of thrombocytopenia, platelet count decreased and platelet production decreased; Lymphopenia includes PTs of lymphocyte count decreased, lymphocyte percentage decreased, lymphopenia; Leukopenia includes PTs of leukopenia and white blood cell count decreased; Hypersensitivity includes PTs of drug hypersensitivity and hypersensitivity; Rash includes PTs of exfoliative rash, generalised erythema, rash, rash erythematous, rash generalised, rash macular, rash maculo-papular, rash papular, and rash pruritic; Dermatitis includes PTs of dermatitis, dermatitis allergic, and dermatitis exfoliative; Cough includes cough and productive cough.

ADRs Adverse drug reactions; AEs Adverse events; CTCAE Common Terminology Criteria for Adverse Events; PTs Preferred terms.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

In  OlympiAD,  the  changes  in  haematological  laboratory  parameters  reported  were  generally  mild  or moderate in severity.

No patients in OlympiAD had CTCAE Grade 4 haemoglobin values during the study in both arms; 16.6% of olaparib-treated patients had decreases to CTCAE Grade 3 haemoglobin values compared with 3.3% of patients in the physician's choice of chemotherapy arm.

A  low  proportion  of  olaparib-treated  patients  (9  patients  [4.4%])  had  CTCAE  Grade  ≥3  reductions  in platelet count during the study; no patients in the physician's choice of chemotherapy arm had a CTCAE Grade ≥3 reduction in platelet count.

The  majority  of  patients  in  both  treatment  arms  in  OlympiAD  had  a  maximum  CTCAE  Grade  of  ≤  2 reported for leukocyte laboratory values thoughout treatment.

The  majority  of  olaparib-treated  patients  in  OlympiAD  had  a  maximum  grade  of  ≤2  reported  for neutrophil  laboratory  values.  Moreover,  9.9%  of  olaparib-treated  patients  had  decreases  to  CTCAE Grade≥3  neutrophil  values  whereas  approximately  one-third  of  patients  in  the  physician's  choice  of chemotherapy arm had CTCAE Grade 3 or 4 absolute neutrophil count (ANC) during the OlympiAD study.

The majority of patients in OlympiAD had a maximum CTCAE Grade of ≤2 reported for lymphocyte laboratory values throughout treatment. The proportion of patients with CTCAE Grade 3 or 4 reductions in lymphocyte count during the study was higher for the olaparib arm (36 of 165 patients [21.8%]) than for the physician's choice of chemotherapy arm (2 patients [2.8%]).

## Potential for drug-induced liver injury (DILI)

There were no confirmed or suspected Hy's Law cases.

In  the  OlympiAD  study,  the  majority  of  patients  in  the  olaparib  arm  and  the  physician's  choice  of chemotherapy  arm  had  AST  (188/205  [91.7%]  and  84/91  [92.3%]  patients,  respectively)  and  ALT (191/205 [93.2%] and 79/91 [86.8%] patients, respectively) below 3 × ULN. The majority of patients with AST or ALT values above 3 × ULN in OlympiAD had values ≥3 × ULN to &lt;5 × ULN, both for the olaparib arm and the physician's choice of chemotherapy arm. ALT and AST values in the range of ≥10 × ULN to &lt;20 × ULN were each reported for 1 olaparib-treated patient; no patients in the physician's choice of chemotherapy arm had values outside the range of ≥5 × ULN to &lt;10 × ULN. No patient in either treatment arm had an AST or ALT value of ≥20 × ULN.

There were 6 (3.0%) patients in the olaparib arm who had a laboratory value of AST elevation of CTCAE Grade 3 (worst grade), and 4 (2.0%) patients with CTCAE Grade 3 elevated ALT (worst grade) during treatment. In general, AST and ALT elevations in all 6 patients were transient in nature and resolved on continued treatment.

An assessment of ALT, AST maximal elevations during treatment by maximal total bilirubin elevations showed that 1 (0.5%) patient in the olaparib arm and 2 (2.2%) physician's choice of chemotherapy arm had concurrent elevation of bilirubin and either ALT or AST. The olaparib-treated patient had transient concurrent elevated AST (CTCAE Grade 2) and bilirubin (&gt; 2 x ULN) at Visit 10 (Day 129). No AEs were reported for this  patient at  the  time of  these laboratory  findings.  There  were  no  dose  interruptions  or dose  reductions  and  AST  and  ALT  values  were  both  normal  at  the  next  visit.  The  patient  had  hepatic metastases at screening.

In the 300 mg bd pool, the majority (695 [91.8%] patients) had combined AST or ALT below 3 × ULN. AST or ALT values above 3 × ULN were reported infrequently (37 [4.9%] patients had values of &gt;3 ×

<div style=\"page-break-after: always\"></div>

ULN to ≤5 × ULN; 17 [2.2%] patients had values &gt;5 × ULN to ≤10 × ULN; 7 [0.9%] patients had values &gt;10 × ULN to ≤20 × ULN, and 1 [0.1%] patient had a value of &gt;20 × ULN).

In the 300 mg bd pool, the proportion of patients who had an AST or an ALT laboratory value of CTCAE Grade 3 is similar to that in the olaparib arm of the OlympiAD study (3.0% and 2.0% respectively).

An assessment of combined elevations of ALT and bilirubin was conducted for all patients in the 300 mg bd pool. Of these 759 patients, 15 (2.0%) reported elevations of both AST and ALT &gt;3 × ULN and total bilirubin &gt;2 × ULN, irrespective of ALP, at any point during their study treatment. A detailed evaluation of medical history, progression of disease, temporal association with elevated ALP (&gt;2 × ULN for 8 patients and &lt;1 × ULN for 1 patient) and other factors showed that all 9 patients had alternative explanations for elevations of ALT and bilirubin, generally suggestive of obstructive causes, or cancer disease progression, including disease progression in the liver.

## Increase in creatinine

In the olaparib arm of OlympiAD, 96.1% of olaparib-treated patients had normal creatinine levels at baseline, 3.4% had CTCAE Grade 1 at baseline and 0.5% had CTCAE Grade 2 at baseline. A total of 31/204 (15.2%) patients had a single change in CTCAE Grade (most changes were normal to Grade 1) and no patients had 2 grade shifts in CTCAE Grade for creatinine; 1 patient had a shift from normal at baseline to CTCAE Grade 3 on treatment (this patient had hydronephrosis at baseline; no patients had a 4 grade shift.

Data from all patients in the 300 mg bd pool showed that a higher proportion of patients in the tablet pool had CTCAE grade shifts in creatinine, compared with OlympiAD. In the 300 mg bd pool, 90.0% of olaparib-treated patients had normal creatinine at baseline, 9.2% had CTCAE Grade 1 at baseline and 0.7% had CTCAE Grade 2 at baseline. A total of 594/757 (78.5%) patients had a single change in CTCAE Grade (changes were normal to Grade 1 in 568 of the 591 patients) and 96/757 (12.7%) had 2 CTCAE grade shifts (all were normal to Grade 2); one patient (0.1%) had a 3 grade shift in creatinine (from Grade 0 to Grade 3).

## Safety in special populations

## Effect of age

Table 71 shows the distribution of AEs by patient age.

Table 71: Number of patients reporting at least one adverse event by age group in the 300 mg bd pool

|                                                  | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   |
|--------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| MedDRA term                                      | Age≤65 year's N=602       | Age 65 to 74 year's N=126 | Age 75 to 84 years N=31   | Age ≥85yeal's N=0         |
| Total AEs                                        | 588 (97.7)                | 123 (97.6)                | 30 (96.8)                 |                           |
| Total SAEsa                                      | 106 (17.6)                | 31 (24.6)                 | 6 (19.4)                  | 0                         |
| Fatalb                                           | 1 (0.2)                   | 1 (0.8)                   | 0                         |                           |
| Hospitalisation/prolong existing hospitalisation | 101 (16.8)                | 27 (21.4)                 | 6 (19.4)                  | 0                         |
| Life-threatening                                 | 11 (1.8)                  | 2 (1.6)                   | 0                         | 0                         |

<div style=\"page-break-after: always\"></div>

| Other (disability incapacity)   | 3 (0.5)   | 0        | 0       |   0 |
|---------------------------------|-----------|----------|---------|-----|
| Other (medically significant)   | 30 (5.0)  | 6 (4.8)  | 1 (3.2) |   0 |
| Total DAEs                      | 37 (6.1)  | 10 (7.9) | 3 (9.7) |   0 |

a. The total is not equal to the sum of the events across the seriousness criteria because investigators are asked to indicate each seriousness criterion valid for the event

b Event was fatal within 30 days of the last dose of olaparib

AE: Adverse event; bd: Twice daily; CSR: Clinical study report; DAEs: Adverse events leading to discontinuation; DCO: Data cut-off; MedDRA: Medical Dictionary for Regulatory Activities; SAEs: Serious adverse events.

Data derived from Table 2.7.4.1.13.1, Table 2.7.4.1.6.1.4,MIodule 5.3.5.3 (DCO: 25 September 2017).

An analysis of AEs by the SOCs most relevant to elderly patients, and age is provided in Table 71. For the majority of the AEs, there were no differences in frequency of AEs by PT in patients aged &lt;65 years when compared with patients aged 65 to 74 years and patients aged 75 to 84 years. ALT increased, leukopenia, headache and nausea were the only AEs that occurred at a higher incidence (≥5% difference) in the &lt;65 years category compared with 65 to 74 and 75 to 84 year categories. For the 65 to 74 years age category, AEs that occurred at a higher incidence (≥5% difference) when compared with &lt;65 years age category were: fatigue, oedema peripheral and urinary tract infection. For the 75 to 84 years age category, AEs that occurred at a higher incidence (≥5% difference) when compared with &lt;65 years were: arthralgia, constipation, decreased appetite, dysgeusia, dyspnoea, dyspnoea exertional, fatigue, haematuria, hypomagnesaemia, hypotension, malaise, pharyngitis and thrombocytopenia.

Table 72: Number of patients with, and reports of adverse events within the SOCs/SMQs of most relevance to elderly patients, by age in the 300 mg bd pool

| Patients, n (%)                                                                                                     | Age ≤65 years N=602   | Age 65 to 74 years N=126   | Age 75 to 84 year's N=31   |   Age ≥85 year's N=0 |
|---------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------|----------------------------|----------------------|
| Total number of patients with AEs                                                                                   | 588 (97.7)            | 123 (97.6)                 | 30 (96.8)                  |                    0 |
| Psychiatric disorders (SOC)                                                                                         | 104 (17.5)            | 19 (15.1)                  | 5 (16.1)                   |                    0 |
| Accidents and injuries (SMQ)                                                                                        | 37 (6.1)              | 4 (3.2)                    | 2 (6.5)                    |                    0 |
| Cardiac disorders (SOC)                                                                                             | 32 (5.3)              | 11 (8.7)                   | 1 (3.2)                    |                    0 |
| Vascular disorders (SOC)                                                                                            | 51 (8.5)              | 17 (13.5)                  | 2 (6.5)                    |                    0 |
| Central nervous system vascular disorders (SMQ)                                                                     | 3 (0.5)               | 0                          | 0                          |                    0 |
| Infections and infestations (SOC)                                                                                   | 262 (43.5)            | 59 (46.8)                  | 13 (41.9)                  |                    0 |
| Quality of life decreased (PT)                                                                                      | 0                     | 0                          | 0                          |                    0 |
| Sum of orthostatic hypertension and loss of consciousness, falls, black outs, syncope, dizziness, ataxia, fractures | 73 (12.1)             | 21 (16.7)                  | 2 (6.5)                    |                    0 |

AE: Adverse event; bd: Twice daily; DCO: Data cut-off; MedDRA: Medical Dictionary for Regulatory Activities; PT: Preferred term; SMQ: Standardised MedDRA query; SOC: System organ class. Data derived from Table 2.7.4.1.13.1, Table 2.7.4.1.13.2, Table 2.7.4.1.13.3, Table 2.7.4.1.13.4 and Iable 2.7.4.1.6.2.4 MIodule 5.3.5.3 (DCO: 25 September 2017).

<div style=\"page-break-after: always\"></div>

## Effect of race

Safety data are presented for the 168 non-White patients who received the proposed dose of 300 mg bd as a monotherapy across the clinical programme. The majority of these patients 155 (92.3%) were of Asian origin, 5 (3.0%) patients were of Black or African American origin and 8 (4.8%) were of other racial origin.

Table 73: Number (%) of patients who had at least 1 AE in any category by race (all patients and non-White patients) in the 300 mg bd pool

| AE category                                             | All patients (advanced solid tumours) N=759   | Non-Vhite patientsb N=168   |
|---------------------------------------------------------|-----------------------------------------------|-----------------------------|
| Any AE                                                  | 741 (97.6)                                    | 163 (97.0)                  |
| Any AE causally related to study drug                   | 654 (86.2)                                    | 149 (88.7)                  |
| Any AE of CTCAE Grade 3 or higher                       | 278 (36.6)                                    | 68 (40.5)                   |
| Any AE with outcome = death                             | 3 (0.4)                                       | 1 (0.6)                     |
| Any SAE (including events with outcome = death)         | 143 (18.8)                                    | 30 (17.9)                   |
| AE 1eading to dose reduction of study treatment         | 134 (17.7)                                    | 25 (14.9)                   |
| Any AE leading to interruption/delay of study treatment | 239 (31.5)                                    | 51 (30.4)                   |
| AE leading to discontinuation of study treatment        | 50 (6.6)                                      | 11 (6.5)                    |

Patients with multiple events reported in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

b Of the 168 Non-White patients, 5 patients were Black, 155 patients were Asian and 8 patients were *other*. As assessed by the investigator C

Includes adverse events with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE: Adverse event; bd: Twice daily; CTCAE: Common Terminology Criteria for Adverse Events; DCO: Data cut-off; N: Total number of patients; SAE: Serious adverse event.

Data derived from Table 2.7.4.1.1.1 and Table 2.7.4.1.11.1, 300 mg bd pool, Module 5.3.5.3 (DC0:

25 September 2017).

AEs  that  occurred  at  a  higher  incidence  in  non-White  patients  (≥5%  difference)  compared  with  White patients  were:  ALT  increased,  anaemia,  AST  increased,  malaise,  neutrophil  count  decreased,  platelet count decreased, upper respiratory tract infection and WBC count decreased.

AEs with a CTCAE Grade ≥3 that occurred at a higher incidence in non-White patients (≥5% difference) compared with White patients were: anaemia, neutrophil count decreased, and WBC count decreased. Anaemia and WBC count decreased were the only AEs that resulted in a dose modification that occurred at a higher incidence in non-White patients (≥5% difference) compared with White patients.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

AEs leading to discontinuation of study treatment were similarly low in OlympiAD and in the 300 mg bd pool, and were reported for 4.9% and 6.6% of patients respectively.  In the physician's choice chemotherapy arm, AEs leading to discontinuation of the study treatment were reported in 7.7% of patients. The most common SOCs reported for AEs leading to discontinuation were blood and lymphatic disorders. Anaemia was the most common AE leading to discontinuation in OlympiAD and in the 300 mg bd pool.

## Dose reductions/interruptions due to adverse events

Dose interruptions or delay and dose reductions were reported respectively in 50.7% and 26.8% patients on olaparib and respectively in 38.5% and 30.8% patients on physician's choice of chemotherapy. A numerically higher proportion of patients in the olaparib arm (35.1%) had a dose interruption due to an AE compared with the proportion of patients in the physician's choice of chemotherapy arm (26.4%). However, a numerically lower proportion of patients in the olaparib arm (25.4%) compared to the physician's choice of chemotherapy arm (30.8%) had a dose reduction due to an AE.

AEs leading to dose reductions were reported for 134 (17.7%) of patients for the 300 mg bd pool and AEs leading to dose interruption were reported for 239 (31.5%) of patients for the 300 mg bd pool.

The types of AEs leading to dose modifications (anaemia, vomiting, neutropenia, nausea and fatigue) were comparable with those observed in OlympiAD.

## Post marketing experience

The capsule formulation of olaparib is currently approved in more than 50 countries worldwide for the treatment of patients with ovarian cancer. The tablet formulation is approved in the US and Japan for patients with PSR ovarian cancer and was recently approved in the US for patients with gBRCAm HER2negative metastatic breast cancer. The reports received do not change the benefit-risk profile of olaparib.

## 2.5.1. Discussion on clinical safety

Across the entire clinical programme, as of 15 December 2017, an estimated 8319 patients are estimated to have received treatment with olaparib. The safety of olaparib 300 mg bid tablet is mainly based on the phase III OlympiAD study. The OlympiAD data have been pooled with the data from patients receiving olaparib 300 mg bid tablet in additional 10 monotherapy studies providing a pooled safety database of about 759 patients (268 of whom had breast cancer). These safety data are considered supplementary to the presentation of data from the OlympiAD study.

The majority of patients exposed to olaparib reported adverse events (AEs), which were generally mild to moderate in severity and did not lead to discontinuation. The toxicity of olaparib was manageable, including by dose interruptions, dose reductions and standard supportive treatment as required. The safety findings in olaparib arm of OlympiAD were consistent with the 300 mg bid pool.

In study OlympiAD, the median total treatment duration was more than twice as long in the olaparib arm (approximately 8.2 months) compared with the physician's choice of chemotherapy arm (approximately 3.4 months). 27.8% of patients in the olaparib arm remained on treatment for ≥1 year compared with 9.9% of patients in the physician's choice of chemotherapy arm.

<div style=\"page-break-after: always\"></div>

The most common AEs in the olaparib arm were: nausea (58.0%), anaemia (39.5%), vomiting (32.2%), fatigue (29.8%), diarrhoea (20.5%), headache (20.5%), neutropenia (18.0%), cough (17.1%), decreased appetite (17.1%), WBC decreased (16.1%), pyrexia (14.6%), back pain (14.6%), upper respiratory tract infection (13.2%), constipation (12.7%), neutrophil count decreased (11.2%), ALT increased (11.7%), arthralgia (11.2%) and leukopenia (11.2%).

It can be noticed than in OlympiAD, anaemia, nausea and vomiting were reported at a significantly higher frequency in olaparib arm than in the physician's choice of chemotherapy arm whereas neutropenia, PPE syndrome and alopecia were reported at a significantly higher frequency in the physician's choice of chemotherapy arm than in olaparib arm.

In OlympiAD, approximately 40% of patients in either treatment arm of the OlympiAD study had AEs leading to either dose reduction or dose interruptions/delays. The proportion of patients who had AEs leading to either dose reduction or dose interruptions were similar for OlympiAD and the 300 mg bd pool.

The proportion of patients who reported AEs leading to discontinuation of treatment was low in both treatment arms.

Grade ≥3 AEs had a higher incidence in the physician's choice of chemotherapy arm (49.5% of patients) than in the olaparib arm (38.0%). Anaemia and neutropenia were the only AEs Grade ≥3 reported in ≥5% of patients in the olaparib arm (respectively 15.6% and 5.4% in the olaparib arm vs. 4.4% and 13.2% in the physician's choice of chemotherapy arm). AEs of CTCAE Grade 3 or higher were similar and occurred at similar frequencies in olaparib between treatment arm of OlympiAD and the 300 mg bid pool.

SAEs were reported in a similar proportion of patients in the olaparib arm (16.6%) compared with the physician's choice of chemotherapy arm (16.5%). The highest frequency of reported SAEs at the system organ class (SOC) level was blood and lymphatic system disorders (2.9% olaparib vs. 6.6% physician's choice of chemotherapy). The most common SAE in both arms was anaemia (2.4% olaparib vs 2.2% physician's choice of chemotherapy). The only SAEs considered by the Investigator to be causally related to olaparib in &gt;1 patient was anaemia (5 [2.4%] patients). The only other SAEs reported in ≥2 patients in olaparib arm only were: dyspnoea (1.5%), pyrexia (1.5%), neutrophil count decreased (1.0%) and platelet count decreased (1.0%). The majority of SAEs had resolved with either no action taken or following a temporary dose interruption or delay/dose change, or were recovering. SAEs were reported at a similar frequency in OlympiAD and in the 300 mg bd pooled dataset.

Most deaths occurring on study were related to the disease under investigation with only one patient in the olaparib arm with an AE leading to death (sepsis) which was not considered related to study treatment by the Investigator. The frequency of deaths for any reason was similar for olaparib-treated patients over patients in the physician's choice of chemotherapy arm (63.4% vs. 63.9% respectively). The frequency of deaths for any reason was twice as large as for olaparib-treated patients (63.4%) in OlympiAD over the 300 mg bd pool (27.0%). But the majority of deaths concern death related to disease under investigation which was twice as many in the olaparib arm than in the physician's choice of chemotherapy arm (respectively 58.5% and 25.0%).

The adverse drug reactions (ADRs) identified for olaparib tablets are the same as previously described in the SmPC of olaparib. Section 4.8 of the SmPC has been revised to reflect updated frequencies based on pooled data from 1525 patients with solid tumours treated with lynparza monotherapy in clinical trials at the recommended dose. The most frequently observed adverse reactions across clinical trials in patients receiving Lynparza monotherapy (≥ 10%) were nausea, fatigue (including asthenia), vomiting, anaemia, diarrhoea, decreased appetite, headache, cough, dysgeusia, dyspepsia, neutropenia, dizziness, and leukopenia.

Back pain was the only AE not listed as an ADR that occurred at a frequency of 10% in the olaparib 300 mg bd arm and a 5% or greater frequency compared with the physician's choice of chemotherapy arm.

<div style=\"page-break-after: always\"></div>

However, back pain is a common disease-related symptom in metastatic breast cancer patients and the event rate data suggests that the difference in crude incidence observed in OlympiAD is likely due to differences in exposure/observation time between arms.

The adverse events of special interest (AESIs) for olaparib are myelodysplastic syndrome (MDS)/AML, pneumonitis and new primary malignancies. These adverse events have been classified in the RMP as important potential risks supported by pharmacovigilance activities.

Investigators in OlympiAD were required to record MDS/AML and new primary malignancies events beyond 30 days after the last dose of olaparib at any point in OS follow-up. A causal relationship between olaparib treatment and the development or acceleration of MDS/AML, new primary malignancies and pneumonitis has not been established.

There were no reports of MDS or AML in either treatment arm of OlympiAD, either on treatment, or within the 30-day follow-up period.

In the OlympiAD study, there was 1 event of new primary malignancy (malignant melanoma in situ of CTCAE Grade 1) reported in the olaparib arm (0.5% of patients) compared with no event in physician's choice  of  chemotherapy  arm.  The  incidence  of  new  primary  malignancies  in  the  pool  of  patients  who received olaparib in monotherapy studies (tablet and capsule formulations; all doses of olaparib) is 1.23% for olaparib (24 patients in a total of 1957 patients, of whom 13 patients had skin cancers).There have also  been  reports  of  new  primary  malignancies  from  post  marketing  surveillance,  consistent  with  the characterisation  of  the  events  reported  from  monotherapy  clinical  studies.  Patients  enrolled  into  the olaparib  clinical  studies  had  already  received  prior  chemotherapy  with  multiple  cycles  of  platinum containing chemotherapy. Whilst it is not possible to exclude a contribution of olaparib, there were other contributory factors for all reports.

In the OlympiAD study, there were no pneumonitis cases reported. There were 8 patients with events of pneumonitis in the pool of patients who received olaparib in monotherapy studies (tablet and capsule formulations; all doses of olaparib) giving an incidence rate of 8 in 1525 patients (0.52%).

Regarding laboratory parameters, changes in haemoglobin, neutrophils, lymphocytes, platelets and mean corpuscular volume were the only significant haematological parameters with clinically relevant changes; these parameters are recognised ADRs for olaparib. Anaemia is the only one important identified risk in the  RMP,  whereas neutropenia and thrombocytopenia are no longer considered as important identified risk in the RMP.

Additional safety measures have been incorporated into the Phase III programme and these measures have also been implemented where olaparib is marketed: specified haematological values are required before inclusion into the studies or treatment and regular monitoring is continued while on treatment to detect haematological abnormalities early. In case of, prolonged cytopenias, patients are to be referred to a  haematologist  and  bone  marrow  analysis  should  be  considered.  If  a  diagnosis  of  MDS  is  confirmed, olaparib treatment must be discontinued and the event, treatment, course and outcome must be reported as an SAE. Based on the updated analysis of MDS/AML, with a DCO date of 15 December 2017, these measures are considered to remain appropriate  for  minimization of  the  risk  for  MDS/AML,  and  do  not require  any  further  amendment.  Section  4.4  of  the  SmPC  has  also  been  updated  to  reflect  that  the incidence of MDS/AML cases was similar among gBRCA1m and gBRCA2m patients (1.4% versus 1.6%).

At the exception of anaemia and neutropenia (see above, paragraph on AEs grade ≥ 3) the changes in the laboratory values for the haematology parameters in the olaparib arm were generally reported in low numbers of patients with a maximum CTCAE Grade of 3 or 4 (leukopenia 2.4%, neutrophil count 4.9%, %, WBC decreased 3.4% and platelet count decreased 2.4%). These changes in haematological parameters are generally mild or moderate, manageable, and reversible.

<div style=\"page-break-after: always\"></div>

The  only  significant  change  in  clinical  chemistry  parameters  occurred  for  creatinine:  increase  in  blood creatinine is a recognised ADR for olaparib and is no longer considered important identified risk in the RMP.  AEs  of  increased  creatinine  were  predominantly  Grade  1  in  severity  and  none  led  to  permanent discontinuation  of  treatment.  The  laboratory  observations  of  elevated  serum  creatinine  were  not associated with renal impairment and had apparently no clinical sequelae. The changes in creatinine are consistent with the finding that olaparib is known to be an inhibitor of organic cation-transporter (OCT)-2 and multi-drug and toxin extrusion protein (MATE)-1.

No hepatobiliary or renal safety concerns were identified from a review of laboratory and AE data.

Regarding  special  populations,  although  there  are  limited  data  in  elderly  patients  ≥75  years  of  age, assessment of the safety of olaparib in patient subgroups showed an acceptable safety profile regardless of age, race, gender, or body weight. No dose adjustment is required on the basis of patient age, racial origin, gender or body weight.

Based on the mode of action of olaparib, women of childbearing potential should not become pregnant while  on  Lynparza  and  not  be  pregnant  at  the  beginning  of  treatment.  A  pregnancy  test  should  be performed on all women of childbearing potential prior to treatment and considered regularly throughout treatment.

Women of childbearing potential must use two forms of reliable contraception before starting Lynparza therapy, during therapy and for 1 month after receiving the last dose of Lynparza, unless abstinence is the chosen method of contraception (see section 4.4). Two highly effective and complementary forms of contraception are recommended.

Since it cannot be excluded that olaparib may reduce exposure to substrates of CYP2C9 through enzyme induction, the efficacy of some hormonal contraceptives may be reduced if co-administered with olaparib. Therefore, an additional non-hormonal contraceptive method should be considered during treatment (see section  4.5).  For  women  with  hormone  dependent  cancer,  two  non-hormonal  contraceptive  methods should be considered.

Olaparib has clastogenic potential it is not known whether olaparib or its metabolites are found in seminal fluid. Therefore, male patients must use a condom during therapy and for 3 months after receiving the last  dose  of  Lynparza  when  having  sexual  intercourse  with  a  pregnant  woman  or  with  a  woman  of childbearing potential. Female partners of male patients must also use highly effective contraception if they  are  of  childbearing  potential.  Male  patients  should  not  donate  sperm  during  therapy  and  for  3 months after receiving the last dose of Lynparza (see sections 4.4 and 4.6).

## Additional expert consultations

See under discussion on clinical efficacy.

## 2.5.2. Conclusions on clinical safety

The safety profile  of olaparib  including  patients  from  OlympiAD is  generally consistent  with  the  known safety profile of olaparib. It includes gastrointestinal AEs, hematologic toxicity and general disorders. No new safety signals were identified from patients with gBRCAm HER2-negative metastatic breast cancer. AEs  associated  with  olaparib  are  generally  mild  or  moderate,  manageable  with  dose  modification  or standard supportive treatment and rarely requiring treatment discontinuation.

Regarding MDS/AML, pneumonitis and new primary malignancies, a causal relationship between olaparib treatment  and  these  adverse  events  has  not  been  established.  Therefore,  they  are  still  considered  as important potential risk for olaparib with ongoing surveillance activities detailed in the RMP.

<div style=\"page-break-after: always\"></div>

The SmPC and RMP have been adequately updated to reflect available safety data.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP endorsed the Risk Management Plan version 16.3 with the following content:

## Safety concerns

Table 74: Summary of safety concerns

| Important identified risks   | None                                                                                                                                                                                                                        |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Myelodysplastic syndrome/acute myeloid leukaemia New primary malignancies Pneumonitis Medication errors associated with dual availability of capsules and tablets Effects on embryofoetal survival and abnormal development |
| Missing information          | Long term exposure to/potential toxicity to olaparib Potential inhibitory effect of olaparib on UGT1A4 and UGT1A9                                                                                                           |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance activities for olaparib.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 75: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern         | Risk minimisation measures                                                                                                                                                                                                                                                                                                       | Pharmacovigilance activities                                                                                                                                                                             |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MDS/AML                | Routine risk communication in: SmPC Section 4.4 PL Section 2 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4: Guidance is provided for monitoring and management. PL Section 2: Advice regarding low blood counts and the signs and symptoms to look out for. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Follow-up targeted safety questionnaire • Cumulative review (provided concurrent with each annual PBRER) |
| New primary malignancy | None                                                                                                                                                                                                                                                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Follow-up targeted safety questionnaire                                                                  |
| Pneumonitis            | Routine risk communication in: • SmPC Section 4.4 • PL Section 2 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4: Guidance is provided for monitoring and management. PL Section 2: Advice on the signs and symptoms of possible pneumonitis.                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Follow-up targeted safety questionnaire                                                                  |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                              | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities   |
|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| Medication errors associated with dual availability of capsules and tablets | Routine risk communication in: • SmPC Section 4.2 • PL Section 3 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.2: Statement informing that olaparib is available as tablets and capsules which are not to be used interchangeably due to differences in the dosing and bioavailability of each formulation. PL Section 3: Statement informing that olaparib is available as tablets and capsules which are not the same and not to be used interchangeably. Additional risk minimisation measures: Distribution of a DHPC to prescribers and pharmacists providing clear information on the 2 formulations. | Routine                        |
| Effects on embryofoetal survival and abnormal development                   | Routine risk communication in: • SmPC Sections 4.4, 4.6 • PL Section 2 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4, 4. 6: Advice on contraception and pregnancy. PL Section 2: Advice on contraception and pregnancy.                                                                                                                                                                                                                                                                                                                                                                                   | Routine                        |
| Long term exposure to/potential toxicity to olaparib                        | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Routine                        |
| Potential inhibitory effect of olaparib on UGT1A4 and UGT1A9                | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | None                           |

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 5.2 of the SmPC of Lynparza tablets have been updated. Particularly, the warning with regard to women of childbearing potential/contraception in females has been modified to the product information. The SmPC of Lynparza capsule has been revised accordingly to reflect updated safety information.

The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the SmPC guideline and excipients guideline which were reviewed by QRD and accepted by the CHMP.

## 2.7.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the MAH show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The indication is for Lynparza in monotherapy for the treatment of adult patients with germline BRCA1/2mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless  patients  were  not  suitable  for  these  treatments.  Patient  with  hormone  receptor  (HR)-positive breast  cancer  should  also  have  progressed  on  or  after  prior  endocrine  therapy,  or  be  considered unsuitable for endocrine therapy.

Breast cancer is a life-threatening disease and is the second leading cause of cancer death among women and the fourth leading cause of cancer death overall (American Cancer Society 2018).

Approximately 5% of breast cancers are associated with a germline mutation in the BRCA1 and/or BRCA2 gene with approximately 3% associated with the BRCA2 gene (generally hormone receptor positive). In the general population, BRCA1/2 mutation carriers have an increased relative risk of breast cancer. The presence of gBRCA1 mutations is associated with a lifetime risk of breast cancer ranging from 60% to 70%. gBRCA2 mutations are associated with a lifetime risk of  breast  cancer  between  40%  to  60%  in women and 5% to 10% in men. Rare individuals carry deleterious mutations in both BRCA1 and BRCA2 genes.

## 3.1.2. Available therapies and unmet medical need

The  selection  of  appropriate  therapy  for  advanced  breast  cancer  comprising  locally  advanced  and metastatic breast cancer is complex because of the many treatment options and biologic heterogeneity of the disease (ABC4 consensus guidelines). The potential treatment options are determined in accordance with ER and PR and HER2 status of the tumour. Treatment options for patients presenting with metastatic

<div style=\"page-break-after: always\"></div>

breast  cancer  may  also  be  influenced  by  what  adjuvant  therapy  was  used,  how  soon  after  adjuvant therapy the patient relapses, and by sites of metastasis.

Currently,  single  agent  chemotherapy  after  previous  exposure  to  anthracyclines  and  taxanes  has  a median progression free survival (PFS) of approximately 4 months and an overall survival (OS) of 9 to 16 months when given early in the metastatic setting.

For patients with HER2-negative  metastatic breast cancer, there is no one preferred first-line chemotherapy. Sequential monotherapy with single agents such as capecitabine, vinorelbine, or eribulin are  among  the  preferred  choices  in  metastatic  breast  cancer  patients  previously  treated  with  an anthracycline  and  a  taxane  in  the  adjuvant  or  metastatic  setting  and  for  whom  further  hormonal treatments  are  not  indicated  (NCCN  2018).  Combination  chemotherapy  is  reserved  for  select  patients with high tumour burden, rapid clinical progression, life-threatening visceral metastases, or need for rapid symptom and/or disease control.

There is no targeted therapy available to date for a treatment of TNBC. The prognosis for patients with TNBC and/or those who carry gBRCA1 mutations with metastatic disease may even be worse than the overall metastatic breast cancer population. According to current NCCN guidelines (2018), carboplatin is considered as one of recommended regimens for recurrent or metastatic disease.

For  the  treatment  of  hormone  receptor  (HR)-positive,  HER2-negative  locally  advanced  or  metastatic breast cancer, CDK4/6 inhibitors have recently been approved in combination with endocrine therapy in first line and in women who have received prior endocrine therapy. Everolimus, an mTOR inhibitor, is also approved  for  the  treatment  of  hormone  receptor-positive,  HER2  negative  advanced  breast  cancer,  in combination  with  exemestane,  in  postmenopausal  women  without  symptomatic  visceral  disease  after recurrence or progression following a non-steroidal aromatase inhibitor.

There are currently no treatments approved in the European Union (EU) specifically for gBRCAm patients with  metastatic  breast  cancer  and  these  patients  are  treated  depending  on  the  hormone  receptor  and HER2 status determined in their tumours.

## 3.1.3. Main clinical studies

This application is based on results from the pivotal Phase III, randomised, controlled, open-label, multicentre study D0819C00003 (OlympiAD) (n=302), in which gBRCAm patients who had previously received chemotherapy in the neoadjuvant, adjuvant or metastatic setting (no more than 2 prior lines of chemotherapy for metastatic breast cancer) and were HER2-negative were randomised 2:1 to receive either olaparib (300 mg bd, tablet formulation) or physician's choice of chemotherapy (capecitabine, eribulin, or vinorelbine). Patients with hormone receptor-positive breast cancer should have been treated with a prior endocrine therapy or should be patients for whom endocrine therapy is not an appropriate option.

Patients with somatic BRCA1/2-mutated tumours were not eligible and have not been included.

The primary endpoint was PFS as determined by blinded independent central review (BICR). OS, PFS2 (investigator assessment) and ORR (by BICR) were secondary endpoints. TFST and TSST were also analysed as supportive endpoints for PFS and PFS2, respectively.

## 3.2. Favourable effects

OlympiAD met its primary endpoint demonstrating a statistically significant and clinically relevant 3months improvement in PFS based on BICR in the FAS population treated with olaparib compared to physician's choice of chemotherapy (HR 0.58; 95% CI: 0.43, 0.80; p&lt;0.0001; median 7.03 vs 4.17

<div style=\"page-break-after: always\"></div>

months) which was supported by investigator assessment (HR 0.50; 95% CI: 0.36, 0.68; p=0.0009; median 7.8 vs 3.8 months).

Following the subgroup analyses of PFS, no subgroups appeared to derive a differential benefit compared with the overall population. The treatment effects observed in individual chemotherapies (capecitabin, vinorelbin or eribulin) were similar to that observed in the intention-to-treat (ITT) set.

A statistical significant improvement on PFS2 was observed in the olaparib arm (HR: 0.57, 95% CI 0.40 0.87; p=0.0033) with a median second PFS 13.17 months in the olaparib arm compared to 9.26 months in the comparator arm. Final post-hoc PFS2 analysis was consistent with PFS2 at the DCO for primary analysis.

Final OS analysis was conducted at 64% maturity of the FAS population. There was no suggestion of a detrimental effect on OS, with the HR numerically favouring olaparib [HR 0.90 (95% Cl: 0.66, 1.23; p=0.5131; median OS 19.3 months in the olaparib arm versus 17.1 months in the physician's choice of chemotherapy arm].

Confirmed ORR (CR or PR) in patients with measurable disease was 52 % (87/167) in the olaparib arm and 23% (15/66) in the chemotherapy arm. A complete response was observed in 13 patients (8%) in the olaparib arm and 1 patient (1.5%) in the comparator arm.

The median DoR was 6.9 months (95%CI 4.2, 10.2) in the olaparib arm and 7.9 months (95%CI 4.5, 12.2) in the chemotherapy arm.

## 3.3. Uncertainties and limitations about favourable effects

Due to the lack of a direct comparison with platinum chemotherapy, the relative efficacy of olaparib with such treatment has not been defined. Furthermore, the efficacy of olaparib has not been evaluated in patients defined as resistant to prior platinum therapy. Patients who had received platinum (cisplatin or carboplatin, either as monotherapy or in combination) for advanced breast cancer were eligible to enter the study provided there had been no evidence of disease progression during the platinum chemotherapy in metastatic setting or as (neo)adjuvant treatment at least 12 months before the randomisation. Thus there  is  a  general  uncertainty  about  the  optimal  sequence  of  treatment  with  olaparib  in  a  treatment context  where  platinum  based  chemotherapy  is  an  option.  Information  about  prior  and  subsequent platinum therapy received is considered relevant for the prescribers and has been included in the section 5.1 SmPC.

Resistance  mechanisms  to  DNA-damaging  agents  including  PARP  inhibitors  has  not  been  sufficiently investigated to date and would be of value to determine the optimal sequence of use for PARP inhibitors and chemotherapy for breast cancer and to elaborate more effective therapeutic strategies in advanced BRCAm  breast  cancer.  The  investigation  of  efficacy  in  platinum-resistant  tumours  and  comparative efficacy to platinum agents is recommended

## 3.1. Unfavourable effects

The  most  common  ADRs  in  the  olaparib  arm  were:  nausea  (58.0%),  anaemia  (39.5%),  vomiting (32.2%), fatigue (29.8%), diarrhoea (20.5%), headache (20.5%), neutropenia (18.0%), cough (17.1%), decreased  appetite  (17.1%),  WBC  decreased  (16.1%),  neutrophil  count  decreased  (11.2%)  and leukopenia (11.2%). These were  generally mild to moderate  in severity and did not lead to discontinuation.

<div style=\"page-break-after: always\"></div>

Gastrointestinal  toxicity  (nausea,  vomiting  and  diarrhoea),  hematologic  toxicity  (anaemia),  fatigue, headache  are  considered  the  main  risks  with  olaparib.  Nausea  and  vomiting  were  reported  at  a significantly higher frequency in olaparib arm than in the physician's choice of chemotherapy arm.

The toxicity of olaparib was manageable by dose interruptions, dose reductions and standard supportive treatment  as  required.  Discontinuation  due  to  adverse  events  occurred  for  4.9%  of  the  patients  in olaparib arm and 7.7% of the patients in the physician's choice of chemotherapy arm. In olaparib arm and  in  the  physician's  choice  of  chemotherapy  arm,  anaemia  was  the  most  common  AE  leading  to discontinuation (2.0% and 2.2% respectively).

AEs of anaemia were reported for a higher proportion of patients in the olaparib arm (40.0%) compared with the physician's choice of chemotherapy arm (26.4%). These events were predominantly Grade 1 or 2  in  severity  and  approximately  half  of  the  patients  in  the  olaparib  arm  and  one  third  in  the chemotherapy arm have been treated for this AE. CTCAE Grade ≥ 3  anaemia  was  reported  in  16.1% patients  in  olaparib  arm  vs.  4.4%  patients  in  the  physician ' s  choice  of  chemotherapy  arm.  In  total, 18.0% patients in the olaparib arm, and 5.5% patients in the physician's choice of chemotherapy arm had blood transfusions.

Grade ≥3 AEs had a higher incidence in the physician's choice of chemotherapy arm (49.5% of patients) than in the olaparib arm (38.0%).

There were no reports of MDS/AML or pneumonitis in the study.  A new primary malignancy was reported for  1  patient  (0.5%)  in  the  olaparib  arm.  This  was  a  non-serious,  CTCAE  grade  1  event  of  malignant melanoma in situ.  The patient also had a medical history of melanoma.

Most deaths occurring on study were related to the disease under investigation with only one patient in the  olaparib  arm  with  an  AE  leading  to  death  (sepsis)  which  was  not  considered  related  to  study treatment by the investigator.

The  safety  profile  of  olaparib  in  patients  with  gBRCA  mutations  in  the  OlympiAD  trial  was  generally consistent with the known safety profile of olaparib.

## 3.2. Uncertainties and limitations about unfavourable effects

Available  long-term  safety  data  are  still  limited.  Long-term  exposure  to/potential  toxicity  to  olaparib remains classified as missing information in the risk management plan supported by pharmacovigilance activities. MDS/AML and NPM will also continue to be closely monitored as reflected in the RMP.

There was no report of myelodysplastic syndrome (MDS)/AML. The causality of olaparib in occurrence of these events has not been established. Long-term exposure to/potential toxicity to olaparib are currently classified  in  the  risk  management  plan  as  important  potential  risks  addressed  by  pharmacovigilance activities. MDS/AML and the risk of new primary malignancies will continue to be closely monitored as reflected in the RMP.

<div style=\"page-break-after: always\"></div>

## 3.3. Effects Table

Table 76: Effects Table for olaparib tablet formulation in gBRCA1/2-mutated HER2-negative metastatic breast cancer (data cut-off 16 December 2017, updated data cut-off 25 September 2017)

| Effect                   | Short description                                                             | Unit                     | Treatm ent               | Control                  | Uncertainties / Strength evidence                      | of                       | References               |
|--------------------------|-------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------------------------------------|--------------------------|--------------------------|
| Favourable Effects       | Favourable Effects                                                            | Favourable Effects       | Favourable Effects       | Favourable Effects       | Favourable Effects                                     | Favourable Effects       | Favourable Effects       |
| DCO at 16 December 2016  | DCO at 16 December 2016                                                       | DCO at 16 December 2016  | DCO at 16 December 2016  | DCO at 16 December 2016  | DCO at 16 December 2016                                | DCO at 16 December 2016  | DCO at 16 December 2016  |
| PFS median               | From randomisation to progression                                             | months                   | 7.03                     | 4.17                     |                                                        |                          | OlympiAD                 |
| HR                       | or death                                                                      | (95% CI)                 | 0.58 (0.43-0.80)         | 0.58 (0.43-0.80)         | p = 0.0009 by BICR                                     |                          |                          |
| Confirmed ORR            | CR or PR                                                                      | %                        | 52                       | 23                       | By BICR                                                |                          | OlympiAD                 |
| DCO at 25 September 2017 | DCO at 25 September 2017                                                      | DCO at 25 September 2017 | DCO at 25 September 2017 | DCO at 25 September 2017 | DCO at 25 September 2017                               | DCO at 25 September 2017 | DCO at 25 September 2017 |
| PFS 2 Median             | the time from the date of                                                     | months                   | 12.8                     | 9.4                      | p = 0.0005                                             |                          | OlympiAD                 |
|                          | or death the time from the date of randomisation until death due to any cause | (95% CI)                 |                          |                          | p=0.5131 64% maturity Consistent with interim analysis |                          |                          |
| OS Median HR             |                                                                               | months                   | 19.3 0.90                | 17.1 (0.66, 1.23)        |                                                        |                          | OlympiAD                 |

## Unfavourable Effects

Adverse

Effect

Blood and lymphatic

disorders;

Short description

Anaemia

All grades

Grade 3 and 4

Treatment discontinuation

Neutropenia

All grade

Grade 3 and 4

Unit

Pts

(%)

Pts

(%)

Study OlympiAD

Olaparib

300 mg

Physician's tablets

bd

N=205

81

(39.5)

32

(15.6)

4 (2.0)

37 (18)

11 (5.4)

choice of chemotherapy

N=91

23 (25.3)

4 (4.4)

2 (2.2)

28 (30.8)

12 (13.2)

Pool

Olaparib 300 mg tablets

N=759

277 (36.5)

111 (14.6)

12 (1.6)

94 (12.4)

29 (3.8)

Uncert ainties

/

Streng th of

eviden ce

Refere nces

Olymp iAD

'

<div style=\"page-break-after: always\"></div>

| Effect                       | Short description                  | Unit    | Treatm ent        | Control           | Uncertainties / Strength evidence   | References   |
|------------------------------|------------------------------------|---------|-------------------|-------------------|-------------------------------------|--------------|
|                              | Leukopenia All grade Grade 3 and 4 | Pts (%) | 23 (11.2) 5 (2.4) | 9 (9.9) 3 (3.3)   | 61 (8.0) 12 (1.6)                   | '            |
| General disorders;           | Fatigue All grade Grade 3 and 4    | Pts (%) | 61 (29.8) 7 (3.4) | 22 (24.2) 1 (1.1) | 297 (39.1) 24 (3.2)                 | '            |
| Nervous system disorders;    | Headache All grade Grade 3 and 4   | Pts (%) | 42 (20.5) 7 (3.4) | 14 (15.4) 1 (1.1) | 129 (17.0) 24 (3.2)                 | '            |
| Gastrointesti nal disorders; | Nausea All grade                   | Pts (%) | 119 (58.0)        | 32 (35.2)         | 455 (59.9)                          | '            |
| Gastrointesti nal disorders; | Vomiting All grade                 | Pts (%) | 66 (32.2)         | 14 (15.4)         | 260 (34.3)                          | '            |
| Gastrointesti nal disorders; | Diarrhoea All grade                | Pts (%) | 42 (20.5)         | 20 (22.0)         | 187 (24.6)                          | '            |

## 3.4. Benefit-risk assessment and discussion

## 3.4.1. Importance of favourable and unfavourable effects

The  benefits  of  olaparib  in  germline  BRCA  mutated  metastatic  breast  cancer  are  supported  by  a statistically  significant improvement in PFS supported by consistent results in PFS2 and ORR compared with  chemotherapy.  There  was  no  suggestion  of  a  detrimental  effect  on  OS  with  the  HR  numerically favouring  olaparib.  Results  appear  robust  and  consistent  in  the  different  sensitivity  and  subgroup analyses provided. The magnitude of the improvement in the ITT population (3-months for median PFS translating into a 67% relative prolongation of median PFS) is of potential clinical relevance in both HER2 negative/ER and/or PgR positive breast cancer and TNBC.

The safety profile  of  olaparib  including  patients  from  OlympiAD is  generally consistent  with  the  known safety  profile  of  olaparib.  No  new  safety  signals  were  identified  from  patients  with  gBRCAm  HER2negative metastatic breast cancer and safety findings in olaparib arm of OlympiAD were consistent with the 300 mg tablet pool. The toxicity of olaparib was manageable with dose interruptions, dose reductions and standard supportive treatment as required. However, it should be highlight that nausea and vomiting were  reported  at  a  significantly  higher  frequency  in  olaparib  arm  than  in  the  physician's  choice  of chemotherapy arm. Among haematological toxicities, anaemia is the most prominent. It was reported at higher  frequency  in  the  olaparib  arm,  lead  to  discontinuation  in  some  patients  and  resulted  in  blood transfusions in 18% of patients in the olaparib arm.

## 3.4.2. Balance of benefits and risks

In view of the poor prognosis of the germinal BRCAm HER2-negative metastatic breast cancer in patients previously treated with an anthracycline and a taxane in the adjuvant /neoadjuvant or metastatic setting and  for  whom  hormonal  treatments  are  not  indicated,  the  results  of  the  pivotal  OlympiAD  trial  are considered  of  clinical  relevance.  The  observed  3  months  gain  in  median  PFS,  supported  by  consistent improvement  in  PFS2  and  no  detriment  to  OS  compared  with  chemotherapy,  is  considered  of  clinical benefit and able to outweigh the treatment related toxicity which compares favourably with chemotherapy-related toxicity.

<div style=\"page-break-after: always\"></div>

## 3.4.3. Additional considerations on the benefit-risk balance

Patients with locally advanced disease with a generally better prognosis have not been included in the pivotal trial, but the extrapolation to this patient population was considered acceptable by the CHMP given a similar clinical management for locally advanced and metastatic disease and based on a biological and pharmacological rationale.

There are no clinical data available on the responsiveness of breast tumours with somatic BRCA mutation to PARPi. The MAH is recommended to collect clinical data in this population. In line with the SAG Oncology advice, extrapolation of results from patients with germline BRCA mutations that developed breast cancer to patients with sporadic breast cancers that harbour somatic BRCA mutations in their tumours is not justified for the time being in the absence of any clinical data and other data supporting the proposed mechanistic rationale. Although the mechanistic theoretical rationale is acknowledged, the magnitude of the potential effect in the context of breast cancer is uncertain. The indication has therefore been restricted to gBRCAm patients only until clinical outcome data for sBRCAm patients become available.

Substantial clinical benefit including OS benefit has been shown for anthracyclines and taxanes that are current  standard  of  care.  As  per  eligibly  criteria,  nearly  all  patients  enrolled  in  the  study  had  prior anthracycline  and  taxane  therapy.  It  is  therefore  considered  that  anthracycline  and  taxane  should  be specified prior regimens in the indication unless patients were not suitable for these treatments. In line with  the  studied  population,  the  indication  also  reflects  that  HR+  breast  cancer  patients  should  have progressed on a prior endocrine therapy or be considered unsuitable for endocrine therapy.

gBRCA mutations are found in 10% of male breast cancer patients with the majority with mutations in BRCA2. Despite the limited number of male patients included in the OlympiAD study (n=7), the CHMP considers that the extrapolation to a very rare population of male breast cancer patients with germline BRCA mutations, predominantly BRCA2 and characterised by high grade and aggressive phenotype (Silvestri et al, 2016) is acceptable based on the common biological and pharmacological rationale.

## 3.5. Conclusions

The overall B/R of Lynparza is positive for the following indication: Lynparza in monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patient with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the use of Lynparza tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer; patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patient with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 5.2 of the SmPC of Lynparza tablets have been updated. The SmPC of Lynparza capsule has been revised to reflect updated safety information and the Package Leaflet has been updated accordingly. Furthermore, RMP version 16.3 has also been accepted. Changes were also made to the PI to bring it in line with the SmPC guideline and excipients guideline which were reviewed by QRD and accepted by the CHMP.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).